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Molecular chaperones are responsible for the maturation of nascent polypeptides and the 
re-maturation of denatured proteins. One chaperone family that has emerged as an attractive 
therapeutic target is the 90 kDa heat shock proteins (Hsp90). Hsp90 is responsible for the 
maturation of proteins associated with all ten hallmarks of cancer, and its inhibition results in a 
multidirectional attack on cancer. More than seventeen small molecule inhibitors have entered 
clinical trials; however, concerns have risen due to toxicities, dosing and scheduling issues, and 
lack of efficacy as a single agent. Therefore, alternative strategies for Hsp90 inhibition are needed 
to take advantage of the unique biological role of Hsp90. All of the molecules evaluated in clinical 
trials exhibit pan-Hsp90 inhibition and target all four Hsp90 isoforms with similar affinities. 
Humans express four different Hsp90 isoforms: Hsp90α and Hsp90β reside in the cytosol, 
Grp94 is localized to the endoplasmic reticulum, and TRAP1 is found in the mitochondria. 
Emerging evidence suggests that each Hsp90 isoform plays a unique role in cancer progression. 
Therefore, to further study the individual roles of each isoform, the development of Hsp90 
isoform-selective inhibitors is highly desirable. However, the development of such inhibitors is 
hindered by the fact that the N-terminal ATP-binding pocket is >85% identical among all four 
isoforms. 
 Described herein is the development of isoform-selective inhibitors of the ER- and 
mitochondria-localized Hsp90 isoforms, Grp94 and TRAP1, respectively. Grp94-selective 
inhibitors were evaluated in models of myocilin-associated open angle glaucoma, cancer 
metastasis, and multiple myeloma. TRAP1-selective inhibitors were evaluated for their ability to 
induce apoptosis in cancer cells. These isoform-selective inhibitors will serve as invaluable tools 
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1. Introduction to Hsp90 Structure, Function, and Isoform-selective 
Inhibition 
Molecular Chaperones 
Molecular chaperones are essential for the maintenance of protein homeostasis, assurance of 
proper folding, stability, activation, trafficking, and the degradation of cellular proteins to preserve 
a viable cellular environment.1-4 Molecular chaperones are responsible for responding to and 
ameliorating the effects of intra- and extracellular stresses. Under stressed conditions, molecular 
chaperones interact with proteins that have undergone deleterious conformational changes to 
restore them into their proper biologically-active conformation. Subsets of proteins that 
demonstrate dependency upon molecular chaperones are referred to as client proteins, with some 
chaperones displaying more selectivity for their clientele than others.1, 3  
One specific family of molecular chaperones is the heat shock protein (HSP) family.5 As 
suggested by the name, these proteins are responsible for responding to cellular stresses, including 
elevated temperature. In addition to temperature, HSPs respond to various cellular insults 
including xenobiotic toxicity, inflammation, hypoxia, nutrient starvation, and protein 
 
Table 1.1. Cellular locations and primary functions of HSP families. 
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aggregation.6-8 The HSP family is further characterized by the molecular weight of its members; 
for example, the 90 kDa heat shock protein is referred to as Hsp90. Members of the HSP family 
serve roles within various cellular compartments promoting protein homeostasis, as highlighted in 
Table 1.1. Upregulation of these HSPs occurs in many disease states, implicating some of these 
proteins as potential therapeutic targets.9-11 
The 90 kDa Heat Shock Protein Family 
The 90 kDa heat shock protein (Hsp90) family is responsible for the maturation of nascent 
polypeptides as well as the refolding of denatured proteins.12 In fact, over 300 client protein 
substrates have been identified as Hsp90-dependent for their maturation into biologically active 
conformations.13 Hsp90 represents one of the most abundantly expressed proteins within the cell, 
constituting 1-2% of total cellular protein under normal conditions, and under stressed conditions 
such as cancer, this can be elevated to as high as 6%.14 In unstressed cells, Hsp90 promotes 
homeostasis through transient protein folding, protein trafficking, and protein turnover. Under 
stressed conditions, especially in cancer, Hsp90 levels are elevated to accommodate the increased 
demand of protein folding due to upregulated metabolism and constant proliferation.15-16 
Hsp90 Structure 
Hsp90 functions as a homodimer and each monomer is comprised of three domains that support 
its function (Figure 1.1).12, 17 The N-terminal ATP-binding domain is responsible for binding ATP 
in an unconventional, bent conformation that is conserved within the GHKL superfamily of 
proteins (DNA gyrase, Hsp90, histidine kinase, and MutL). This bent conformation, known as a 
Bergerat fold, is in contrast to the typical extended conformation used by most kinases.18 
Consequently, this domain has been the focus of intense drug discovery research, as the majority 
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of known Hsp90 inhibitors bind competitively versus ATP to this pocket.19-22 The middle domain 
is connected to the N-terminal domain via a charged linker and is important for facilitating protein-
protein interactions with various Hsp90 client proteins and co-chaperones. The C-terminal 
dimerization domain is responsible for maintaining the functional Hsp90 homodimer within cells. 
In addition to dimerization, this domain also interacts with co-chaperones that facilitate client 
protein maturation and progression through the Hsp90 chaperone cycle.23-25 
 
Hsp90 Client Proteins 
Hsp90 is responsible for the maturation of more than 300 client protein substrates, many of 
which are involved in signaling pathways that are commonly hijacked during transformation. In 
fact, Hsp90 client proteins are represented in all ten hallmarks of cancer (Table 1.2), including the 
important anti-cancer targets Her2, Bcr-Abl, Raf, ALK, Src, and Akt, suggesting that Hsp90 
inhibition could simultaneously target multiple oncogenic pathways and provide a multi-pronged 
approach toward cancer inhibition.26-28 Due to the high number of Hsp90 client proteins that play 
vital roles in cancer progression, the most studied indication for Hsp90 inhibitors has been for the 
 
Figure 1.1. Homodimeric state of Hsp90 depicting the three different domains. (PDBID: 2O1U). 
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potential treatment of cancer, however Hsp90 has also been implicated in other pathologies.22, 29-
33 
Hsp90 Chaperone Cycle 
While the Hsp90 chaperone cycle is complex, advances in technology and small molecule 
probes have provided insight into this catalytic cycle. The cycle begins with the Hsp90 homodimer 
(A, Figure 1.2), to which a nascent polypeptide or denatured protein is delivered by Hsp70 (B). 
This process is facilitated by the Hsp70-Hsp90 organizing co-chaperone, HOP. After association 
with the nascent polypeptide, various immunophilins, co-chaperones, and partner proteins interact 
with the Hsp90/polypeptide complex to form the heteroprotein complex, C.34 ATP then binds to 
the N-terminal ATP-binding site, followed by p23 association that stabilizes the closed form of 
Hsp90 (D). ATP hydrolysis provides the requisite energy necessary for maturation of the substrate 
protein (E), as well as release of the mature client protein and regeneration the Hsp90 homodimer, 
A.35-36 
 




The Hsp90 chaperone cycle can be disrupted through competitive inhibition of the N-terminal 
ATP-binding domain. In the presence of a competitive, non-hydrolysable inhibitor, ATP is not 
able to bind the N-terminal ATP-binding pocket, which halts the Hsp90 chaperone cycle and 
results in the degradation of client protein substrates via the ubiquitin-proteasome pathway (F).37 
Malignant cells undergo constant proliferation, resulting in an increased need for the synthesis and 
maturation of proteins to maintain cell viability. This increased metabolic rate creates a reliance 
upon Hsp90 for cellular survival, which in turn, results in Hsp90 existing predominantly as the 
heteroprotein complex (C) in oncogenic cells.38-39 This complex possesses ~200-fold higher 
affinity for ATP and other small molecules that bind the N-terminal domain, as compared to the 
Hsp90 homodimer (A), resulting in inherent differential selectivities. Consequently, Hsp90 
inhibitors accumulate in transformed cells at significantly higher concentrations than normal 
tissue.  
 




Humans express four different isoforms of Hsp90: Hsp90α and Hsp90β reside in the cytosol, 
Hsp75/tumor necrosis factor receptor associated protein 1 (TRAP1) is found predominantly in the 
mitochondria, and glucose regulated protein 94 (Grp94) the endoplasmic reticulum (ER) resident 
isoform.12, 40 Deconvolution of the biological processes mediated by of each isoform has proven 
difficult; however, recent work has begun to delineate these roles.33, 41-44 45 
Cytosolic Hsp90α/β 
The cytosolic Hsp90 isoforms have been the most studied isoforms due to their role in the 
maturation of many proteins that are both essential to cell viability and reside in this compartment. 
Numerous crystal and co-crystal structures have been solved for these isoforms, which provides a 
wealth of structural information that has been used to guide the development of Hsp90 inhibitors.46-
49 These two isoforms are 86% identical over the length of the protein, and their N-terminal ATP-
binding domains are 95% identical, differing by only two residues. Many client proteins for these 
isoforms have been identified and include protein kinases, transcription factors, mutated signaling 
proteins, and cell cycle regulators.  
Distinct roles for Hsp90α and Hsp90β have been difficult to elucidate due to their high sequence 
identity, antibody cross reactivity, and the presence of Hsp90α/β heterodimers. However, 
generation of Hsp90α and Hsp90β knockdown cells has assisted in the identification of client 
proteins that are dependent upon each of these isoforms. Hsp90α knockdown studies have 
identified the tyrosine-protein kinase, c-Src, and the anti-apoptotic protein, survivin, as client 
proteins specifically dependent upon this isoform (Table 1.3).41 In addition, Hsp90α is secreted 
into the extracellular matrix, where it contributes to tumor metastasis by stabilizing matrix-
metalloproteinase-2 promoting its proteolytic activity.50 Hsp90β knockdown studies have also 
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identified client proteins dependent upon this isoform, including the chemokine receptor, CXCR4, 
and cell cycle regulators CDK-4 and CDK-6 (Table 1.3).41 In addition to these isoform-specific 
client proteins, other protein substrates that depend upon both isoforms include the MAP kinase, 
ERK5, the steroid hormone receptors, and the receptor tyrosine kinase, Her2.45, 51-52 While client 
proteins of each cytosolic Hsp90 isoform have been identified, many Hsp90-dependent proteins 
have not yet been investigated for their isoform-dependency and therefore warrant further 
investigation to delineate the roles played by each cytosolic isoform.  
ER-resident Grp94 
Grp94 is the Hsp90 resident isoform in the ER and is a major member of the ER chaperone 
system along with other glucose regulated proteins (GRPs, e.g. Grp78). The ER chaperone system 
is responsible for responding to cellular insults, such as redox stress, calcium imbalance, and 
hypoxia, which result in the unfolded protein response (UPR) or ER stress.53-54 Compared to 
Hsp90, Grp94 is only 42-43% identical, but it is ~85% identical within the N-terminal ATP-
binding pocket. This difference in the ATP-binding pocket results from a 5 amino acid insertion 
upstream of the binding pocket, which produces a unique, hydrophobic binding region in the ATP-
binding cavity.55-56 This region can be further divided into two distinct sub-pockets that have been 
utilized to gain selectivity for Grp94 versus the other Hsp90 isoforms.45, 57-58 Such Grp94-selective 
inhibitors and genetic knockdown studies have identified Grp94-dependent client proteins. 
Grp94 is responsible for the maturation and trafficking of proteins associated with cell-to-cell 
signaling and cellular adhesion.43, 54, 59-61 Additional roles played by Grp94 include embryonic 
development, calcium binding, and regulation of innate and adaptive immunity.62 Some Grp94-
specific client proteins include select integrins (α2, α4, αL, and β4), Toll-like receptors (TLR1, 
TLR2, TLR4, and TLR9), insulin-like growth factor-I and –II (IGF-I and –II, respectively), 
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immunoglobulins, low-density lipoprotein receptor-related protein 6 (LRP6), and mutant myocilin 
(Table 1.3).44-45, 59, 63 Recently, Grp94 has gained interest as a potential therapeutic target for 
myocilin-associated open angle glaucoma (mutant myocilin), cancer metastasis (integrins), and 
multiple myeloma (LRP6), which are discussed more thoroughly in Chapters 2, 3, and 4, 
respectively. 43-44, 58, 63-64 
Mitochondrial TRAP1 
The second organelle-specific Hsp90 isoform is the mitochondrial-localized isoform, 
TRAP1.65-66   This isoform exhibits the lowest sequence identity to other Hsp90s (~35%); however 
within its N-terminal ATP-binding site, TRAP1 differs by only four (Hsp90β) and five (Hsp90α) 
residues from the cytosolic isoforms, making TRAP1 more similar to Hsp90 than Grp94. Few co-
crystal structures of TRAP1 are available, and all of these structures are bound to purine-based 
small molecules (non-hydrolysable ATP mimics and purine-based inhibitors).67-69 However, these 
structures provide some insight into TRAP1-structural features that can be utilized to develop 
selective inhibitors.  
TRAP1 is highly expressed in tumorigenic cells and is only expressed at basal (occasionally 
undetectable) levels in normal tissues.70 Unlike other Hsp90 isoforms, no co-chaperones have been 
reported to interact with TRAP1, likely due to predominant localization of TRAP1 to the 
mitochondrial matrix wherein other Hsp90 co-chaperones do not accumulate as they lack a 
genetically encoded mitochondrial targeting sequence.65 TRAP1 was first identified to play a 
cytoprotective role against mitochondrial apoptosis. Further studies via TRAP1 silencing by small 
interfering RNA (siRNA) revealed that decreased levels of TRAP1 activated apoptosis, 
culminating in the release of apoptogenic proteins into the cytosol, including cytochrome c, and 
activation of caspase induced cell death.71-72 In addition to its apparent anti-apoptotic function, 
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TRAP1 also plays an important role during oxidative stress, by allowing cells to escape activation 
of reactive oxygen species-mediated apoptosis. Studies aimed at the identification of TRAP1 
interactors within the mitochondria revealed cyclophilin D (CypD).70 CypD is a component of the 
mitochondrial membrane transition pore (MTP), and formation of the MTP is widely believed to 
initiate mitochondrial apoptosis. Under normal conditions, TRAP1 antagonizes the actions of 
CypD, but disruption of this interaction can lead to the initiation of apoptosis. Additional TRAP1 
interacting proteins include the calcium binding protein, sorcin, the AAA-ATPase proteasome 
regulatory protein, TBP7, the β-subunit of F1F0 ATP synthase, and succinate dehydrogenase 
(Table 1.3).73 Low basal expression of TRAP1 in non-transformed cells could represent a 
mechanism to selectively target cancer via disruption of TRAP1 interactions with apoptogenic 
proteins. 
Pan-Hsp90 Inhibitors in Clinical Trials 
Traditionally, Hsp90 inhibitors have been inspired by the endogenous ligand ATP and natural 
products. The first Hsp90 inhibitor discovered was the benzoquinone ansamycin natural product, 
geldanamycin (GDA, Figure 1.3). GDA exhibited potent antitumor activity in a variety of cancer 
cell lines and was identified as an Hsp90 inhibitor in 1994, when Whitesell and co-workers 
demonstrated that treatment of prostate cancer cells with GDA inhibited Hsp90 led to degradation 
 
Table 1.3. Some Hsp90 interactors demonstrate specificity towards individual Hsp90 isoforms. 
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of the oncogenic client protein, v-Src.74 Despite the excellent tumor activity exhibited by GDA, 
its clinical utility was hindered by hepatoxicity, low chemical stability, and poor solubility.75 
However, structural analogues of GDA are currently under clinical investigation, including 17-N-
allylamino-17-demethoxygeldanamycin (17-AAG). 17-AAG was the first Hsp90 inhibitor to enter 
into clinical trials in 1999 for cancer; however, further development has been hindered by dose-
limiting toxicities.76 
The resorcinol lactone, radicicol (RDC, Figure 1.3), was identified as an Hsp90 inhibitor after 
it exhibited similar cellular effects and competed with GDA for the Hsp90 N-terminal ATP-
binding site.77 Despite the potent anti-cancer effects in cellular cancer models, RDC exhibited no 
 
Figure 1.3. pan-Hsp90 inhibitory classes and clinical candidates. Pharmacophores are colored by individual 
classes of inhibitors. 
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activity in animal models due to rapid metabolism to inactive metabolites and its electrophilic 
nature (allylic epoxide and α,β,γ,δ-unsaturated ketone). Although RDC never advanced beyond 
cellular studies, it did provide a new pharmacophore for development of the resorcinol class of 
Hsp90 inhibitors. This class of inhibitors possesses the resorcinol ring of RDC along with a 
surrogate of the macrolactone via heterocycles (STA-9090 and NVP-AUY922) or an amide 
(AT13387) that increases affinity and modulates the pharmacokinetic properties.78-80 Currently, 
these three resorcinol-based inhibitors are under clinical investigation for various forms of cancer. 
In addition to the inspiration derived from natural products GDA and RDC, the endogenous 
ligand ATP has served as a starting point for development of the purine-based Hsp90 inhibitor 
class. Utilizing the purine-core of ATP, Chiosis and co-workers used a structure-based approach 
to append the purine ring to a non-hydrolysable aryl side chain that could mimic the phosphate 
group of ATP within the nucleotide-binding site.81 Optimization of the aryl side chain and the 
inclusion of a solubilizing amine produced the first purine-based clinical candidate, PU-H71 
(Figure 1.3), which remains under Phase 1 clinical evaluation in patients with metastatic solid 
tumors, lymphoma, or myeloproliferative neoplasms.75 
Detriments Associated with pan-Hsp90 Inhibition 
While there have been significant efforts to develop Hsp90 inhibitors for the treatment of 
cancer, noteworthy challenges have emerged during clinical evaluation. Ocular, hepato-, and 
cardiotoxicities, as well as scheduling and dosing issues have dampened enthusiasm for the 
advancement of such inhibitors.  
Induction of the Heat Shock Response 
The pro-survival heat shock response (HSR) is a natural cellular occurrence to exogenous 
stresses in which the production of HSPs is increased to restore homeostasis.82-84 One clinically 
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relevant concern is that administration of N-terminal Hsp90 inhibitors induces the HSR. This effect 
is mediated through the transcription factor, heat shock factor-1 (HSF-1). Under normal 
conditions, HSF-1 is associated with Hsp90 in an inactive state.85-86 However, in the presence of 
an N-terminal inhibitor or a stress stimulus, HSF-1 dissociates from Hsp90, trimerizes and 
becomes phosphorylated to generate the activated form of this transcription factor (Figure 1.4).87-
89 Upon activation, HSF-1 translocates to the nucleus, where it binds the heat shock element and 
induces transcription of Hsp90 and other HSPs. Due to the upregulation of Hsp90 and other heat 
shock proteins that serve a cytoprotective role within the cell, the effects of Hsp90 inhibitors are 
negated and represent a serious obstacle in the clinical setting. The increased expression of Hsp90 
produces severe dosing and scheduling difficulties.90-91 
Toxicities 
Additional challenges were also observed in the clinic, including ocular, hepato-, and 
cardiotoxicities. It is not well understood whether these toxicities result from on-target effects or 
are a consequence of the different inhibitory scaffolds. During the clinical evaluation of 17-AAG 
(Figure 1.3), dose-limiting hepatotoxicities were observed, which is likely scaffold-dependent, as 
 




this molecule contains a redox-active quinone.90, 92 Quinones are susceptible to oxidation via 
cytochromes P450, producing reactive intermediates that can result in oxidative damage to the 
cell.93-95 In addition, quinones are electrophilic and can react with biological nucleophiles, such as 
thiols. This reactivity can deplete reducing agents (e.g. glutathione) and produce toxic byproducts 
that further increase toxicities.96 These detriments, combined with the modest efficacy exhibited 
by 17-AAG as a monotherapy, have tapered enthusiasm for development of the ansamycin-based 
Hsp90 inhibitors. 
A second toxicity observed during clinical trials with Hsp90 inhibitors is cardiotoxicity.75, 90 A 
major source of cardiotoxicity during the drug development process results from disruption of the 
potassium rectifier channel, human ether a-go-go-related gene (hERG) channel, expressed in the 
heart. The hERG channel is responsible for the repolarization of electrical current in cardiac action 
potential.97-98 Inhibition or disruption of this process results in elongation of the QT interval, and 
potentially death.98-101 Previous studies have demonstrated that the α-subunit of this channel, which 
constitutes a major portion of the protein complex, is dependent upon Hsp90 for its maturation and 
trafficking to the cell surface.102-103 Treatment of HEK293 cells expressing the hERG channel with 
GDA (Figure 1.3) retained immature hERG within the ER, which produced decreased hERG-
associated cardiac action potential amplitude.102 Recently, it was determined that hERG maturation 
and trafficking to the cell surface are solely dependent upon the Hsp90α isoform, suggesting that 
inhibition of Hsp90α may contribute to the cardiotoxicities observed in the clinic.104-105  However, 
this effect has not been validated with isoform-selective inhibitors to determine whether this is an 
on-target effect related to Hsp90α inhibition. 
Another major toxicity that has emerged from the clinical evaluation of Hsp90 inhibitors is 
ocular toxicity.105-106 In particular, in a Phase 1 study with NVP-AUY922 (Figure 1.3), 43% of 
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patients reported grade 1 or 2 visual adverse effects in a dose-dependent manner.107 These effects 
included night blindness, photopsia, blurred vision, and visual impairment, which was reversible 
upon discontinuation of NVP-AUY922. The biological mechanism by which these effects 
occurred is not well understood; however, STA-9090 (Figure 1.3) does not appear to produce 
similar effects, suggesting these adverse events may be specific to NVP-AUY922 (Figure 1.3).108-
109 Further investigations into the mechanism by which these ocular toxicities occur is necessary 
to understand whether these effects are scaffold specific or a consequence of on-target toxicities 
related to pan-Hsp90 inhibition. 
Hsp90 Isoform-selective Inhibitors 
As a result of these toxicities and the lack of an approved Hsp90 inhibitor nearly 20 years after 
the first clinical trial was initiated, alternative approaches toward Hsp90 inhibition appear 
necessary to take advantage of the unique biological role played by Hsp90 in various diseases. One 
approach that has gained popularity during the last 5 years is the development of Hsp90 isoform-
selective inhibitors.110 This approach could lower toxic liabilities, as compared to pan-Hsp90 
inhibitors, by reducing the number of client proteins affected by a single agent. The development 
of such agents has been hindered by the fact that the N-terminal ATP-binding site is >85% identical 
between the four Hsp90 isoforms. However, in depth analysis of the N-terminal binding pockets 
of the four isoforms has revealed subtle differences that can be exploited to gain selectivity.  
Hsp90α/β N-terminal ATP-binding Site 
The cytosolic Hsp90 isoforms possess nearly identical N-terminal binding sites and differ by 
only two amino acids. Hsp90β contains Ala52 and Leu91, whereas Ser52 and Ile91 are present in 
Hsp90α (Figure 1.5). These residues are buried deep within the binding site and participate in a 
hydrogen bonding network with Leu48, Asp93, and Thr184 (conserved between the two isoforms) 
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and conserved water molecules. This hydrogen bond network forms interactions with the 
pharmacophores of Hsp90 inhibitors (see Figure 1.3) and induce significant affinity.111 Although 
these differences are small, they have been utilized to selectively inhibit each isoform. The 
presence of Ala52 and Leu91 in Hsp90β results in a small pocket that is typically occupied by 
water molecules that participate in a hydrogen bonding network. Displacement of these water 
molecules via KUNB31 (Figure 1.6) afforded 47-fold selectivity for Hsp90β over the other Hsp90 
isoforms.42 Additionally, the presence of Ser52 in Hsp90α increases these hydrogen bond 
interactions and can be utilized to gain selectivity for this isoform. Hsp90α-selective inhibitors 
have been proposed to utilize this more extensive hydrogen bonding network in order to produce 
 
Figure 1.5. Hydrogen bonding network present at the base of the Hsp90 N-terminal ATP-binding site. (a) 
Interactions of RDC in the ATP-binding site of Hsp90α. The hydrogen bonding network in this isoform is more 
extensive than other isoforms due to the presence of Ser52. (b) Interactions of RDC in the ATP-binding site of 
Hsp90β. Due to the presence of Leu91 and Ala52, Hsp90β is less sterically demanding and displacement of the 













Figure 1.6. KUNB31 is the first Hsp90β-selective inhibitor. 
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selectivity. It is important to note that Hsp90α is the only isoform that possesses Ser52, whereas 
all three other Hsp90 isoforms possess an Ala residue in this location. 
Grp94 Binding Site 
Grp94 is the most unique of the four isoforms, due to a five amino acid insertion into its primary 
sequence resulting in access to a secondary binding pocket. This hydrophobic binding pocket can 
be further divided into two different sub-pockets (S1 and S2). 
The S1 sub-pocket is hydrophobic in nature and is found near the solvent exposed region of the 
Grp94 binding site. The residues that comprise this pocket are Val82, Ile166, Ala167, Phe195, 
Val197, Phe199, Tyr200, and Trp223. Co-crystallization of radamide (RDA, Figure 1.8), a pan-
Hsp90 inhibitor, with Grp94 revealed that the cis-amide conformation could project the quinone 
moiety into the S1 sub-pocket, whereas the co-crystal structure of RDA in complex with yHsp82 
(yeast ortholog of cytosolic Hsp90s) revealed RDA bound solely in the trans-amide conformation 
(Figure 1.7).57 Therefore, the RDA scaffold was predisposed to bind in the cis-amide 
conformation via the incorporation of a cis-amide bioisostere, imidazole, which led to the 
development of the first Grp94-selective inhibitor, BnIm (Figure 1.8).112  Optimization of BnIm 
for Grp94-selectivity and development of second generation Grp94-selective inhibitors are 
discussed in Chapters 2 and 3, respectively.43, 64 
 
Figure 1.7. RDA bound to Grp94 (a) in the cis- and trans-amide conformations and Hsp90 (b) RDA was found 
only in the trans-amide conformation. 
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A high throughput screen of purine-based Hsp90 inhibitors led to the discovery of the S2 sub-
pocket, which is distinct from the S1 sub-pocket utilized by BnIm. The S2 sub-pocket results from 
reorganization of helices 1, 4, and 5, which rotates Phe199 and provides access to the S2 sub-
pocket (Figure 1.9).45 This pocket is located near the adenine-binding region and buried further 
into the protein as compared to the S1 sub-pocket. Similar to the S1 sub-pocket, the S2 sub-pocket 
Figure 1.9. Grp94-selective inhibitors. 
Figure 1.8. Rotation of Phe199 to expose the S2 sub-pocket in Grp94 upon binding of the purine-based inhibitor 
PU-H54. Green = RDA co-crystal structure with Grp94 (PDBID: 2GFD) with the S1 sub-pocket, RDA removed 






is outlined by hydrophobic residues and include Leu104, Phe199, Ala202, Trp223, Val211, and 
Leu249. The S2 sub-pocket has been utilized for Grp94-selecivity by purine-based inhibitors (PU-
H54 and PU-WS13, Figure 1.8) that preferentially interact with this sub-pocket.113 Resorcinol-
based inhibitors have more recently been developed to bind the S2 sub-pocket for increased 
selectivity and are discussed in Chapter 4.58 
TRAP1 Binding Site 
When compared to Hsp90, there are considerably fewer crystal structures of TRAP1. The first 
crystal structure of TRAP1 in complex with a non-hydrolysable ATP mimic was reported in 
2014.67 This structure confirmed a high amino acid identity within the N-terminal ATP-binding 
pocket to the cytosolic Hsp90 isoforms. Subsequent co-crystal structures revealed a four amino 
acid difference between TRAP1 and Hsp90β: Asp102(Glu), Gln157(Val), Asn171(Leu), and 
Ile253(Val).68-69 The side chain of Gln157 extends away from the binding pocket and exposes the 
backbone carbonyl and amide NH for interactions with ligands, suggesting this difference cannot 
be utilized to develop selective inhibitors. The only difference that appears useful for the 
development of selective inhibitors is Asn171 (Figure 1.10a versus 1.10b), which is located just 
before the TRAP1 lid that closes over the N-terminal ATP-binding site upon occupancy by ATP. 
TRAP1 crystal structures revealed the lid (residues 172-201) to be disordered when bound to PU-
H71 (Figure 1.10a), whereas in the presence of ATP mimics bound to TRAP1, this lid was ordered 
(Figure 1.10c). Therefore, stabilization of this lid could provide a mechanism to selectively inhibit 
TRAP1 versus other Hsp90 isoforms. Further discussion of the TRAP1 binding site and the 
development of TRAP1-selective ligands is presented in Chapter 5. 
Due to the predominant localization of TRAP1 to the mitochondria, the attachment of 
mitochondrial targeting moieties to small molecule Hsp90 inhibitors has been utilized to study 
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TRAP1. Mitochondria are responsible for production of ATP through oxidative phosphorylation. 
In order to perform this process, a proton gradient exists across the mitochondrial membrane, 
resulting in a membrane potential that is used to drive the synthesis of ATP. Delocalized lipophilic 
cations (DLCs) are capable of penetrating the cellular and mitochondrial membranes due to their 
lipophilicity and accumulate within the mitochondria due to the negative inner membrane potential 
of functioning mitochondria.68, 114-115 The most commonly utilized DLC is the 
triphenylphosphonium (TPP) cation. Incorporation of this moiety, via a linker, onto the ansamycin 
scaffold provided the mitochondria-targeted gamitrinib class of inhibitors (Figure 1.11).115 These 
inhibitors induced mitochondrial apoptosis against a variety of prostate cancer cell lines. 
 
Figure 1.10. TRAP1 co-crystal structures reveal differences that can be utilized for selectivity. (a) PU-H71 bound 
to TRAP1 depicts the disordered lid region (oval) and Asn171. (b) PU-H71 bound to Hsp90α showing Leu107 in 
a similar position to Asn171 of TRAP1. (c) ADPNP, a non-hydrolysable ATP mimic, bound to TRAP1 revealing 









Additionally, the TPP moiety has been incorporated into the purine scaffold (SMTIN-P01, Figure 
1.11), and these compounds demonstrated superior efficacy in cell models as compared to the non-
TPP conjugated purine inhibitor (PU-H71).68 While this strategy has proven successful for the 
development of mitochondrial-targeted small molecules, these compounds exhibit reduced drug-
like properties that hinder their utilization in the clinic.116 Therefore, the development of TRAP1-
selective inhibitors that do not require a mitochondrial targeting motif are highly sought after. 
Recently, the small molecule DN401 (Figure 1.11) was reported that utilizes the Asn171 
substitution described above for TRAP1-selective inhibition.69 This compound forms a water-
mediated hydrogen bond with Asn171 and exhibited 8-fold selectivity for TRAP1 over Hsp90α. 
Cellular studies with this inhibitor demonstrated induction of mitochondrial apoptosis; however, 
western blot analysis at similar concentrations of DN401 revealed this compound to induce the 
degradation of the cytosolic Hsp90-dependent client protein, Akt, suggesting that greater TRAP1-
selectivity is needed in order to eliminate interactions with other Hsp90 isoforms. 
 
Figure 1.11. Mitochondria-targeted Hsp90 inhibitors (left) and TRAP1-selective inhibitor (right). 
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Conclusions and Future Directions for Hsp90 Research 
Molecular chaperones are essential to maintaining a viable cellular environment, especially 
during times of increased cellular stress. The family of Hsp90 isoforms is responsible for restoring 
and stabilizing the biologically active conformation of more than 300 client proteins. Many of 
these proteins are essential for cancer progression, making Hsp90 a highly sought after target for 
the development of anti-cancer therapeutics. To date, more than 17 small molecule Hsp90 
inhibitors have entered clinical trials; however, no inhibitor has been approved by the Food and 
Drug Administration due to the fact that these inhibitors manifest several concerns, including dose-
limiting toxicities (ocular, hepato-, and cardiotoxicity), dosing and scheduling problems due to 
induction of the HSR, and limited efficacy as single agents. These issues have diminished 
enthusiasm for Hsp90 as a therapeutic target; however, they also demonstrate a need for alternative 
strategies for Hsp90 inhibition to further understand the biological roles of this molecular 
chaperone. 
One strategy that has gained considerable attention in recent years is the development of 
isoform-selective inhibitors. Investigations into the roles played by individual isoforms has 
revealed that some client proteins are dependent upon a specific isoform suggesting that cancers 
driven by specific oncogenic proteins may depend upon a unique Hsp90 isoform. In addition, 
isoform-selective inhibitors could reduce the liabilities and issues associated with pan-Hsp90 
inhibitors and potentially provide superior efficacy for the disease states that are reliant upon a 
specific isoform.  
The development of Hsp90 isoform-selective inhibitors is hindered by the fact that all four 
isoforms possess >85% identity within their N-terminal ATP-binding site. However, through 
rational, structure-based drug design, these small differences can be exploited to develop such 
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inhibitors. Grp94-selective inhibitors have been the most investigated to date, since Grp94 is the 
most unique isoform. In fact, these inhibitors have demonstrated efficacy in cellular models for 
glaucoma, cancer metastasis, multiple myeloma, and Her2-positive breast cancers, suggesting a 
potential for the development of targeted therapies for these diseases. It is hypothesized that 
isoform-selective inhibitors of the remaining isoforms could demonstrate a similar, if not larger, 
impact on various disease states. 
The development of isoform-selective inhibitors provides an attractive strategy to revive Hsp90 
research. In order to fully utilize isoform-selective inhibitors, much work must be done in order to 
identify client proteins dependent upon specific isoforms since there are currently only a handful 
of isoform-specific client proteins identified, but the family of Hsp90 proteins is known to interact 
with more than 300 distinct proteins within the cell. These studies would aid in the identification 
of disease states that are dependent upon specific isoforms and allow for the development of 
isoform-selective inhibitors as potential targeted therapies for these indications. 
References 
1.    Hartl, F. U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and 
proteostasis. Nature 2011, 475, 324-332. 
2.    Kim, Y. E.; Hipp, M. S.; Bracher, A.; Hayer-Hartl, M.; Hartl, F. U. Molecular chaperone 
functions in protein folding and proteostasis. Annu. Rev. Biochem 2013, 82, 323-355. 
3.    Buchberger, A.; Bukau, B.; Sommer, T. Protein quality control in the cytosol and the 
endoplasmic reticulum: brothers in arms. Mol. Cell 2010, 40, 238-252. 
4.    Walter, S.; Buchner, J. Molecular chaperones--cellular machines for protein folding. Angew. 
Chem. Int. Ed. Engl. 2002, 41, 1098-1113. 
23 
 
5.    Li, Z.; Srivastava, P. Heat-shock proteins. Curr. Protoc. Immunol. 2004, Appendix 1, Appendix 
1T. 
6.    Koller, M.; Hensler, T.; Konig, B.; Prevost, G.; Alouf, J.; Konig, W. Induction of heat-shock 
proteins by bacterial toxins, lipid mediators and cytokines in human leukocytes. Zentralbl. 
Bakteriol. 1993, 278, 365-376. 
7.    Pockley, A. G. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 
2002, 105, 1012-1017. 
8.    Benjamin, I. J.; Kroger, B.; Williams, R. S. Activation of the heat shock transcription factor 
by hypoxia in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 6263-6267. 
9.    Almeida, M. B.; do Nascimento, J. L.; Herculano, A. M.; Crespo-Lopez, M. E. Molecular 
chaperones: toward new therapeutic tools. Biomed. Pharmacother. 2011, 65, 239-243. 
10.    Soti, C.; Nagy, E.; Giricz, Z.; Vigh, L.; Csermely, P.; Ferdinandy, P. Heat shock proteins as 
emerging therapeutic targets. Br. J. Pharmacol. 2005, 146, 769-780. 
11.    Ciocca, D. R.; Calderwood, S. K. Heat shock proteins in cancer: diagnostic, prognostic, 
predictive, and treatment implications. Cell Stress Chaperones 2005, 10, 86-103. 
12.    Csermely, P.; Schnaider, T.; Soti, C.; Prohaszka, Z.; Nardai, G. The 90-kDa molecular 
chaperone family: structure, function, and clinical applications. A comprehensive review. 
Pharmacol. Ther. 1998, 79, 129-168. 
13.    Picard, D. Hsp90 Interactors. https://www.picard.ch/downloads. 
14.    Lai, B. T.; Chin, N. W.; Stanek, A. E.; Keh, W.; Lanks, K. W. Quantitation and intracellular 
localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies. Mol. 
Cell. Biol. 1984, 4, 2802-2810. 
24 
 
15.    Prodromou, C. Strategies for stalling malignancy: targeting cancer's addiction to Hsp90. 
Curr. Top. Med. Chem. 2009, 9, 1352-1368. 
16.    Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic 
opportunity. Mol. Cancer Ther. 2004, 3, 1021-1030. 
17.    Li, J.; Buchner, J. Structure, function and regulation of the hsp90 machinery. Biomed. J. 
2013, 36, 106-117. 
18.    McLaughlin, S. H.; Ventouras, L. A.; Lobbezoo, B.; Jackson, S. E. Independent ATPase 
activity of Hsp90 subunits creates a flexible assembly platform. J. Mol. Biol. 2004, 344, 813-826. 
19.    Centenera, M. M.; Fitzpatrick, A. K.; Tilley, W. D.; Butler, L. M. Hsp90: still a viable target 
in prostate cancer. Biochim. Biophys. Acta 2013, 1835, 211-218. 
20.    Hong, D. S.; Banerji, U.; Tavana, B.; George, G. C.; Aaron, J.; Kurzrock, R. Targeting the 
molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer 
Treat. Rev. 2013, 39, 375-387. 
21.    Messaoudi, S.; Peyrat, J. F.; Brion, J. D.; Alami, M. Heat-shock protein 90 inhibitors as 
antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 2011, 21, 
1501-1542. 
22.    Trepel, J.; Mollapour, M.; Giaccone, G.; Neckers, L. Targeting the dynamic HSP90 complex 
in cancer. Nat. Rev. Cancer 2010, 10, 537-549. 
23.    Meyer, P.; Prodromou, C.; Liao, C.; Hu, B.; Mark Roe, S.; Vaughan, C. K.; Vlasic, I.; 
Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural basis for recruitment of the ATPase activator 
Aha1 to the Hsp90 chaperone machinery. EMBO J. 2004, 23, 511-519. 
25 
 
24.    Harris, S. F.; Shiau, A. K.; Agard, D. A. The crystal structure of the carboxy-terminal 
dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. 
Structure 2004, 12, 1087-1097. 
25.    Wayne, N.; Bolon, D. N. Dimerization of Hsp90 is required for in vivo function. Design and 
analysis of monomers and dimers. J. Biol. Chem. 2007, 282, 35386-35395. 
26.    Miyata, Y.; Nakamoto, H.; Neckers, L. The therapeutic target Hsp90 and cancer hallmarks. 
Curr. Pharm. Des. 2013, 19, 347-365. 
27.    Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-
674. 
28.    Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70. 
29.    Barrott, J. J.; Haystead, T. A. Hsp90, an unlikely ally in the war on cancer. FEBS J. 2013, 
280, 1381-1396. 
30.    Blair, L. J.; Sabbagh, J. J.; Dickey, C. A. Targeting Hsp90 and its co-chaperones to treat 
Alzheimer's disease. Expert Opin. Ther. Targets 2014, 18, 1219-1232. 
31.    Luo, W.; Sun, W.; Taldone, T.; Rodina, A.; Chiosis, G. Heat shock protein 90 in 
neurodegenerative diseases. Mol. Neurodegener. 2010, 5, 24. 
32.    Dobrowsky, R. T. Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy. 
Curr. Diab. Rep. 2016, 16, 71. 
33.    Suntharalingam, A.; Abisambra, J. F.; O'Leary, J. C.; Koren, J.; Zhang, B.; Joe, M. K.; Blair, 
L. J.; Hill, S. E.; Jinwal, U. K.; Cockman, M.; Duerfeldt, A. S.; Tomarev, S.; Blagg, B. S.; 
Lieberman, R. L.; Dickey, C. A. Glucose-regulated protein 94 triage of mutant myocilin through 
endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance 
mechanism. J. Biol. Chem. 2012, 287, 40661-40669. 
26 
 
34.    Rohl, A.; Rohrberg, J.; Buchner, J. The chaperone Hsp90: changing partners for demanding 
clients. Trends Biochem. Sci. 2013, 38, 253-262. 
35.    Prodromou, C. The 'active life' of Hsp90 complexes. Biochim. Biophys. Acta 2012, 1823, 
614-623. 
36.    Hall, J. A.; Forsberg, L. K.; Blagg, B. S. Alternative approaches to Hsp90 modulation for the 
treatment of cancer. Future Med. Chem. 2014, 6, 1587-1605. 
37.    Tillotson, B.; Slocum, K.; Coco, J.; Whitebread, N.; Thomas, B.; West, K. A.; MacDougall, 
J.; Ge, J.; Ali, J. A.; Palombella, V. J.; Normant, E.; Adams, J.; Fritz, C. C. Hsp90 (heat shock 
protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor 
growth arrest in vivo. J. Biol. Chem. 2010, 285, 39835-39843. 
38.    Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. 
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 
2003, 425, 407-410. 
39.    Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol. 
Med. 2004, 10, 47-51. 
40.    Sreedhar, A. S.; Kalmar, E.; Csermely, P.; Shen, Y. F. Hsp90 isoforms: functions, expression 
and clinical importance. FEBS Lett. 2004, 562, 11-15. 
41.    Liu, W.; Vielhauer, G. A.; Holzbeierlein, J. M.; Zhao, H.; Ghosh, S.; Brown, D.; Lee, E.; 
Blagg, B. S. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that 




42.    Khandelwal, A. K., C. N.; Balch, M.; Peng, S.; Mishra, S. J.; Deng, J.; Day, V. W.; Liu, W.; 
Holzbeierlein, J. M.; Matts, R.; Blagg, B. S. Structure-guided design of the first Hsp90b N-terminal 
isoform-selective inhibitor. Nat. Commun. 2017, In Press. 
43.    Crowley, V.; Huard, D.; Lieberman, R.; Blagg, B. Second Generation Grp94-selective 
Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer. Chem. Eur. J. 2017, In 
press. 
44.    Hua, Y.; White-Gilbertson, S.; Kellner, J.; Rachidi, S.; Usmani, S. Z.; Chiosis, G.; Depinho, 
R.; Li, Z.; Liu, B. Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. 
Clin. Cancer Res. 2013, 19, 6242-6251. 
45.    Patel, P. D.; Yan, P.; Seidler, P. M.; Patel, H. J.; Sun, W.; Yang, C.; Que, N. S.; Taldone, T.; 
Finotti, P.; Stephani, R. A.; Gewirth, D. T.; Chiosis, G. Paralog-selective Hsp90 inhibitors define 
tumor-specific regulation of HER2. Nat. Chem. Biol. 2013, 9, 677-684. 
46.    Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Structural 
basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and 
geldanamycin. J. Med. Chem. 1999, 42, 260-266. 
47.    Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; 
Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; 
Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to 
HSP90 isoforms. Chem. Biol. 2004, 11, 775-785. 
48.    Ernst, J. T.; Liu, M.; Zuccola, H.; Neubert, T.; Beaumont, K.; Turnbull, A.; Kallel, A.; 
Vought, B.; Stamos, D. Correlation between chemotype-dependent binding conformations of 
HSP90alpha/beta and isoform selectivity-Implications for the structure-based design of 
28 
 
HSP90alpha/beta selective inhibitors for treating neurodegenerative diseases. Bioorg. Med. Chem. 
Lett. 2014, 24, 204-208. 
49.    Ernst, J. T.; Neubert, T.; Liu, M.; Sperry, S.; Zuccola, H.; Turnbull, A.; Fleck, B.; Kargo, 
W.; Woody, L.; Chiang, P.; Tran, D.; Chen, W.; Snyder, P.; Alcacio, T.; Nezami, A.; Reynolds, 
J.; Alvi, K.; Goulet, L.; Stamos, D. Identification of novel HSP90alpha/beta isoform selective 
inhibitors using structure-based drug design. demonstration of potential utility in treating CNS 
disorders such as Huntington's disease. J. Med. Chem. 2014, 57, 3382-3400. 
50.    Song, X.; Wang, X.; Zhuo, W.; Shi, H.; Feng, D.; Sun, Y.; Liang, Y.; Fu, Y.; Zhou, D.; Luo, 
Y. The regulatory mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2 
processing and tumor angiogenesis. J. Biol. Chem. 2010, 285, 40039-40049. 
51.    Echeverria, P. C.; Picard, D. Molecular chaperones, essential partners of steroid hormone 
receptors for activity and mobility. Biochim. Biophys. Acta 2010, 1803, 641-649. 
52.    Citri, A.; Kochupurakkal, B. S.; Yarden, Y. The achilles heel of ErbB-2/HER2: regulation 
by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004, 
3, 51-60. 
53.    Wang, M.; Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding 
environment on cancer development. Nat. Rev. Cancer 2014, 14, 581-597. 
54.    Lee, A. S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic 
potential. Nat. Rev. Cancer 2014, 14, 263-276. 
55.    Dollins, D. E.; Warren, J. J.; Immormino, R. M.; Gewirth, D. T. Structures of GRP94-
nucleotide complexes reveal mechanistic differences between the Hsp90 chaperones. Mol. Cell 
2007, 28, 41-56. 
29 
 
56.    Immormino, R. M.; Dollins, D. E.; Shaffer, P. L.; Soldano, K. L.; Walker, M. A.; Gewirth, 
D. T. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 
chaperone. J. Biol. Chem. 2004, 279, 46162-46171. 
57.    Immormino, R. M.; Metzger, L. E. t.; Reardon, P. N.; Dollins, D. E.; Blagg, B. S.; Gewirth, 
D. T. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications 
for paralog-specific drug design. J. Mol. Biol. 2009, 388, 1033-1042. 
58.    Khandelwal, A. C., V. M.; Blagg, B. S. Resorcinol-Based Grp94-Selective Inhibitors. ACS 
Med. Chem. Lett. 2017, 8, 1013-1018. 
59.    Marzec, M.; Eletto, D.; Argon, Y. GRP94: An HSP90-like protein specialized for protein 
folding and quality control in the endoplasmic reticulum. Biochim. Biophys. Acta 2012, 1823, 774-
787. 
60.    Ghosh, S.; Shinogle, H. E.; Galeva, N. A.; Dobrowsky, R. T.; Blagg, B. S. Endoplasmic 
reticulum resident heat shock protein 90 (Hsp90) isoform glucose-regulated protein 94 (Grp94) 
regulates cell polarity and cancer cell migration by affecting intracellular transport. J. Biol. Chem. 
2016, 291, 8309-8323. 
61.    Wu, S.; Hong, F.; Gewirth, D.; Guo, B.; Liu, B.; Li, Z. The molecular chaperone gp96/GRP94 
interacts with Toll-like receptors and integrins via its C-terminal hydrophobic domain. J. Biol. 
Chem. 2012, 287, 6735-6742. 
62.    Wanderling, S.; Simen, B. B.; Ostrovsky, O.; Ahmed, N. T.; Vogen, S. M.; Gidalevitz, T.; 
Argon, Y. GRP94 is essential for mesoderm induction and muscle development because it 
regulates insulin-like growth factor secretion. Mol. Biol. Cell 2007, 18, 3764-3775. 
30 
 
63.    Stothert, A. R.; Suntharalingam, A.; Huard, D. J.; Fontaine, S. N.; Crowley, V. M.; Mishra, 
S.; Blagg, B. S.; Lieberman, R. L.; Dickey, C. A. Exploiting the interaction between Grp94 and 
aggregated myocilin to treat glaucoma. Hum. Mol. Genet. 2014, 23, 6470-6480. 
64.    Crowley, V. M.; Khandelwal, A.; Mishra, S.; Stothert, A. R.; Huard, D. J.; Zhao, J.; Muth, 
A.; Duerfeldt, A. S.; Kizziah, J. L.; Lieberman, R. L.; Dickey, C. A.; Blagg, B. S. Development of 
Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold. J. 
Med. Chem. 2016, 59, 3471-3488. 
65.    Cechetto, J. D.; Gupta, R. S. Immunoelectron microscopy provides evidence that tumor 
necrosis factor receptor-associated protein 1 (TRAP-1) is a mitochondrial protein which also 
localizes at specific extramitochondrial sites. Exp. Cell Res. 2000, 260, 30-39. 
66.    Felts, S. J.; Owen, B. A.; Nguyen, P.; Trepel, J.; Donner, D. B.; Toft, D. O. The hsp90-related 
protein TRAP1 is a mitochondrial protein with distinct functional properties. J. Biol. Chem. 2000, 
275, 3305-3312. 
67.    Lavery, L. A.; Partridge, J. R.; Ramelot, T. A.; Elnatan, D.; Kennedy, M. A.; Agard, D. A. 
Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step 
ATP hydrolysis mechanism. Mol. Cell 2014, 53, 330-343. 
68.    Lee, C.; Park, H. K.; Jeong, H.; Lim, J.; Lee, A. J.; Cheon, K. Y.; Kim, C. S.; Thomas, A. P.; 
Bae, B.; Kim, N. D.; Kim, S. H.; Suh, P. G.; Ryu, J. H.; Kang, B. H. Development of a 
mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. J. Am. 
Chem. Soc. 2015, 137, 4358-4367. 
69.    Park, H. K.; Jeong, H.; Ko, E.; Lee, G.; Lee, J. E.; Lee, S. K.; Lee, A. J.; Im, J. Y.; Hu, S.; 
Kim, S. H.; Lee, J. H.; Lee, C.; Kang, S.; Kang, B. H. Paralog Specificity Determines Subcellular 
31 
 
Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors. J. Med. Chem. 
2017, 60, 7569-7578. 
70.    Kang, B. H.; Plescia, J.; Dohi, T.; Rosa, J.; Doxsey, S. J.; Altieri, D. C. Regulation of tumor 
cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 
131, 257-270. 
71.    Green, D. R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 
305, 626-629. 
72.    Masuda, Y.; Shima, G.; Aiuchi, T.; Horie, M.; Hori, K.; Nakajo, S.; Kajimoto, S.; Shibayama-
Imazu, T.; Nakaya, K. Involvement of tumor necrosis factor receptor-associated protein 1 
(TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J. Biol. Chem. 2004, 279, 
42503-42515. 
73.    Amoroso, M. R.; Matassa, D. S.; Laudiero, G.; Egorova, A. V.; Polishchuk, R. S.; Maddalena, 
F.; Piscazzi, A.; Paladino, S.; Sarnataro, D.; Garbi, C.; Landriscina, M.; Esposito, F. TRAP1 and 
the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control 
cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ. 2012, 19, 592-604. 
74.    Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of 
heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone 
ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. 
U. S. A. 1994, 91, 8324-8328. 
75.    Khandelwal, A.; Crowley, V. M.; Blagg, B. S. Natural product inspired N-terminal Hsp90 
inhibitors: from bench to bedside? Med. Res. Rev. 2016, 36, 92-118. 
76.    Bhat, R.; Tummalapalli, S. R.; Rotella, D. P. Progress in the discovery and development of 
heat shock protein 90 (Hsp90) inhibitors. J. Med. Chem. 2014, 57, 8718-8728. 
32 
 
77.    Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; Toft, D.; Neckers, L. M. 
Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic 
activities with geldanamycin. Cell Stress Chaperones 1998, 3, 100-108. 
78.    Shimamura, T.; Perera, S. A.; Foley, K. P.; Sang, J.; Rodig, S. J.; Inoue, T.; Chen, L.; Li, D.; 
Carretero, J.; Li, Y. C.; Sinha, P.; Carey, C. D.; Borgman, C. L.; Jimenez, J. P.; Meyerson, M.; 
Ying, W.; Barsoum, J.; Wong, K. K.; Shapiro, G. I. Ganetespib (STA-9090), a nongeldanamycin 
HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung 
cancer. Clin. Cancer Res. 2012, 18, 4973-4985. 
79.    Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, 
K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; 
Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, 
A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; 
Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, 
M.; Workman, P.; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential 
therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218. 
80.    Woodhead, A. J.; Angove, H.; Carr, M. G.; Chessari, G.; Congreve, M.; Coyle, J. E.; Cosme, 
J.; Graham, B.; Day, P. J.; Downham, R.; Fazal, L.; Feltell, R.; Figueroa, E.; Frederickson, M.; 
Lewis, J.; McMenamin, R.; Murray, C. W.; O'Brien, M. A.; Parra, L.; Patel, S.; Phillips, T.; Rees, 
D. C.; Rich, S.; Smith, D. M.; Trewartha, G.; Vinkovic, M.; Williams, B.; Woolford, A. J. 
Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-
dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 
by fragment based drug design. J. Med. Chem. 2010, 53, 5956-5969. 
33 
 
81.    Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold 
novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the 
degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564. 
82.    Hecker, M.; Schumann, W.; Volker, U. Heat-shock and general stress response in Bacillus 
subtilis. Mol. Microbiol. 1996, 19, 417-428. 
83.    Conde, R.; Belak, Z. R.; Nair, M.; O'Carroll, R. F.; Ovsenek, N. Modulation of Hsf1 activity 
by novobiocin and geldanamycin. Biochem. Cell Biol. 2009, 87, 845-851. 
84.    McCollum, A. K.; TenEyck, C. J.; Stensgard, B.; Morlan, B. W.; Ballman, K. V.; Jenkins, 
R. B.; Toft, D. O.; Erlichman, C. P-Glycoprotein-mediated resistance to Hsp90-directed therapy 
is eclipsed by the heat shock response. Cancer Res. 2008, 68, 7419-7427. 
85.    Shi, Y.; Mosser, D. D.; Morimoto, R. I. Molecular chaperones as HSF1-specific 
transcriptional repressors. Genes Dev. 1998, 12, 654-666. 
86.    Zou, J.; Guo, Y.; Guettouche, T.; Smith, D. F.; Voellmy, R. Repression of heat shock 
transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive 
complex with HSF1. Cell 1998, 94, 471-480. 
87.    Bagatell, R.; Paine-Murrieta, G. D.; Taylor, C. W.; Pulcini, E. J.; Akinaga, S.; Benjamin, I. 
J.; Whitesell, L. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic 
activity of hsp90-binding agents. Clin. Cancer Res. 2000, 6, 3312-3318. 
88.    Zuo, J.; Rungger, D.; Voellmy, R. Multiple layers of regulation of human heat shock 
transcription factor 1. Mol. Cell. Biol. 1995, 15, 4319-4330. 
89.    Xia, W.; Voellmy, R. Hyperphosphorylation of heat shock transcription factor 1 is correlated 




90.    Holzbeierlein, J. M.; Windsperger, A.; Vielhauer, G. Hsp90: a drug target? Curr. Oncol. Rep. 
2010, 12, 95-101. 
91.    Gao, Z.; Garcia-Echeverria, C.; Jensen, M. R. Hsp90 inhibitors: clinical development and 
future opportunities in oncology therapy. Curr. Opin. Drug Discov. Devel. 2010, 13, 193-202. 
92.    Biamonte, M. A.; Van de Water, R.; Arndt, J. W.; Scannevin, R. H.; Perret, D.; Lee, W. C. 
Heat shock protein 90: inhibitors in clinical trials. J. Med. Chem. 2010, 53, 3-17. 
93.    Ishihara, Y.; Ishii, S.; Sakai, Y.; Yamamura, N.; Onishi, Y.; Shimamoto, N. Crucial role of 
cytochrome P450 in hepatotoxicity induced by 2,3-dimethoxy-1,4-naphthoquinone in rats. J. Appl. 
Toxicol. 2011, 31, 173-178. 
94.    Ishihara, Y.; Shimamoto, N., A Role of Cytochrome P450 in Quinone-Induced 
Hepatotoxicity. In Hepatotoxicity, John Wiley & Sons, Ltd: 2008; pp 287-297. 
95.    Berlin, V.; Haseltine, W. A. Reduction of adriamycin to a semiquinone-free radical by 
NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular 
oxygen. J. Biol. Chem. 1981, 256, 4747-4756. 
96.    Brunmark, A.; Cadenas, E. Redox and addition chemistry of quinoid compounds and its 
biological implications. Free Radic. Biol. Med. 1989, 7, 435-477. 
97.    Perrin, M. J.; Subbiah, R. N.; Vandenberg, J. I.; Hill, A. P. Human ether-a-go-go related gene 
(hERG) K+ channels: function and dysfunction. Prog. Biophys. Mol. Biol. 2008, 98, 137-148. 
98.    Vandenberg, J. I.; Walker, B. D.; Campbell, T. J. HERG K+ channels: friend and foe. Trends 
Pharmacol. Sci. 2001, 22, 240-246. 
99.    Fermini, B.; Fossa, A. A. The impact of drug-induced QT interval prolongation on drug 
discovery and development. Nat. Rev. Drug Discov. 2003, 2, 439-447. 
35 
 
100.    Brown, A. M. HERG block, QT liability and sudden cardiac death. Novartis Found. Symp. 
2005, 266, 118-131; discussion 131-115, 155-118. 
101.    Wible, B. A.; Hawryluk, P.; Ficker, E.; Kuryshev, Y. A.; Kirsch, G.; Brown, A. M. HERG-
Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. 
Toxicol. Methods 2005, 52, 136-145. 
102.    Ficker, E.; Dennis, A. T.; Wang, L.; Brown, A. M. Role of the cytosolic chaperones Hsp70 
and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. 2003, 92, e87-100. 
103.    Nanduri, J.; Bergson, P.; Wang, N.; Ficker, E.; Prabhakar, N. R. Hypoxia inhibits maturation 
and trafficking of hERG K(+) channel protein: Role of Hsp90 and ROS. Biochem. Biophys. Res. 
Commun. 2009, 388, 212-216. 
104.    Peterson, L. B.; Eskew, J. D.; Vielhauer, G. A.; Blagg, B. S. The hERG channel is dependent 
upon the Hsp90 isoform for maturation and trafficking. Mol. Pharm. 2012, 9, 1841-1846. 
105.    Rajan, A.; Kelly, R. J.; Trepel, J. B.; Kim, Y. S.; Alarcon, S. V.; Kummar, S.; Gutierrez, 
M.; Crandon, S.; Zein, W. M.; Jain, L.; Mannargudi, B.; Figg, W. D.; Houk, B. E.; Shnaidman, 
M.; Brega, N.; Giaccone, G. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable 
heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and 
lymphomas. Clin. Cancer Res. 2011, 17, 6831-6839. 
106.    Wu, W. C.; Wu, M. H.; Chang, Y. C.; Hsieh, M. C.; Wu, H. J.; Cheng, K. C.; Lai, Y. H.; 
Kao, Y. H. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment 
epithelial cells. Exp. Eye Res. 2010, 91, 211-219. 
107.    Sessa, C.; Shapiro, G. I.; Bhalla, K. N.; Britten, C.; Jacks, K. S.; Mita, M.; 
Papadimitrakopoulou, V.; Pluard, T.; Samuel, T. A.; Akimov, M.; Quadt, C.; Fernandez-Ibarra, 
C.; Lu, H.; Bailey, S.; Chica, S.; Banerji, U. First-in-human phase I dose-escalation study of the 
36 
 
HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin. Cancer Res. 2013, 19, 
3671-3680. 
108.    Roman, D.; VerHoeve, J.; Schadt, H.; Vicart, A.; Walker, U. J.; Turner, O.; Richardson, T. 
A.; Wolford, S. T.; Miller, P. E.; Zhou, W.; Lu, H.; Akimov, M.; Kluwe, W. Ocular toxicity of 
AUY922 in pigmented and albino rats. Toxicol. Appl. Pharmacol. 2016, 309, 55-62. 
109.    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, 
P.; Sugarman, S.; Wasserheit-Leiblich, C.; Fasano, J.; Moynahan, M. E.; D'Andrea, G.; Lim, K.; 
Reddington, L.; Haque, S.; Patil, S.; Bauman, L.; Vukovic, V.; El-Hariry, I.; Hudis, C.; Modi, S. 
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with 
metastatic breast cancer. Clin. Breast Cancer 2014, 14, 154-160. 
110.    Gewirth, D. T. Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future. 
Curr. Top. Med. Chem. 2016, 16, 2779-2791. 
111.    Zubriene, A.; Gutkowska, M.; Matuliene, J.; Chaleckis, R.; Michailoviene, V.; Voroncova, 
A.; Venclovas, C.; Zylicz, A.; Zylicz, M.; Matulis, D. Thermodynamics of radicicol binding to 
human Hsp90 alpha and beta isoforms. Biophys. Chem. 2010, 152, 153-163. 
112.    Duerfeldt, A. S.; Peterson, L. B.; Maynard, J. C.; Ng, C. L.; Eletto, D.; Ostrovsky, O.; 
Shinogle, H. E.; Moore, D. S.; Argon, Y.; Nicchitta, C. V.; Blagg, B. S. Development of a Grp94 
inhibitor. J. Am. Chem. Soc. 2012, 134, 9796-9804. 
113.    Patel, H. J.; Patel, P. D.; Ochiana, S. O.; Yan, P.; Sun, W.; Patel, M. R.; Shah, S. K.; 
Tramentozzi, E.; Brooks, J.; Bolaender, A.; Shrestha, L.; Stephani, R.; Finotti, P.; Leifer, C.; Li, 
Z.; Gewirth, D. T.; Taldone, T.; Chiosis, G. Structure-activity relationship in a purine-scaffold 
compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. J. Med. 
Chem. 2015, 58, 3922-3943. 
37 
 
114.    Modica-Napolitano, J. S.; Aprille, J. R. Delocalized lipophilic cations selectively target the 
mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 2001, 49, 63-70. 
115.    Kang, B. H.; Plescia, J.; Song, H. Y.; Meli, M.; Colombo, G.; Beebe, K.; Scroggins, B.; 
Neckers, L.; Altieri, D. C. Combinatorial drug design targeting multiple cancer signaling networks 
controlled by mitochondrial Hsp90. J. Clin. Invest. 2009, 119, 454-464. 
116.    Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 




2. Development of Grp94-selective Inhibitors based on the BnIm Scaffold 
as a Potential Treatment for Myocilin-associated Primary Open Angle 
Glaucoma  
Grp94 Possesses a Unique Secondary Binding Pocket 
Glucose regulated protein 94 (Grp94) is the endoplasmic reticulum (ER) resident isoform of 
the Hsp90 family. Grp94 is responsible for the maturation of proteins associated with cell-to-cell 
signaling and cell adhesion. Client proteins dependent upon Grp94 have been identified, including 
select integrins (α2, α4, αL, and β4), Toll-like receptors (TLR1, TLR2, TLR4, and TLR9), LRP6, 
Her2, IGF-I and -II, and mutant myocilin.1-4 Grp94 is essential only during embryonic 
development, and therefore, selectively targeting Grp94 may exhibit fewer toxic liabilities than 
observed with pan-Hsp90 inhibitors in the clinic.5 Recently, mutant myocilin was identified as a 
Grp94-dependent substrate, and studies have shown that inhibition of Grp94 leads to the 
disaggregation of mutant myocilin and, consequently, represents a novel target for the treatment 
of myocilin-associated primary open-angle glaucoma (POAG).6-8 To date, few Hsp90 isoform-
selective inhibitors have been developed, due to the >85% identity within the N-terminal ATP-
binding pocket of all four isoforms.  
Grp94 is most unique in its N-terminal ATP-binding pocket amongst the Hsp90 isoforms due 
to a five amino acid insertion (residues 182-186) into its primary sequence.3 This insertion, while 
not located directly in the ATP-binding site, produces a hydrophobic binding region within the N-
terminal ATP-binding site of Grp94.9 As such, this unique pocket provides an opportunity to 
develop Grp94-selective inhibitors. Prior studies, via a high throughput screen, identified NECA 
(1, Figure 2.1), as a Grp94-selective inhibitor that bound to the S1 sub-pocket of the Grp94 unique 
secondary pocket.3, 10 Recently, a library screen identified a series of Grp94-selective inhibitors 
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based on the purine scaffold and subsequent optimization led to the development of 2 and 3, which 
preferentially bind the S2 sub-pocket of Grp94 to impart selectivity.11-12 Co-crystallization of the 
resorcinol containing pan-Hsp90 inhibitor, radamide (4, Figure 2.1) with canine Grp94 (cGrp94) 
revealed the amide bond existed in both the cis- and trans-amide conformations.13-14 The cis-amide 
conformation projected the quinone moiety directly toward the unique secondary binding pocket 
of Grp94, while the trans-amide did not. Alternatively, when co-crystallized with yeast Hsp82 
(yHsp82, yeast ortholog of cytosolic Hsp90 isoforms), 4 bound solely in the trans-amide 
conformation. These data suggested that the predisposition of 4 to bind in the cis-amide 
conformation could lead to selective Grp94 inhibition. Incorporation of a cis-amide bioisostere, 
imidazole, into the scaffold of 4 projects the aryl ring into the unique S1 sub-pocket of Grp94, 
which led to the discovery of the first Grp94-selective inhibitor, BnIm (5, Figure 2.1).15  5 
demonstrated Grp94 selectivity via a competitive fluorescence polarization assay and in cells by 
inhibiting secretion of the Grp94-dependent client protein IGF-II, as well as inhibition of Toll-like 
 
Figure 2.1. Purine-based Grp94-selective inhibitors (1-3). Resorcinol-based pan-Hsp90 (4) and Grp94-selective 
(5, KUNG65) inhibitors. 
40 
 
receptor trafficking at concentrations lower than those necessary for cytosolic Hsp90-dependent 
client protein degradation. 5 provided an excellent lead to pursue Grp94-selective inhibitors that 
impart improved selectivity and affinity for Grp94. 
Design of First Generation Grp94-selective Inhibitors based on the BnIm Scaffold 
The co-crystal structure of 4 with cGrp94 revealed the cis-amide to project the aryl side chain 
into the S1 sub-pocket, which is surrounded by hydrophobic amino acids (Val82, Ile166, Ala167, 
Phe195, Val197, Phe199, Tyr200, and Trp223), suggesting that affinity may be increased through 
additional hydrophobic interactions with this pocket (Figure 2.2a).13 In contrast, yHsp82 contains 
the backbone carbonyl of Asn92 and the ε-NH2 of Lys98, which blocks access to these 
hydrophobic residues, suggesting that modifications to the benzyl side chain of 5 could provide 
improved Grp94 selectivity (Figure 2.2b). Docking of 5 into the co-crystal structure of 4 with 
Grp94 (PDBID: 2GFD) suggested that substitutions on the aryl side chain could provide additional 
 
Figure 2.2. Co-crystal structures of 4 with Hsp90 isoforms. (a) cGrp94 (PDBID: 2GFD) highlights the 
hydrophobic and π-rich nature of the unique secondary binding pocket of Grp94. Only the cis-amide form of 4 
shown for clarity. (b) yHsp82 (PDBID: 2FXS) highlighting the hydrogen bonding network present and restricted 
access to the aromatic residues. Residues are numbered as in their respective proteins. (c) 5 docked in to Grp94 


























interactions with the S1 sub-pocket of Grp94 and allow for improved Grp94-selective inhibition 
through optimization of the aryl side chain. Non-polar substitutions at the 4-position were 
proposed to extend further into the hydrophobic pocket and produce increased affinity and 
selectivity. However, larger substitutions at this position would likely produce a steric clash with 
Val82 and exhibit decreased affinity. Due to the close proximity of Tyr200 to the 3-position of the 
aryl side chain, substitutions at this position appeared detrimental to Grp94 affinity. Substitutions 
at the 2-position might increase affinity through hydrophobic interactions with the secondary 
pocket. Based on these observations, the aryl side chain of BnIm was investigated to probe the 
unique pocket present in Grp94 and to elucidate structure-activity relationships for optimal affinity 
and selectivity. 
Synthesis and Biochemical Evaluation of Modifications to the Benzyl Ring of BnIm 
The cis-amide bioisostere, imidazole, could be prepared via a multi-component cyclization 
reaction with a previously reported resorcinolic aldehyde, ammonium bicarbonate, glyoxal, and 
various benzylamines. Therefore, access to the desired analogues was achieved by varying 
substitutions on the benzylamine component, which were either commercially available or readily 
Scheme 2.1. Synthesis of benzylamines 6a-6f. 
 
Conditions: a) LiAlH4, THF, 0˚C to 25˚C, 12 h; b) DBU, DPPA, Toluene, 0˚C to 25˚C, 12h; c) PPh3, THF:Water 
(10:1), 25˚C, 12h. 
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accessible (Scheme 2.1). 4-Ethynylbenzylamine (6a) was synthesized from 4-iodobenzylamine 
following literature precedent.16 Aromatic nitriles were reduced using lithium aluminum hydride 
to produce the requisite amines (6b-e). The substituted benzoic acid was reduced to the 
corresponding benzyl alcohol, 8, using lithium aluminum hydride, which was then converted to 
the benzyl azide and subsequently reduced to the desired amine, 6f, via Staudinger reduction. The 
basic amines were then cyclized with aldehyde 9 in the presence of ammonium bicarbonate and 
glyoxal, followed by desilylation with tetrabutylammonium fluoride to provide the desired 
analogues, 10-44 (Scheme 2.2).14-15, 17 
Once in hand, the analogues were screened via a competitive binding fluorescence polarization 
assay using Grp94 or Hsp90α and FITC-labeled geldanamycin (FITC-GDA).18 Geldanamcyin is a 
potent, natural product N-terminal, pan-Hsp90 inhibitor that competes with these Grp94 inhibitors 
for the N-terminal ATP-binding site.19 Analogues were evaluated against Grp94 and Hsp90α in 
order to determine selectivity. Hsp90α was chosen to evaluate selectivity, because of its 
similarities to both Hsp90β and TRAP1, and was therefore expected to produce similar selectivity 
profiles. Analogues were initially screened at 25µM to determine the percent of FITC-GDA 
(tracer) bound compared to vehicle control (0% tracer displaced, Table 2.1).  
The 25µM screen provided insight into the structural requirements for binding of the aryl side 
chain to the Grp94 secondary pocket. Substitutions at the 4-position typically produced similar 




affinity compared to 5, but provided increased selectivity in several cases. As hypothesized, polar 
substitutions (17 and 21) produced lower affinity due to the hydrophobic nature of the secondary 
Grp94 binding pocket (Figure 2.2). Incorporation of a bicyclic system was not tolerated as the 
naphthyl (23 and 24) and quinoline (25) derivatives exhibited decreased affinity for both Grp94 
and Hsp90α. Substitutions at the 3-position were not beneficial, as all of the analogues synthesized 
reduced affinity for both isoforms compared to the parent inhibitor, 5. Alternatively, substitutions 
at the 2-position typically increased Grp94 affinity and improved selectivity versus Hsp90α (e.g. 
38 – 42)   
Analogues that displaced ≥ 70% of the tracer, when incubated with Grp94 at 25µM, were 
subsequently evaluated to determine their apparent Kd values against Grp94 and Hsp90α. 
Compound 5 manifests an apparent Kd of 1.1 µM for Grp94 and 13.1 µM for Hsp90α, resulting in 
12-fold Grp94 selectivity. Substitutions at the 4-position were designed to extend further into the 
hydrophobic pocket present in Grp94 to increase selectivity over other isoforms. Modest increases 
in selectivity were observed with these compounds (11, 12 and 18), while increases in affinity 
were observed with analogues containing halogen substitutions.  Incorporation of the hydrophobic 
methyl group (14) substantially increased selectivity for Grp94 as well as increased affinity.  
Extended alkyl chains (15 and 16) were too large to be accommodated into the secondary pocket 























98.9 ± 0.2 72.9 ± 1.2 1.14 ± 0.1 13.1 ± 1.1 12 
10 
 
90.3 ± 0.5 40.3 ± 3.2 3.2 ± 0.5 23.4 ± 1.2 7 
11 
 
99.1 ± 0.5 52.1 ± 2.1 0.81 ± 0.09 12.1 ± 1.6 15 
12 
 
1.0 ± 0.4 57.2 ± 3.7 0.96 ± 0.1 12.5 ± 1.8 13 
13 
 
43.6 ± 4.4 43.5 ± 2.5 n.d. n.d. n.d. 
14 
 
98.9 ± 0.8 33.5 ± 4.4 0.73 ± 0.1 25.2 ± 2.1 34 
15 
 
24.2 ± 8.7 17.3 ± 5.6 n.d. n.d. n.d. 
16 
 
23.9 ± 7.7 15.9 ± 6.3 n.d. n.d. n.d. 
17 
 
75.8 ± 4.1 49.7 ± 3.6 4.7 ± 0.7 18.2 ± 1.1 4 
18 
 




















52.1 ± 5.5 10.0 ± 12.1 n.d. n.d. n.d. 
20 
 
18.0 ± 8.5 12.8 ± 6.1 n.d. n.d. n.d. 
21 
 
78.7 ± 4.7 30.1 ± 5.3 6.9 ± 1.3 >150 >22 
22 
 
13.7 ± 7.2 17.1 ± 9.2 n.d. n.d. n.d. 
23 
 
29.5 ± 6.4 9.6 ± 10.3 n.d. n.d. n.d. 
24 
 
34.0 ± 5.7 11.1 ± 9.7 n.d. n.d. n.d. 
25 
 
64.2 ± 3.9 35.5 ± 4.7 n.d. n.d. n.d. 
26 
 
70.9 ± 4.6 57.0 ± 5.6 1.53 ± 0.1 9.63 ± 1.4 6 
27 
 
56.0 ± 7.1 25.8 ± 6.2 n.d. n.d. n.d. 
28 
 
35.6 ± 5.1 25.3 ± 6.7 n.d. n.d. n.d. 
29 
 
16.5 ± 8.5 14.9 ± 9.4 n.d. n.d. n.d. 
30 
 
27.0 ± 7.2 32.0 ± 6.4 n.d. n.d. n.d. 
31 
 




















67.3 ± 4.3 60.9 ± 4.5 n.d. n.d. n.d. 
33 
 
89.2 ± 3.7 59.8 ± 7.5 1.36 ± 0.1 11.4 ± 1.2 8 
34 
 
86.0 ± 4.2 60.4 ± 2.3 1.39 ± 0.1 8.47 ± 0.9 6 
35 
 
84.2 ± 2.1 45.5 ± 5.2 1.60 ± 0.3 21.1 ± 3.7 13 
36 
 
79.9 ± 2.7 38.8 ± 6.6 3.0 ± 0.8 68.1 ± 8.7 23 
37 
 
30.8 ± 8.1 20.9 ± 8.3 n.d. n.d. n.d. 
38 
 
93.5 ± 1.3 36.6 ± 5.8 1.3 ± 0.2 53.9 ± 7.6 41 
39 
 
99.5 ± 0.1 39.8 ± 7.3 0.81 ± 0.08 38.8 ± 5.3 48 
40 
 
99.6 ± 0.1 57.3 ± 5.8 0.20 ± 0.08 8.1 ± 1.8 41 
41 
 
99.7 ± 0.1 99.7 ± 0.22 0.09 ± 0.01 0.24 ± 0.03 3 
42 
 




















82.6 ± 3.2 54.8 ± 3.6 1.53 ± 0.23 19.3 ± 2.8 13 
44 
 
94.9 ± 1.6 31.0 ± 6.7 2.35 ± 0.31 72.5 ± 8.4 30 
a % Tracer bound determined when incubated with 25 µM of inhibitors. Data are the average of at least 2 experiments 
± SEM n.d. = not determined. 
As observed in the 25 µM screen, substitutions at the 3-position (26-32) did not manifest 
improved affinity nor selectivity for Grp94 compared to 5. Alternatively, substitutions at the 2-
position provided additional insights into the binding mode for these analogues. Small 
substitutions at the 2-position were tolerated; however, such substitutions did not increase 
selectivity or affinity (33 and 34). Larger substitutions produced increased selectivity for Grp94 
versus Hsp90α, as 38, 39, and 40 exhibited >40-fold Grp94 selectivity, potentially due to induction 
of a conformational shift in the tertiary structure of Grp94.  
 
Figure 2.3. Substitutions at the 2-position potentially result in reorganization of Grp94 tertiary structure. (a) 
Tertiary structure of 4 bound to Grp94 (PDBID: 2GFD) showing the open conformation of the N-terminal domain 
of Grp94. (b) Tertiary structure of 3 bound to Grp94 (PDBID: 3O2F) showing the conformational shift (blue, 











Patel and colleagues previously reported the co-crystallization of 3 with Grp94 (PDBID: 3O2F) 
in which a conformational shift was observed (compared to 4, PDBID: 2GFD) to form the S2 sub-
pocket within the Grp94 ATP-binding site.11, 20 This sub-pocket is distinct from the S1 sub-pocket 
utilized by 1 and 4 (Figure 2.3a) due to migration of Phe199. This migration allows access to the 
S2 sub-pocket that is observed with 3. Substitutions at the 2-position may also induce a similar 
conformational change in Grp94. Modeling studies suggested substitutions at this position project 
into this extended region which could produce increased Grp94 selectivity. In the case of 40 
(Grp94 apparent Kd = 0.2 µM; 41-fold selective), the increased selectivity was accompanied by a 
~6-fold increase in affinity for Grp94 compared to 5. Extension or branching of the alkyl ether (41 
and 42) improved affinity for Grp94, although a loss in selectivity was observed. These larger 
alkyl ethers did not appear to be accommodated within the S1 or S2 sub-pockets of Grp94, and 
likely push the benzyl side chain towards the solvent exposed region via ~180˚ rotation of the 
imidazole ring to form hydrogen bonds with polar amino acids present in this region (See Chapter 
3 for further discussion).21 These polar residues are conserved in both Grp94 and Hsp90 and 
provide an explanation for the loss of selectivity and an increase in affinity. In an attempt to 
combine beneficial substitutions observed with the 2- and 4-positions, 44 was synthesized, 
however affinity was compromised compared to the parent compounds (14 and 38), suggesting 
the effects of these substitutions are not additive (Table 2.1). 
49 
 
Due to the high density of aromatic amino acids within the unique secondary binding pocket of 
Grp94, the incorporation of heterocycles was proposed to improve both π-π interactions and 
affinity for Grp94.13 The requisite heterocyclic amines (6g-l) were synthesized from the 
corresponding aldehydes through conversion to the oximes (46a-e), followed by reduction via 
lithium aluminum hydride (Scheme 2.3). Chlorination of thiophen-2-ylmethanamine via sulfuryl 
chloride provided 6m (Scheme 2.4). Radical bromination of 5-methylisoxazole followed by 
conversion to the azide and subsequent Staudinger reduction provided 6n. Reduction of the 
substituted furoic acid 48 to the corresponding furfuryl alcohol was achieved using lithium 
aluminum hydride followed by conversion to the azide and then Staudinger reduction to yield 6o. 
Deprotonation of 3-chlorothiophene with n-butyllithium followed by the addition of CO2(g) 
provided a mixture of carboxylate regioisomers which were separable via flash chromatography 
after reduction to the corresponding alcohols (49b and 49c) with lithium aluminum hydride. These 
isomers were then converted to the corresponding azides, followed by Staudinger reduction to 
provide the requisite basic amines, 6p and 6q (Scheme 2.4). The desired analogues were obtained 
through the multicomponent reaction detailed in Scheme 2.2 to produce analogues 50-69. 
Scheme 2.3. Synthesis of heterocyclic amines 6g-6l.  
 
Conditions: a) HNO3, H2SO4, Ac2O, 0˚C, 1h; b) 50% H2SO4 (aq.), 110˚C, 5 min; c) conc. HCl, 40˚C, 12 h; d) 
NH2OH•HCl, NaOAc, MeOH, 25˚C, 8 h; e) LiAlH4, THF, 0˚C to 25˚C, 12 h; f) Potassium vinyltrifluoroborate, 
Pd(dppf)Cl2, iPr2EtN, Toluene, 110˚C, 14 h; g) H2, 10% Pd/C, EtOH, 25˚C, 6 h. 
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As can be seen in Table 2.2, incorporation of an electron poor (compared to benzene) pyridine 
ring (66-69) decreased selectivity and affinity for Grp94. In contrast, incorporation of electron rich 
5-membered heterocycles proved beneficial for Grp94 affinity. Converting the phenyl ring of 5 to 
the bioisosteric replacement thiophene (55) significantly increased affinity for Grp94 compared to 
5. The 2-furan and 2-thiophene (51 and 55, respectively) analogues exhibited both increased 
affinity and selectivity, and consequently, substitutions about these rings were explored. The 
energy minimized structures of 5 and 51 were overlaid and revealed the 5-position of the 
heterocycle aligned similarly to the 4-position of the benzyl side chain of 5 (Figure 2.4). Therefore, 
substitutions at the 5-position of both the furan and thiophene rings were sought to increase 
selectivity and affinity. 
Scheme 2.4. Synthesis of heterocyclic amines 6m-6q. 
Conditions: a) SO2Cl2, 15˚C, AcOH:Et2O (9:1), 1 h; b) NBS, AIBN, CCl4, 80˚C, 4 h; c) NaN3, MeOH:H2O (10:1), 
25˚C, 12 h; d) PPh3, THF:H2O (10:1), 25˚C, 12 h; e) LiOH, THF:MeOH:H2O (9:1:1), 25˚C, 10 h; f) LDA, MeI, 
THF, -40˚C, 3 h; g) LiAlH4, THF, 0˚C to 25˚C, 12 h; h) DBU, DPPA, Toluene, 25˚C, 12 h, i) n-BuLi, CO2 (g), 
THF, -78˚C, 2 h. 
51 
 
58 exhibited improved selectivity for Grp94 compared to the 3- and 4-chloro substituted 
thiophene analogues (59 and 60), supporting the hypothesis that these 5-substituted heterocycles 
bind similarly to the 4-substituted phenyl ring. Incorporation of a 5-chloro substitution onto the 
smaller furan ring (53) increased Grp94 selectivity and affinity.  In an effort to mimic the 2-
substitutions on the benzene ring, modifications to the 3-position of the 5-membered ring were 
incorporated. Unfortunately, these substitutions exhibited both reduced selectivity and affinity. 



















98.9 ± 0.2 72.9 ± 1.2 1.14 ± 0.1 13.1 ± 1.1 12 
50 
 
97.4 ± 0.8 78.3 ± 4.7 1.50 ± 0.12 3.77 ± 0.41 3 
51 
 
99.2 ± 0.1 75.0 ± 2.3 0.55 ± 0.06 5.91 ± 0.88 11 
52 
 
99.1 ± 0.07 73.4 ± 2.3 0.65 ± 0.10 26.6 ± 2.3 41 
 





















99.3 ± 0.09 91.7 ± 1.2 0.44 ± 0.05 8.31 ± 1.2 19 
54 
 
99.3 ± 0.1 65.1 ± 2.4 0.35 ± 0.06 9.2 ± 1.6 26 
55 
 
99.4 ± 0.08 76.7 ± 2.1 0.47 ± 0.07 3.92 ± 0.51 8 
56 
 
87.9 ± 1.9 64.5 ± 3.8 2.14 ± 0.22 6.54 ± 0.86 3 
57 
 
99.0 ± 0.2 49.8 ± 6.1 0.68 ± 0.08 5.13 ± 0.42 8 
58 
 
99.0 ± 0.2 59.2 ± 3.6 0.93 ± 0.09 34.7 ± 2.6 37 
59 
 
99.1 ± 0.1 97.6 ± 1.1 0.67 ± 0.08 1.8 ± 0.17 3 
60 
 
99.1 ± 0.08 97.2 ± 1.2 0.76 ± 0.07 3.16 ± 0.41 4 
61 
 
99.3 ± 0.06 99.1 ± 0.08 0.40 ± 0.02 0.81 ± 0.07 2 
62 
 
91.7 ± 2.1 62.5 ± 4.0 2.5 ± 0.23 16.0 ± 1.8 6 
63 
 
99.1 ± 0.2 46.2 ± 7.6 0.75 ± 0.12 36.7 ± 3.2 49 
64 
 
94.8 ± 1.3 59.9 ± 5.0 2.36 ± 0.17 7.5 ± 1.2 3 
65 
 
99.1 ± 0.1 63.1 ± 3.6 0.72 ± 0.08 6.94 ± 0.94 10 
66 
 




















93.3 ± 1.5 73.3 ± 4.9 4.04 ± 0.39 5.41 ± 0.67 1 
68 
 
62.1 ± 2.7 49.7 ± 4.2 n.d. n.d. n.d. 
69 
 
73.9 ± 3.9 59.2 ± 5.0 9.18 ± 1.1 9.92 ± 1.6 1 
a % Tracer bound determined when incubated with 25 µM of inhibitors. Data are the average of at least 2 experiments 
± SEM. n.d. = not determined 
Co-Crystallization of Grp94 with the Grp94-Selective Inhibitor, 53 
The co-crystal structure of the N-terminal domain of Grp94 in complex with 53 was solved to 
2.6 Å resolution and supported the proposed docking interactions (Figure 2.5a). The structure 
reveals 53 in the ATP-binding site with the resorcinol ring stabilized by hydrogen bonding 
interactions with Asp149 (Figure 2.5b, c) similar to other resorcinol-based pan-Hsp90 
inhibitors.13, 22 Other direct interactions between 53 and the ATP-binding site are mediated through 
conserved water molecules (Figure 2.5c). In contrast to 4, compound 53 is bound to Grp94 in a 
single orientation, illustrating the effectiveness of the cis-amide bioisostere in reducing binding 
heterogeneity.   
The electron density of 53 was largely continuous for the length of the molecule, with the 
notable exception of the chlorinated furan moiety (Figure 2.5d), which apparently samples 
multiple conformations within the ATP-binding site and results in low electron density for this 
region of the molecule. It is possible that the chlorinated furan dwells within the extended 
hydrophobic region to increase selectivity (as predicted through modeling studies); however, the 
final binding mode modeled, based on optimal fit to 2Fo-Fc (Figure 2.5d), is one in which the 
chloride substituent is nestled in an ordered loop (residues 165-170) at the entry to the ATP-
54 
 
binding site (arrow, Figure 2.5a and b). Notably, this loop is disordered in the structure complexed 
with 4 (grey, Figure 2.5b). The furan moiety also appears to be involved in a cation-π interaction 
with Lys168 to stabilize this loop. In general, phenyl rings form stronger cation-π interactions due 
to a larger quadrupole moment compared to furan rings.23 However, modeling studies suggest that 
the phenyl ring of 5 cannot orient in a manner to allow this interaction, which therefore accounts 
for the increased affinity manifested by the smaller heterocycles (50-65). Taken together, 53, and 
by analogy other analogues described within this series, bind to the ATP-binding site of Grp94 in 
a mode that manifests increased selectivity over the other Hsp90 isoforms.  
 
Figure 2.5. Crystal structure of 53 bound to Grp94. (a) Surface representation of ATP-binding pocket with 53 as 
ball and stick. Arrow points to a well ordered loop at the mouth of the active site. (b) Cartoon representation of 
the structure as in (a) highlighting H-bonding interactions (≤ 3.5 Å) and loop configuration. (c) Zoomed view of 





Grp94-Selective Inhibition Offers a Potential Treatment for Primary Open Angle 
Glaucoma 
Glaucoma is the second leading cause of blindness in the world and is characterized by 
increased intraocular pressure that leads to irreversible optic nerve damage and blindness.24-26 The 
clinically observable risk factor of elevated intraocular pressure (IOP) typically results from 
decreased outflow of the aqueous humor through the trabecular meshwork (TM) in the anterior 
segment of the eye (Figure 2.6a).27 Nonsynonymous mutations in myocilin, localized to its 
olfactomedin domain, result in a non-native tertiary structure and promote facile aggregation that 
leads to TM cell death and ultimately glaucoma and blindness.28-29 Recently, it was demonstrated 
that Grp94 associates with amyloid-like aggregates of mutant myocilin but cannot triage these 
aggregates through the ER-associated degradation (ERAD) pathway (Figure 2.6b).7  
Prior studies showed that Grp94 inhibition allows mutant myocilin degradation through an 
autophagic mechanism, which decreases intracellular levels of myocilin and, ultimately, reduces 
toxicity (Figure 2.6b).6 Therefore, these Grp94-selective inhibitors were evaluated for their ability 
 
Figure 2.6. Myocilin-associated open angle glaucoma. (a) Anatomical diagram of the anterior segment of the eye 
depicting the normal outflow of aqueous humor. Image courtesy of National Eye Institute, National Institutes of 
Health. (b) Grp94 recognizes small mutant myocilin aggregates and attempts to triage them through ERAD 
however this results in their deposition in the ER leading to toxicity. In the presence of a Grp94-selective inhibitor, 
Grp94 is dissociated from mutant myocilin resulting in degradation of mutant myocilin via autophagy and 
reduction of toxicities. 
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to promote mutant myocilin clearance in a cellular model that is transfected to overexpress mutant 
myocilin. Treatment with 12 produced degradation of five disease relevant mutant forms of 
myocilin (Figure 2.7a). Compound 40 produced similar degradation of mutant myocilin at 
comparable concentrations to that of 12, and compound 53 produced significant degradation of 
mutant myocilin at 1 µM (Figure 2.7b). Surprisingly, KUNG65 (Figure 2.1), a second generation 
Grp94-selective inhibitor (see Figure 2.1 and Chapter 3), only produces modest degradation of 
mutant myocilin at 30 µM. Compounds 12, 40, and 53 do not induce the pro-survival heat shock 
response, which is in contrast to the pan-Hsp90 inhibitor 17-AAG. Additionally, these inhibitors 
do not result in the degradation of the cytosolic Hsp90 isoform-dependent client protein Akt at 
concentrations similar to those needed to degrade myocilin, suggesting these inhibitors manifest 
Grp94-selectivity in cells (Figure 2.7c). 
In order to evaluate the translational potential of Grp94-selective inhibition for the treatment of 
myocilin-associated glaucoma, 12 was evaluated in a previously characterized Tg-MYOCY437H 
mouse model wherein the glaucoma phenotype appears around three months of age.27 Therefore, 
treatment was initiated at four months of age. Mice were treated with 300 µM of 12 or vehicle 
control via eye drops once per day for 12 weeks and IOP measurements were recorded biweekly 
on each eye. After 8 weeks of treatment, the test group displayed reduced IOP compared to vehicle 
treated transgenic mice. After 12 weeks, treatment with 12 reduced IOP levels to those that were 
 
Figure 2.7.  Western blot analysis of HEK293 cells overexpressing myocilin mutants treated with indicated 
Grp94-selective inhibitors. (a) treatment with 12 results in degradation of 5 disease-relevant mutants (b) 
Compounds KUNG65, 40, and 53 produce degradation of myocilin. (c) Grp94-selective inhibitors do not induce 
the heat shock response or result in the degradation of Akt, a cytosolic Hsp90 isoform-dependent client protein. 





















indistinguishable from the WT group (Figure 2.8a). Reduced IOP levels were accompanied by a 
clearance of mutant myocilin within TM cells after treatment with 12, recapitulating the clearance 
observed in cellular studies (Figure 2.8b). In addition to clearance of myocilin, no induction of 
the pro-survival heat shock response was observed, as monitored by Hsp70 levels in TM cells 
(Figure 2.8c). This study represents the first animal model in which a Grp94-selective inhibitor 
 
Figure 2.8.  In vivo evaluation of 12 in a transgenic mutant myocilin mouse model. (a) IOP was measured 
biweekly over 12 weeks of treatment with veh. or 12. **P < 0.05, ***P < 0.001. Time = 0 = mouse age of 22 
weeks. (b) Quantification of myocilin levels. **P < 0.01. (c) Quantification of Hsp70 levels normalized to WT 
vehicle-treated controls. No significant difference was observed between groups. 
WT + veh. (n = 3)
WT + 12 (n = 3)
TgMYOCY437H + veh. (n = 6)


























































has demonstrated efficacy and suggests that Grp94-selective inhibition represents a novel 
mechanism for the treatment of myocilin-associated POAG that does not exhibit the toxic 
liabilities associated with pan-Hsp90 inhibitors.  
Conclusions & Future Directions 
Structure-activity relationship studies were performed on the aryl side chain of 5, which 
interacts with the unique secondary pocket of Grp94 (Figure 2.9). Substitutions at the 2- and 4-
positions were tolerated within this binding region. Incorporation of an ethoxy group at the 2-
position significantly increased affinity, as well as selectivity. 40 exhibited nearly a 10-fold 
increase in affinity for Grp94 compared to 5 and 40-fold selectivity for Grp94 over the cytosolic 
Hsp90 isoforms. Replacing the phenyl ring of the side chain with 5-membered heterocycles also 
increased affinity for Grp94, as observed with 53. A co-crystal structure of the N-terminal domain 
of Grp94 with 53 was solved and revealed a cation-π interaction between the furan ring and 
Lys168. This interaction stabilized a loop of Grp94 (residues 165-170) that was disordered in the 
co-crystal structure of 4 bound to Grp94, and this stabilization appears to account for the increased 
affinity observed with the 5-membered heterocycles. Grp94-selective inhibition resulted in the 
degradation of myocilin aggregates in cells without the liabilities associated with pan-Hsp90 
inhibitors. Additionally, 12 was evaluated in a mutant myocilin transgenic mouse model and 
demonstrated restoration of normal IOP levels after 12 weeks of treatment without any apparent 
toxicities, thus suggesting that Grp94-selective inhibition could serve as a novel treatment for 
myocilin-associated POAG. Going forward, this scaffold provides an excellent starting point for 
further modifications that can improve Grp94 selectivity (See Chapter 3). In general, increased ER 
stress is an emerging characteristic of many forms of glaucoma, suggesting that Grp94-selective 
inhibition could produce similar effects in non-myocilin-associated forms of glaucoma.27, 30 
59 
 
Specifically, ER stress was identified as a causative factor in retinal ganglion cell death following 
elevated IOP levels, and this increased ER stress was observed in an animal model of steroid-
induced glaucoma.31 These observations suggest that reduction of ER stress may represent a 
promising treatment opportunity for glaucoma. 
Experimental Section 
Chemistry General. 1H NMR were recorded at 400 (Bruker AVIIIHD 400 MHz NMR with a 
broadband X-channel detect gradient probe) or 500 MHz (Avance AVIII 500MHz spectrometer 
with a dual carbon/proton cryoprobe) and 13C were recorded at 125 MHz (Bruker AVIII 
spectrometer equipped with a cryogenically-cooled carbon observe probe); chemical shifts are 
reported in δ (ppm) relative to the internal standard (CDCl3, 7.26 ppm or MeOD, 3.31 ppm). HRMS 
spectra were recorded with a LCT Premier. The purity of compounds was determined by HPLC 
(Agilent 1100 series quaternary pump; 60% MeCN/40% Water; Agilent C-18 column, 
4.6x150mm, 5µM) with UV detection. All biologically tested compounds were determined to be 
>95% pure. TLC analysis was performed on glass backed silica gel plates and visualized by UV 
light. All solvents were reagent grade and used without further purification. 
 
Figure 2.9. Summary of structure-activity relationships for the analogues of 5 for Grp94-selective inhibition. 
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General Procedure for multicomponent cyclization reaction. Basic amines (e.g., 6a-6q, 
0.26 mmol, 1 equiv.) were added to a stirred solution of 9 (125 mg, 0.26 mmol, 1 equiv.) in wet 
MeOH (2 mL) and stirred for 30 minutes at rt followed before the addition of NH4HCO3 (0.26 
mmol, 1 equiv.) and glyoxal (0.26 mmol, 1 equiv.). After stirring for 12 h, tetrabutylammonium 
fluoride (0.52 mL of 1 M solution in THF, 0.52 mmol, 2 equiv.) was added and then stirred for 30 
minutes before the reaction was quenched with saturated aqueous NH4Cl (10 mL) and extracted 
with EtOAc (3x 10 mL). The organic layers were combined, dried (Na2SO4), filtered, and 
concentrated. The residue was purified via flash chromatography (SiO2, 1:49 MeOH:DCM) to 
afford the desired product as an amorphous solids: 
 
Methyl 2-(2-(1-benzyl-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (5) 54 mg 
(54% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3,  MeOD) δ 7.28 – 7.23 (m, 3H), 
7.01 – 6.97 (m, 2H), 6.95 (d, J = 1.5 Hz, 1H), 6.81 (d, J = 1.5 Hz, 1H), 6.40 (s, 1H), 5.02 (s, 2H), 
3.79 (s, 3H), 3.48 – 3.41 (m, 2H), 2.89 – 2.83 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 
170.8, 162.1, 158.1, 147.7, 141.7, 136.2, 128.9, 128.0, 126.9, 126.5, 120.1, 114.8, 105.9, 102.5, 
52.5, 49.4, 30.8, 26.1. HRMS (ESI) m/z [M–H]- C20H19ClN2O4 385.0955, found 385.0953. tR = 






(4-Ethynylphenyl)methanamine (6a) was synthesized from 4-iodobenzylamine hydrochloride 
following procedures detailed in reference 16. 93 mg (78% yield) as a dark yellow oil. 1H NMR 
(500 MHz, MeOD) δ 7.54 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.3 Hz, 2H), 4.13 (s, 2H), 3.60 (s, 1H). 
13C NMR (126 MHz, MeOD) δ 133.6, 132.3 (2C), 128.7 (2C), 123.3, 82.1, 78.6, 42.5. HRMS 
(ESI) m/z [M+H]+ for C9H10N: 132.0813, found: 132.0809. 
General Procedure for reduction of aromatic nitriles. Benzonitriles (e.g., 7a-7c, 0.7 M in 
THF, 1 equiv.) were added dropwise to a stirred solution of LiAlH4 (0.5 M in dry THF, 5 equiv.) 
at 0˚C. The reaction mixture warmed to rt and stirred for 12h. H2O (1 mL/g of LiAlH4) was added 
dropwise to quench the excess hydride, followed by 4 M NaOH (1 mL/g of LiAlH4), and EtOAc 
(3 mL/g of LiAlH4). The resulting suspension was filtered through a pad of celite and the celite 
washed with warm EtOAc (30 mL) and the eluent concentrated. The residue was purified via flash 
chromatography (SiO2, 1:49, MeOH:DCM to 1:20, MeOH:DCM) to afford the desired product as 
oils: 
 
(2-Ethylphenyl)methanamine (6b) 653 mg (79% yield) as a colorless oil. 1H NMR (400 MHz, 
MeOD) δ 6.77 – 6.69 (m, 1H), 6.63 – 6.56 (m, 2H), 6.58 – 6.48 (m, 1H), 4.51 (s, 2H), 2.07 (q, J = 
7.6 Hz, 2H), 0.60 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, MeOD) δ 143.2, 129.8, 129.4, 129.1, 
127.5, 127.0, 42.3, 26.4, 16.0. HRSM (ESI) m/z [M+NH4]





(2-Ethoxyphenyl)methanamine (6c) 215 mg (59% yield) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.25 – 7.16 (m, 2H), 6.90 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 4.07 (q, J = 7.6, 
7.1 Hz, 2H), 3.82 (s, 2H), 1.73 (br s, 2H), 1.44 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
156.8, 131.8, 128.5, 128.1, 120.4, 111.1, 63.3, 42.9, 15.0. HRMS (ESI) m/z [M+H]+ for C9H14NO: 
152.1075, found: 152.1077. 
 
(2-Isopropoxyphenyl)methanamine (6d) 243 mg (59% yield) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.19 (t, J = 6.6 Hz, 2H), 6.92 – 6.83 (m, 2H), 4.59 (hept, J = 6.0 Hz, 1H), 3.79 (s, 
2H), 1.74 (br s, 2H), 1.36 (d, J = 6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 155.7, 132.7, 128.7, 
128.0, 120.2, 112.5, 69.7, 43.1, 22.2 (2C). MS (EI) m/z [M]+ for C10H15NO: 165.1, found: 165.2. 
 
(2-Propoxyphenyl)methanamine (6e) 265 mg (67% yield) as a colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.24 – 7.16 (m, 2H), 6.90 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 3.96 (t, J = 
6.4 Hz, 2H), 3.83 (s, 2H), 1.90 – 1.78 (m, 4H), 1.06 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 156.9, 131.7, 128.5, 128.1, 120.3, 111.0, 69.3, 42.9, 22.7, 10.8. MS (EI) m/z [M]
+ for 
C10H15NO: 165.1, found: 165.2.  
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General procedure for Staudinger reduction. PPh3 (1.1 equiv.) was added to a stirred 
solution of the benzyl azide (1 equiv.) in THF:H2O (0.1 M, 10:1) and stirred at rt for 12 h. The 
reaction mixture was concentrated and the residue was purified via flash chromatography (SiO2, 
1:49, MeOH:DCM to 1:20, MeOH:DCM) to afford the desired product as oils: 
 
(2-Methoxy-4-methylphenyl)methanamine (6f) 99 mg (73% yield) as a colorless oil. 1H NMR 
(500 MHz, CDCl3) δ 7.08 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 7.4 Hz, 1H), 6.69 (s, 1H), 3.83 (s, 3H), 
3.77 (s, 2H), 2.34 (s, 3H), 1.87 (br s, 2H). 13C NMR (126 MHz, CDCl3) δ 157.3, 138.2, 128.5, 
121.0, 111.2, 74.8, 55.1, 42.4, 21.6. HRMS (ESI) m/z [M+H]+ for C9H14NO: 152.1075, found 
152.1076. 
General Procedure for Oxime Reduction. Aryl oximes (e.g., 66a-66e, 0.7 M in THF, 1 
equiv.) were added dropwise to a stirred solution of LiAlH4 (0.5 M in dry THF, 5 equiv.) at 0˚C. 
The reaction mixture warmed to rt and stirred for 12h. H2O (1 mL/g of LiAlH4) was added 
dropwise to quench the excess hydride, followed by 4 M NaOH (1 mL/g of LiAlH4), and EtOAc 
(3 mL/g of LiAlH4). The resulting suspension was then filtered through a pad of celite and the 
celite washed with warm EtOAc (30 mL) and the eluent was concentrated. The residue was 
purified via flash chromatography (SiO2, 1:49, MeOH:DCM to 1:20, MeOH:DCM) to afford the 
desired products as oils: 
 
(5-Chlorofuran-2-yl)methanamine (6g) 93 mg (47% yield), yellow oil. 1H NMR (500 MHz, 
CDCl3) δ 6.12 (d, J = 3.2 Hz, 1H), 6.06 (d, J = 3.2 Hz, 1H), 3.76 (d, J = 0.8 Hz, 2H), 1.58 (br s, 
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2H). 13C NMR (126 MHz, CDCl3) δ 156.2, 156.2, 135.1, 107.5, 106.6, 39.4. HRMS (ESI) m/z 
[M+H]+ for C5H7ClNS: 147.9988, found: 147.9990. HRMS (ESI) m/z [M+H]
+ for C5H7ClNO: 
132.0216, found: 132.0221. 
 
Thiazol-2-ylmethanamine (6h) 42 mg (9% yield) as a red oil. 1H NMR (400 MHz, CDCl3) δ 
7.72 (d, J = 3.1 Hz, 1H), 7.26 (d, J = 3.2 Hz, 1H), 4.20 (s, 2H), 1.80 (br, s, 2H). 13C NMR (126 
MHz, CDCl3) δ 174.0, 142.6, 118.6, 44.0. HRMS (ESI) m/z [M+H]
+ for C4H7N2S: 115.0330, 
found: 115.0331. 
 
(5-Methylthiophen-2-yl)methanamine (6i) 72 mg (16% yield) as a yellow oil. 1H NMR (500 
MHz, CDCl3) δ 6.70 (d, J = 3.4 Hz, 1H), 6.57 (dd, J = 3.3, 1.3 Hz, 1H), 3.96 (s, 2H), 2.72 (br s, 
2H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 143.9, 138.9, 124.8, 124.0, 41.2, 15.4. HRMS 
(ESI) m/z [M+H]+ for C6H10NS: 128.0534, found: 128.0532. HRMS (ESI) m/z [M+H]
+ for 
C9H10NS: 164.0534, found: 164.0541. 
 
(3-Vinylthiophen-2-yl)methanamine (6j) 152 mg (42% yield) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.20 – 7.07 (m, 1H), 6.73 (dd, J = 17.5, 11.0 Hz, 1H), 5.54 (dd, J = 17.4, 1.3 Hz, 
1H), 5.24 (dd, J = 11.0, 1.3 Hz, 1H), 4.07 (s, 1H), 2.03 (s, 1H). 13C NMR (126 MHz, CDCl3) δ 





(3-Vinylfuran-2-yl)methanamine (6k) 57 mg (24% yield) as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.29 (dd, J = 2.0, 0.7 Hz, 1H), 6.57 (dd, J = 17.3, 10.7 Hz, 1H), 6.50 (d, J = 2.0 Hz, 1H), 
5.42 (dd, J = 17.4, 1.4 Hz, 1H), 5.14 (dd, J = 10.8, 1.4 Hz, 1H), 3.85 (s, 2H), 1.67 (br s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 152.8, 141.7, 126.2, 119.3, 113.2, 107.7, 37.1. HRMS (ESI) [M+H]
+ 
for C7H10NO: 124.0762, found: 124.0768. 
 
(3-Ethylthiophen-2-yl)methanamine (6l) 10% Pd/C (5 mol%) was added to a stirred solution of 
(3-vinylthiophen-2-yl)methanamine (6k, 50 mg, 0.36 mmol) in MeOH (5 mL) and stirred at rt 
under a hydrogen atmosphere for 12 h. The reaction mixture was filtered through a pad of celite 
and the eluent was concentrated to produce the title compound which was used without further 
purification.  45 mg (89% yield) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.16 (d, J = 5.1 
Hz, 1H), 6.87 (d, J = 5.2 Hz, 1H), 4.56 (s, 2H), 4.05 (s, 2H), 2.61 (q, J = 7.6 Hz, 2H), 1.20 (t, J = 
7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 141.5, 134.9, 128.6, 123.8, 37.8, 21.5, 15.3. HRMS 
(ESI) m/z [M+H]+ for C7H12NS: 147.0690, found: 147.0692. 
 
(5-Chlorothiophen-2-yl)methanamine (6m) A solution of thiophene-2-ylmethanamine (1 mL, 
9.7 mmol, 1 equiv.) in AcOH:Et2O (9:1, 0.5 M) was cooled to 5˚C followed by the dropwise 
addition of SO2Cl2 (1.18 mL, 14.6 mmol, 1.5 equiv.) maintaining the reaction temperature under 
20˚C. The reaction was stirred at rt for 1 h at which time Et2O (20 mL) was added and stirred for 
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an additional 30 min. The precipitate (hydrochloride salt of desired product) was filtered and the 
solid washed with Et2O. The isolated solid was dissolved in DCM (25 mL) and washed with sat’d 
NaHCO3 (2 x 30 mL). The organic layer was separated, dried (Na2SO4), and concentrated. The 
residue was purified via flash chromatography (SiO2, 1:49 MeOH:DCM to 1:20 MeOH:DCM) to 
provide the title compound. 658 mg (37% yield) as a yellow oil. 1H NMR (400 MHz, MeOD) δ 
5.51 (d, J = 3.0 Hz, 1H), 5.40 (d, J = 3.8 Hz, 1H), 2.69 (s, 2H), 1.73 (br s, 2H). 13C NMR (126 
MHz, MeOD) δ 134.7, 132.7, 130.6, 127.9, 38.7. HRMS (ESI) m/z [M+H]+ for C5H6ClNS: 
148.9990, found: 148.9988. 
 
Isoxazol-5-ylmethanamine (6n) 159 mg (77% yield) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 8.17 (s, 1H), 6.13 (s, 1H), 4.00 (s, 2H), 1.53 (br, s, 2H). 
13C NMR (126 MHz, CDCl3) δ 
172.5, 150.3, 100.0, 37.6. MS (EI) m/z [M]+ for C4H6N2O: 98.0, found: 98.1. 
 
 (3,5-Dimethylfuran-2-yl)methanamine (6o) 98 mg (65% yield) as a yellow oil. 1H NMR (400 
MHz, MeOD) δ 5.78 (s, 1H), 3.70 (s, 2H), 2.17 (s, 3H), 1.92 (s, 3H). 13C NMR (126 MHz, MeOD) 
δ 152.0, 147.9, 118.5, 110.1, 36.4, 13.4, 9.8. HRMS (ESI) m/z [M+H]+ for C7H12NO: 126.0919, 
found 126.0924. 
  
(3-Chlorothiophen-2-yl)methanamine (6p) 113 mg (59% yield) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 7.15 (dd, J = 5.2, 1.2 Hz, 1H), 6.86 (dd, J = 5.3, 1.1 Hz, 1H), 3.98 (s, 2H), 1.79 
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(br s, 2H). 13C NMR (126 MHz, CDCl3) δ 148.2, 124.5, 123.9, 118.3, 41.5. HRMS (ESI) m/z 
[M+H]+ for C5H7ClNS: 147.9988, found: 147.9990. 
 
(4-Chlorothiophen-2-yl)methanamine (6q) 79 mg (67% yield) as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ 6.96 (s, 1H), 6.78 (s, 1H), 3.99 (s, 2H), 1.71 (br s, 2H). 
13C NMR (126 MHz, 
CDCl3) δ 148.24, 124.45, 123.90, 118.33, 41.51.
 13C NMR (126 MHz, CDCl3) δ 139.2, 127.9, 
127.7, 123.0, 39.2. HRMS (ESI) m/z [M+H]+ for C5H7ClNS: 147.9988, found: 147.9995. 
General procedure for alkylation of 2-hydroxybenzonitrile. Alkyliodides (3.7 mmol, 1.1 
equiv.) and K2CO3 (930 mg, 6.7 mmol, 2 equiv.) were added to a stirred solution of 2-
hydroxybenzonitrile (400 mg, 3.4 mmol, 1 equiv.) in DMF (20 mL) at rt and stirred for 4 h. The 
reaction was quenched with the addition of H2O (20 mL) and EtOAc (40 mL). The organic layer 
was washed with water (5 x 40 mL), dried (Na2SO4), filtered, and concentrated. The residue was 
purified by column chromatography (SiO2, 4:1 Hex:EtOAc) to afford the desired alkyl ethers as 
colorless oils: 
 
2-Ethoxybenzonitrile (7a) 360 mg (71% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ 7.63 – 7.45 (m, 2H), 7.04 – 6.89 (m, 2H), 4.15 (q, J = 7.1 Hz, 2H), 1.48 (t, J = 7.0 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 161.0, 134.7, 134.2, 120.9, 117.0, 112.5, 102.4, 65.0, 14.9. MS (EI) 
m/z [M]+ for C9H9NO: 147.1, found: 147.1; [M+H]




2-Isopropoxybenzonitrile (7b) 405 mg (71% yield) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 7.57 (dt, J = 7.7, 1.5 Hz, 1H), 7.52 (td, J = 7.9, 7.3, 1.5 Hz, 1H), 6.99 (dd, J = 8.2, 5.2 
Hz, 2H), 4.68 (hept, J = 6.1 Hz, 1H), 1.43 (d, J = 6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 
159.9, 134.1, 133.9, 120.5, 116.8, 113.6, 103.0, 71.8, 21.9 (2C). MS (EI) m/z [M]+ for C10H11NO: 
161.1, found: 161.1; [M+H]+ for C10H12NO: 162.1, found: 162.1. 
 
2-Propoxybenzonitrile (7c) 385 mg (71% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3) 
δ 7.55 (d, J = 7.8 Hz, 1H), 7.50 (td, J = 8.1, 7.4, 1.5 Hz, 1H), 7.00 – 6.93 (m, 2H), 4.03 (t, J = 6.5 
Hz, 2H), 1.88 (h, J = 7.0 Hz, 2H), 1.08 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 160.8, 
134.3, 133.8, 120.5, 116.6, 112.2, 102.0, 70.5, 22.3, 10.5. MS (EI) m/z [M]+ for C10H11NO: 161.1, 
found: 161.1; [M+H]+ for C10H12NO: 162.1, found: 162.1.  
General procedure for the reduction of carboxylic acids. The aromatic carboxylic acids 
(e.g., 68, 0.7 M in THF, 1 equiv.) were added dropwise to a stirred solution of LiAlH4 (0.5M in 
THF, 5 equiv.) at 0˚C. The reaction warmed to rt and stirred for 12 h. H2O (1 mL/g of LiAlH4) 
was added, to quench the excess hydride, then 4 M NaOH (1 mL/g of LiAlH4) and EtOAc (3 mL/g 
of LiAlH4). The resulting suspension was filtered through a pad of celite then the celite was washed 
with warm EtOAc and the eluent concentrated. The residue was purified via flash chromatography 





(2-Methoxy-4-methylphenyl)methanol (8) 187 mg (50% yield), colorless oil. 1H NMR (400 
MHz, CDCl3) δ 7.14 (d, J = 7.5 Hz, 1H), 6.78 (dd, J = 7.5, 0.8 Hz, 1H), 6.75 (s, 1H), 4.32 (s, 2H), 
3.86 (s, 3H), 2.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.6, 140.1, 130.1, 121.1, 120.8, 111.5, 
55.3, 50.0, 21.7. HRSM (ESI) m/z [M]+ for C9H12O2: 152.0837, found: 152.0846. 
 
Methyl 4,6-bis((tert-butyldimethylsilyl)oxy)-3-chloro-2-(3-oxopropyl)benzoate (9) was 
synthesized following procedures detailed in references 14 and 17. 1.8 g (68% yield), white 
amorphous solid. 1H NMR (500 MHz, CDCl3) δ 9.80 (s, 1H), 6.31 (s, 1H), 3.84 (s, 3H), 2.96 – 
2.92 (m, 2H), 2.80 – 2.74 (m, 2H), 1.02 (s, 9H), 0.95 (s, 9H), 0.23 (s, 6H), 0.21 (s, 6H). 13C NMR 
(126 MHz, CDCl3) δ 201.5, 168.4, 153.5, 151.9, 138.1, 121.4, 118.8, 110.2, 110.0, 52.7, 43.8, 26.0 
(3C), 25.8 (3C), 18.7, 18.4, -3.9 (2C), -4.00 (2C). HRMS (ESI) m/z [M+H]+ for C23H40ClO5Si2: 
487.2103, found 487.2120. 
 
Methyl 3-chloro-2-(2-(1-(4-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (10) 
22 mg (21% yield), white amorphous solid. 1H NMR (500 MHz, MeOD) δ 7.07–6.94 (m, 5H), 
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6.86 (d, J = 1.4 Hz, 1H), 6.29 (s, 1H), 5.00 (s, 2H), 3.69 (s, 3H), 3.22–3.19 (m, 2H), 2.84 (m, 2H). 
13C NMR (126 MHz, MeOD) δ 171.2, 164.8, 162.8, 160.7, 158.8, 148.8, 141.4, 134.2, 130.0, 
129.9, 127.3, 121.7, 116.8, 116.6, 112.6 (d, J = 558.4 Hz), 103.3, 52.9, 31.5, 27.3. HRMS (ESI) 
m/z [M+H] for C20H19ClFN2O4:  405.1017, found: 405.1009. 
 
Methyl 3-chloro-2-(2-(1-(4-chlorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (11)  
28 mg, (25% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.24 (d, J = 
8.4 Hz, 2H), 6.98 (d, J = 1.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 2H), 6.78 (d, J = 1.4 Hz, 1H), 6.40 (s, 
1H), 4.97 (s, 2H), 3.81 (s, 3H), 3.46–3.40 (m, 2H), 2.89–2.80 (m, 2H). 13C NMR (126 MHz, 
CDCl3, MeOD ) δ 170.6, 162.3, 157.7, 147.6, 141.6, 134.6, 134.0, 129.2 (2C), 127.9 (2C), 127.1, 
120.0, 114.6, 106.1, 102.7, 52.6, 30.9, 29.7, 26.0 HRMS (ESI) m/z [M+H] for C20H19Cl2N2O4: 
421.0722, found: 421.0714. 
 
Methyl 2-(2-(1-(4-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (12) 
45 mg (38% yield), off white amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.36 (d, J = 
8.4 Hz, 2H), 6.91 (d, J = 1.4 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H), 6.77 (d, J = 1.5 Hz, 1H), 6.35 (s, 
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1H), 4.93 (s, 2H), 3.78 (s, 3H), 3.42 – 3.34 (m, 2H), 2.84 – 2.77 (m, 2H). 13C NMR (101 MHz, 
CDCl3, MeOD) δ 170.2, 161.4, 157.6, 147.3, 141.1, 134.8, 131.7 (2C), 127.9 (2C), 126.6, 121.6, 
119.7, 114.3, 102.1, 100.0, 52.0, 30.4, 25.7. HRMS (ESI) m/z [M + H]+ for C20H19BrClN2O4: 
465.0217, found 465.0237. tR = 4.17 min, 95.3%. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-iodobenzyl)-1H-imidazol-2-yl)ethyl)benzoate (13) 
22 mg (35% yield), white amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD): δ 7.59-7.57 (dd, 
J=11.6 Hz, 2H), 7.14-7.11 (dd, J=10.0 Hz, 2H), 7.05 (s, 1H), 6.86 (s, 1H), 6.44 (s, 1H), 5.14 (s, 
2H), 3.87 (s, 3H), 3.48-3.44 (t, J=16.8, 2H), 2.91-2.87 (t, J=18.4 Hz, 2H. ). 13C NMR (125 MHz, 
CDCl3, MeOD): δ = 170.6, 162.4, 157.6, 147.6, 141.5, 138.1, 128.4, 127.2, 120.0, 114.6, 106.1, 
102.7, 93.6, 52.6, 52.2, 49.0, 30.9, 26.1, 25.2, 20.1. HRMS (ESI) m/z [M+H]+ for C20H18ClIN2O4: 
513.0020, found: 513.0070. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-methylbenzyl)-1H-imidazol-2-yl)ethyl)benzoate (14) 
44 mg (43% yield), off white amorphous solid. 1H NMR (500 MHz, MeOD) δ 7.15 (d, J = 7.9 Hz, 
2H), 7.03 (d, J = 1.4 Hz, 1H), 7.00-6.96 (m, 2H), 6.94 (d, J = 1.5 Hz, 1H), 6.39 (s, 1H), 5.05 (s, 
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2H), 3.77 (s, 3H), 3.37-3.30 (m, 2H), 2.97-2.89 (m, 2H), 2.31 (s, 3H). 13C NMR(125 MHz, MeOD) 
δ 171.3, 160.9, 159.0, 148.8, 141.5, 138.9, 135.1, 130.5 (2C), 127.9 (2C), 127.1, 121.8, 115.0, 
110.1, 103.3, 52.8, 50.1, 31.5, 27.3, 21.1. HRMS (ESI) m/z [M+H]+ for C21H22ClN2O4: 401.1268, 
found: 401.1266. 
 
Methyl 3-chloro-2-(2-(1-(4-ethylbenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (15) 
37 mg (39% yield), off white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.14 (d, J 
= 8.1 Hz, 2H), 7.11-7.08 (m, 1H), 6.98 -6.91 (m, 2H), 6.85 (d, J = 1.5 Hz, 1H), 6.44 (s, 1H), 4.96 
(s, 3H), 3.54-3.45 (m, 2H), 3.04 (t, J = 7.9 Hz, 2H), 2.59 (q, J = 7.6 Hz, 2H), 1.17 (td, J = 7.6, 1.0 
Hz, 3H). 13CNMR (125 MHz, CDCl3,MeOD) δ 170.6, 162.1, 158.2, 147.2, 145.0, 140.9, 132.1, 
128.8 (2C), 127.2 (2C), 124.2, 120.6, 114.9, 106.2, 103.0, 50.0, 49.9, 30.7, 28.6, 25.6, 15.6. HRMS 
(ESI) m/z [M + H]+ for C22H24ClN2O4: 415.1425, found: 415.1432. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-isopropylbenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(16) 25 mg (22% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.1 
Hz, 2H), 7.03 (s, 1H), 6.90 (d, J = 8.2 Hz, 2H), 6.80 (d, J = 1.5 Hz, 1H), 6.49 (s, 1H), 4.95 (s, 2H), 
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3.79 (s, 3H), 3.50 (t, J = 7.9 Hz, 2H), 3.00 – 2.92 (m, 2H), 2.82 (hept, J = 6.9 Hz, 1H), 1.16 (d, J 
= 7.0 Hz, 6H).  13C NMR (126 MHz, CDCl3) δ 170.6, 162.9, 157.3, 149.3, 147.2, 127.2 (2C), 126.8 
(2C), 120.2, 114.5, 106.2, 103.0, 100.0, 52.8, 49.6, 33.8, 30.8, 29.7, 23.9 (2C). HRMS (ESI) m/z 
[M+H]+ for C23H26ClN2O4: 429.1581, found: 429.1588. 
 
Methyl 3-chloro-2-(2-(1-(4-cyanobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (17) 
37 mg (39% yield), off white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.79 (q, J = 7.8, 6.0 
Hz, 2H), 7.61-7.36 (m, 2H), 7.20-7.12 (m, 1H), 7.05 (s, 1H), 6.57  (s, 1H), 5.44 – 5.25 (m, 2H), 
4.00 (s, 3H), 3.57 (q, J = 7.7 Hz, 2H), 3.02 (t, J = 7.9 Hz, 2H). 13C NMR (125 MHz, CDCl3):  
170.4, 161.5, 158.0, 147.8, 142.0, 141.2 132.8, (2C), 127.7, 127.4, 127.0 (2C), 120.2, 118.2, 114.5, 




(18). 37 mg (35% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 8.3 Hz, 
1H), 7.06 (d, J = 1.4 Hz, 1H), 7.00 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 1.4 Hz, 1H), 6.48 (s, 1H), 5.12 
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(s, 1H), 3.84 (s, 2H), 3.50 (dd, J = 9.3, 6.7 Hz, 1H), 3.09 (s, 1H), 2.94 (dd, J = 9.0, 7.0 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 170.7, 162.7, 158.4, 147.7, 141.3, 136.7, 132.8, 129.1, 126.8, 
126.6, 126.5, 122.1, 120.2, 120.2, 115.0, 105.7, 102.8, 82.9, 52.6, 49.3, 30.9, 26.0. HRMS (ESI) 
m/z [M+H]+ for C22H20ClN2O4: 411.1112, found: 411.1121. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-(trifluoromethyl)benzyl)-1H-imidazol-2-
yl)ethyl)benzoate (19). 24 mg (36% yield), white amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD): δ 7.56-.755 (dd, J=9.7 Hz, 2H), 7.15 (s, 1H), 7.10-7.08 (dd, J=11.3 Hz, 2H), 6.86 (s, 1H), 
6.44 (s, 1H), 5.06 (s, 2H), 3.86 (s, 3H), 3.47-3.43 (t, J=16.3 Hz, 2H), 3.04-3.00 (t, J=16.3 Hz, 2H). 
13C NMR (125 MHz, CDCl3, MeOD): δ 170.2, 162.1, 157.8, 147.3, 140.3, 138.7, 131.1, 130.8, 
127.1, 126.3, 126.2, 124.7, 122.6, 120.5, 114.6, 111.4, 106.1, 103.1, 52.9, 30.6, 25.3. HRMS (ESI) 
m/z [M+H+] for C21H18ClF3N2O4: 455.0937, found 455.0972. 
 
Methyl 2-(2-(1-([1,1'-biphenyl]-4-ylmethyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (20). 35 mg (29% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3, 
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MeOD) δ 7.54 – 7.48 (m, 4H), 7.39 (ddd, J = 8.0, 7.0, 1.7 Hz, 2H), 7.31 (td, J = 7.2, 1.4 Hz, 1H), 
7.07 (dd, J = 8.3, 1.6 Hz, 2H), 6.98 (s, 1H), 6.86 (s, 1H), 6.41 (s, 1H), 5.07 (s, 2H), 3.83 (s, 3H), 
3.52 – 3.45 (m, 2H), 2.92 – 2.87 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.8, 162.1, 
157.8, 147.7, 141.8, 141.0, 140.2, 135.2, 128.8 (2C), 127.6 (2C), 127.5, 127.2, 127.0 (2C), 127.0 
(2C), 120.1, 114.7, 106.1, 102.5, 52.5, 49.6, 30.9, 26.2. HRMS (ESI) m/z [M+H]+ for 
C26H23ClN2O4: 463.1425, found: 463.1447. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(4-methoxybenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(21) 25 mg (23% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 6.86 – 6.84 
(m, 1H), 6.82 (d, J = 1.4 Hz, 1H), 6.74 – 6.69 (m, 4H), 6.31 (s, 1H), 4.85 (s, 2H), 3.72 (s, 3H), 
3.65 (s, 3H), 3.38 – 3.32 (m, 2H), 2.82 – 2.76 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 
174.6, 165.6, 163.2, 162.1, 151.4, 145.5, 135.4, 132.1 (2C), 132.0, 130.4, 123.9, 118.2 (2C), 110.2, 







(22) 27 mg (23% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.30 (d, J = 
8.3 Hz, 1H), 7.05 (d, J = 1.9 Hz, 2H), 6.92 (d, J = 1.7 Hz, 1H), 6.81 (dd, J = 8.3, 2.2 Hz, 1H), 6.32 
(s, 1H), 4.94 (s, 2H), 3.76 (s, 3H), 3.36 – 3.29 (m, 2H), 2.95 (t, J = 7.8 Hz, 2H). 13C NMR (126 
MHz, CDCl3, MeOD) δ 173.6, 164.9, 161.9, 141.3, 137.4, 135.2, 133.1, 130.9, 130.5, 125.3 (2C), 
118.4, 116.4, 111.0, 107.0 (2C), 56.5, 53.1, 34.0, 28.9. HRMS (ESI) m/z [M+H]+ for 
C20H18Cl3N2O4: 455.0332, found: 455.0354. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(naphthalen-1-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (23). 32 mg (28% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.79 (dd, J = 6.8, 2.5 Hz, 1H), 7.71 (dd, J = 8.0, 3.9 Hz, 2H), 7.48 – 7.40 (m, 2H), 7.28 
(d, J = 1.2 Hz, 1H), 6.93 (d, J = 1.4 Hz, 1H), 6.72 (d, J = 1.5 Hz, 1H), 6.71 – 6.67 (m, 1H), 6.32 
(s, 1H), 5.43 (s, 2H), 3.73 (s, 3H), 3.45 – 3.35 (m, 2H), 2.94 – 2.84 (m, 2H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 170.6, 161.6, 158.0, 147.9, 141.5, 133.6, 131.6, 130.3, 128.9, 128.7, 126.8 (2C), 
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126.2, 125.4, 123.9, 122.0, 120.4, 114.6, 106.3, 102.4, 52.3, 47.3, 30.7, 26.2. HRMS (ESI) m/z 
[M+H]+ for C24H21ClN2O4: 437.1268, found: 437.1250. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(naphthalen-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (24) 28 mg (25% yield), tan amorphous solid. 1H NMR (400 MHz, DMSO-d6) 
δ 7.88 (dd, J = 9.1, 4.0 Hz, 2H), 7.83 – 7.78 (m, 1H), 7.51 – 7.46 (m, 1H), 7.25 (dd, J = 8.4, 1.9 
Hz, 1H), 7.18 (d, J = 1.3 Hz, 1H), 6.85 (d, J = 1.3 Hz, 1H), 6.42 (s, 1H), 5.29 (s, 2H), 3.57 (s, 3H), 
2.92 – 2.86 (m, 2H), 2.77 – 2.71 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 167.9, 155.0, 154.5, 
146.4, 137.7, 135.2, 132.8, 132.2, 128.4, 127.6 (2C), 127.5, 126.8, 126.4 (2C), 126.0, 124.9, 124.8, 
120.6, 113.7, 110.8, 101.7, 51.8, 48.4, 29.9, 26.2. HRMS (ESI) m/z [M+H]+ for C24H21ClN2O4: 
437.1268, found: 437.1280. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(quinolin-5-ylmethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(25) 29 mg (25% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 8.87 (dd, 
J = 4.3, 1.6 Hz, 1H), 8.20 – 8.16 (m, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.60 (dd, J = 8.5, 7.2 Hz, 1H), 
7.49 – 7.44 (m, 1H), 6.99 (s, 1H), 6.86 – 6.83 (m, 1H), 6.76 (s, 1H), 6.36 (s, 1H), 5.48 (s, 2H), 
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3.83 (s, 3H), 3.48 – 3.44 (m, 2H), 2.95 – 2.89 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 
170.6, 161.9, 157.9, 150.2, 147.9, 141.6, 132.3, 131.1, 129.5, 129.4, 127.4, 125.6, 124.8, 121.6, 
120.1, 114.6, 106.1, 102.5, 100.0, 52.5, 46.6, 30.9, 26.2. HRMS (ESI) m/z [M+H]+ for 
C23H21ClN3O4: 438.1221, found: 438.1207. 
 
Methyl 3-chloro-2-(2-(1-(3-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (26)  
26 mg, (25% yield), pale yellow amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.20 (m, 
1H), 7.01 (d, J = 1.4 Hz, 1H), 6.92 (m, 1H), 6.82 (d, J = 1.4 Hz, 1H), 6.75 (m, 1H), 6.70 – 6.58 
(m, 1H), 6.46 (s, 1H), 5.01 (s, 2H), 3.80 (s, 3H), 3.52 – 3.40 (m, 2H), 2.88 – 2.74 (m, 2H). 13C 
NMR (126 MHz, CDCl3) δ 157.1, 147.6, 141.8, 130.9, 127.8, 122.1, 120.2 (2C), 115.3, 115.1, 
113.7, 113.5, 106.7, 103.0 (2C), 100.1, 53.6, 49.0, 31.0, 26.3. HRMS (ESI) m/z [M+H] for 
C20H19ClFN2O4:  405.1017, found: 405.1009. 
 
Methyl 3-chloro-2-(2-(1-(3-chlorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (27) 
47 mg (44 % yield), pale yellow amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.25-
7.20 (m, 2H), 7.03 (d, J = 1.6 Hz, 1H), 6.99- 6.96 (m, 1H), 6.91-6.84 (m, 2H), 6.40 (s, 1H), 5.00 
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(s, 2H), 3.82 (s, 3H), 3.49-3.33 (m, 2H), 3.01-2.83 (m, 2H). 13CNMR (125 MHz, CDCl3, MeOD): 
170.6, 161.9, 158.2, 147.5, 141.1, 137.7, 135.1, 130.5, 128.5, 126.8, 125.9, 124.9, 120.5, 114.8, 
106.2, 102.7, 52.6 (2C), 30.6, 25.8. HRMS (ESI) m/z [M+H]+ for C20H19Cl2N2O4:
 421.0722, found: 
421.0728. 
 
Methyl 2-(2-(1-(3-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (28) 
23 mg, (19% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.38 (m, 1H), 
7.19 – 7.09 (m, 2H), 6.99 (d, J = 1.5 Hz, 1H), 6.91 (m, 1H), 6.84 (d, J = 1.5 Hz, 1H), 6.40 (s, 1H), 
5.00 (s, 2H), 3.83 (s, 3H), 3.46–3.38 (m, 2H), 2.92 –2.79 (m, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 168.0, 159.3, 155.5, 145.0, 138.8, 135.7, 128.7, 128.0, 127.0, 124.1, 122.6, 120.5, 117.6, 
112.2, 103.6, 100.0, 50.0, 46.2, 28.1, 23.4. HRMS (ESI) m/z [M+H] for C20H19BrClN2O4: 
465.0217, found: 465.0225. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(3-iodobenzyl)-1H-imidazol-2-yl)ethyl)benzoate (29). 
4 mg (11% yield), white amorphous solid. 1H NMR (400 MHz, DMSO-d6): δ 7.67-7.64 (dd, J=7.05 
Hz, 1H), 7.43 (s, 1H), 7.18-7.14 (m, 2H), 7.08-7.06 (dd, J=9.24 Hz, 1H), 6.86 (s, 1H), 6.47 (s, 1H), 
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5.14 (s, 2H), 3.68 (s, 3H), 2.92-2.88 (t, J=16.3 Hz, 2H), 2.73-2.67 (t, J=18.2 Hz, 2H). 13C NMR 
(125 MHz, DMSO-d6): δ 167.9, 155.0, 154.5, 146.4, 140.2, 137.7, 136.2, 135.1, 130.9, 126.0, 
120.6, 113.8, 110.8, 101.8, 99.5, 95.2, 52.0, 47.4, 29.8, 26.1. HRMS (FAB) m/z [M+H+] for 
C20H18ClIN2O4: 513.0023, found 513.0065. 
 
Methyl 2-(2-(1-(3-methoxybenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate 
(30). 32 mg (31% yield), white amorphous solid. 1H NMR (400 MHz, CDCl3) δ 7.06 (s, 1H), 6.88 
(s, 1H), 6.82 (d, J = 9.0 Hz, 1H), 6.62 (d, J = 7.7 Hz, 1H), 6.55 (s, 1H), 6.53 (s, 1H), 5.04 (s, 2H), 
3.85 (s, 3H), 3.76 (s, 3H), 3.59 – 3.51 (m, 2H), 2.95 – 2.89 (m, 2H). 13C NMR (126 MHz, CDCl3) 
δ 170.7, 162.9, 160.1, 157.0, 147.5, 141.6, 137.8, 130.1, 127.1, 120.2, 118.7, 114.3, 113.0, 112.5, 




(31). 18 mg (17% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.06 (t, J = 
7.6 Hz, 1H), 6.95 (d, J = 7.7 Hz, 1H), 6.85 (d, J = 1.5 Hz, 1H), 6.75 (d, J = 1.5 Hz, 1H), 6.72 – 
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6.66 (m, 2H), 6.30 (s, 1H), 4.87 (s, 2H), 3.69 (s, 3H), 3.36 – 3.30 (m, 2H), 2.81 (dd, J = 9.2, 6.9 
Hz, 2H), 2.16 (s, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.5, 165.5, 162.0, 151.4, 145.2, 
142.7, 139.6, 132.8 (2C), 131.3, 129.8, 127.7, 124.3, 118.6, 110.3, 106.4, 56.3, 53.5, 34.5, 29.9, 
25.1. HRMS (ESI) m/z [M+H]+ for C21H22ClN2O4: 401.1268, found 401.1255. 
 
Methyl 2-(2-(1-([1,1'-biphenyl]-3-ylmethyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-
dihydroxybenzoate (32) 46 mg (39% yield), pale yellow amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.53-7.47 (m, 3H), 7.41 (dd, J = 9.1, 7.3 Hz, 3H), 7.38 -7.33 (m, 1H), 7.23 (s, 
1H), 7.03 (d, J = 1.3 Hz, 1H), 6.99 (d, J = 7.8 Hz, 1H), 6.89 (d, J = 1.4 Hz, 1H), 6.46 (s, 1H), 5.12 
(s, 2H), 3.82 (s, 3H), 3.56-3.46 (m, 2H), 2.97 -2.89 (m, 2H). 13CNMR δ (100 MHz, CDCl3, 
MeOD): 170.8, 163.0, 157.9, 147.7, 142.4, 141.5, 140.5, 136.6, 129.8 (3C), 129.1(2C), 128.0, 
127.3, 127.3, 125.7, 125.6, 120.5, 114.9, 106.3, 103.2, 52.8, 49.9, 31.1, 26.2. HRMS (ESI) m/z 
[M-H]- for C26H22ClN2O4: 461.1268, found: 461.1259. 
 
Methyl 3-chloro-2-(2-(1-(2-fluorobenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (33) 
23 mg (22% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.27 – 7.23 (m, 
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1H), 7.06 – 6.98 (m, 2H), 6.94 (d, J = 1.4 Hz, 1H), 6.81 (d, J = 1.4 Hz, 1H), 6.78 (dd, J = 7.5, 1.7 
Hz, 1H), 6.40 (s, 1H), 5.05 (s, 2H), 3.82 (s, 3H), 3.64 – 3.38 (m, 2H), 3.05 – 2.68 (m, 2H). 13C 
NMR (126 MHz, CDCl3, MeOD) δ 170.8, 162.2, 157.8, 147.7, 141.8, 130.0, 128.4, 127.3, 124.6, 
123.6, 123.5, 119.9, 115.6 (d, J =21.0 Hz), 114.7, 106.0, 102.6, 52.5, 43.5, 30.8, 26.0. HRMS (ESI) 
m/z [M+H] for C20H18ClFN2O4: 405.1029, found 405.1017. 
 
Methyl 2-(2-(1-(2-chlorobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (34) 
23 mg (21% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ7.27 (s, 1H), 
7.24 – 7.16 (m, 2H), 7.01 (d, J = 1.6 Hz, 1H), 6.94 (dd, J = 1.9, 1.0 Hz, 1H), 6.84 (m, 2H), 6.38 
(s, 1H), 4.98 (s, 2H), 3.80 (s, 3H), 3.45 – 3.35 (m, 2H), 2.94 – 2.85 (m, 2H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 170.6, 162.4, 157.4, 147.6, 141.2, 133.5, 132.6, 129.8, 129.6, 127.7, 127.5, 
126.2, 120.2, 114.5, 106.2, 102.9, 52.7, 47.5, 30.9, 25.8. HRMS (ESI) m/z [M+H] for 
C20H19Cl2N2O4: 421.0722, found: 421.0714. HRMS (ESI) m/z [M+H] for C20H19Cl2N2O4: 






Methyl 2-(2-(1-(2-bromobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (35)  
26 mg (22% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J = 8.0, 1.3 
Hz, 1H), 7.24 – 7.20 (m, 1H), 7.15 (td, J = 7.7, 1.7 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 6.78 (d, J = 
1.6 Hz, 1H), 6.67 – 6.57 (m, 1H), 6.48 (s, 1H), 5.06 (s, 2H), 3.85 (s, 3H), 3.48–3.33 (m, 2H), 3.06–
2.89 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.5, 162.6, 157.8, 147.6, 140.6, 133.2 (2C), 130.1, 
128.2 (2C), 122.6, 120.3 (2C), 114.7, 105.9, 103.1, 52.9, 50.2, 30.8, 25.6. HRMS (ESI) m/z [M+H] 
for C20H19BrClN2O4 : 465.0217, found : 465.0231. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-methylbenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(36). 32 mg (31% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.25 (s, 1H), 
7.08 – 7.02 (m, 2H), 6.88 – 6.83 (m, 1H), 6.66 – 6.58 (m, 1H), 6.47 (t, J = 6.7 Hz, 1H), 6.29 (s, 
1H), 4.87 (s, 2H), 3.72 (s, 3H), 3.35 – 3.25 (m, 2H), 2.81 (dd, J = 10.9, 5.1 Hz, 2H), 2.10 (s, 3H). 
13C NMR (126 MHz, CDCl3, MeOD) δ 174.4, 165.5, 162.0, 151.5, 145.1, 139.3, 137.7, 134.5, 
132.1, 130.5, 130.1, 129.9, 124.1, 118.5, 110.4, 106.4, 56.3, 51.7, 34.5, 29.9, 22.6. HRMS (ESI) 




Methyl 2-(2-(1-(2-aminobenzyl)-1H-imidazol-2-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (37) 
20 mg (19% yield), white amorphous solid. 1H NMR (500 MHz, MeOD) δ 7.07 (td, J = 7.8, 1.6 
Hz, 1H), 6.98 (dd, J = 7.8, 1.4 Hz, 2H), 6.78 (dd, J = 8.0, 1.2 Hz, 1H), 6.65 (td, J = 7.5, 1.2 Hz, 
1H), 6.52 (dd, J = 7.6, 1.5 Hz, 1H), 6.39 (s, 1H), 5.03 (s, 2H), 3.79 (s, 3H), 3.37 – 3.33 (m, 1H), 
3.01 – 2.96 (m, 2H). 13C NMR (126 MHz, MeOD) δ 169.9, 159.4, 157.5, 147.6, 145.0, 140.0, 
128.6, 127.0, 125.1, 120.4, 120.3, 117.9, 116.0, 113.5, 108.8, 101.9, 51.5, 45.8, 29.9, 25.7. HRMS 
(ESI) m/z [M+H] for C20H20ClN3O4: 402.1221, found: 402.1230. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-methoxybenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(38) 46 mg (42% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.26 – 7.23 (m, 1H), 
6.97 (d, J = 1.4 Hz, 1H), 6.89 – 6.84 (m, 2H), 6.83 (d, J = 1.4 Hz, 1H), 6.70 (dd, J = 7.8, 1.7 Hz, 
1H), 6.44 (s, 1H), 5.03 (s, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 3.49 – 3.44 (m, 2H), 2.94 – 2.90 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 171.0, 162.4, 157.8, 156.6, 147.7, 141.9, 129.3, 127.6, 126.7, 
124.7, 120.7, 120.1, 114.7, 110.3, 105.9, 102.5, 55.3, 52.5, 44.9, 30.9, 26.0. HRMS (ESI) m/z 




Methyl 3-chloro-2-(2-(1-(2-ethylbenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate (39) 
33 mg (31% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.43 (d, J = 2.1 
Hz, 1H), 7.40 (d, J = 3.0 Hz, 1H), 7.32 – 7.28 (m, 1H), 7.26 (d, J = 7.7 Hz, 1H), 6.83 (d, J = 7.7 
Hz, 1H), 6.79 (s, 1H), 6.55 (s, 1H), 4.98 (s, 2H), 4.02 (s, 3H), 3.68 (t, J = 7.3 Hz, 2H), 3.45 (t, J = 
7.1 Hz, 3H), 2.52 (q, J = 7.5 Hz, 3H), 1.19 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3, MeOD) 
δ 169.9, 162.0, 158.2, 146.2, 145.3, 142.1, 138.9, 129.9, 129.3, 128.2, 127.0, 120.8, 119.1, 114.8, 
106.3, 103.5, 53.2, 30.9, 30.0, 25.2, 24.3, 14.5. HRMS (ESI) m/z [M+H]+ for C22H24ClN2O4: 
415.1425, found: 415.1419. tR = 4.27 min, 95.3%.  
 
Methyl 3-chloro-2-(2-(1-(2-ethoxybenzyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate 
(40). 44 mg (39% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.18 (t, J = 
8.0 Hz, 1H), 6.88 (d, J = 1.9 Hz, 1H), 6.83 – 6.76 (m, 3H), 6.67 (d, J = 7.6 Hz, 1H), 6.38 (s, 1H), 
4.99 (s, 2H), 3.97 (q, J = 7.7, 6.8 Hz, 2H), 3.80 (s, 3H), 3.45 – 3.39 (m, 2H), 2.88 (t, J = 8.1 Hz, 
2H), 1.32 (t, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 171.0, 162.2, 158.0, 156.0, 
147.7, 142.0, 129.3, 127.7, 126.7, 124.6, 120.5, 120.1, 114.7, 111.0, 105.9, 102.4, 63.5, 52.5, 45.0, 
86 
 
30.9, 26.1, 14.7. HRMS (ESI) m/z [M+H]+ for C22H24ClN2O5: 431.1374, found: 431.1378. tR = 
2.71 min, 98.3%. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-isopropoxybenzyl)-1H-imidazol-2-yl)ethyl)benzoate 
(41). 18 mg (16% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.21 (t, J = 
8.0 Hz, 1H), 6.95 (s, 1H), 6.86 – 6.78 (m, 3H), 6.72 (d, J = 7.5 Hz, 1H), 6.44 (s, 1H), 5.00 (s, 2H), 
4.56 (hept, J = 10.8, 5.3 Hz, 1H), 3.85 (s, 3H), 3.52 – 3.45 (m, 2H), 2.97 – 2.87 (m, 2H), 1.27 (d, 
J = 6.0 Hz, 6H). 13C NMR (126 MHz, CDCl3, MeOD) δ 171.0, 162.2, 158.0, 156.0, 147.7, 142.0, 
129.3, 127.7, 126.7, 124.6, 120.5, 120.1, 114.7, 111.0, 105.9, 102.4, 100.0, 63.5, 52.5, 45.0, 30.9, 




(42). 34 mg (29% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3) δ 7.29 – 7.26 (m, 1H), 
7.02 (d, J = 1.4 Hz, 1H), 6.90 – 6.85 (m, 3H), 6.76 – 6.73 (m, 1H), 6.49 (s, 1H), 5.10 (s, 2H), 3.95 
(t, J = 6.5 Hz, 2H), 3.84 (s, 3H), 3.56 – 3.50 (m, 2H), 3.03 – 2.96 (m, 2H), 1.80 (qt, J = 7.4, 6.5 
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Hz, 2H), 1.01 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.9, 162.9, 157.8, 156.1, 147.6, 
141.6, 129.4, 127.8, 126.5, 124.6, 120.6, 120.2, 114.7, 111.0, 105.9, 102.7, 69.5, 52.6, 45.0, 30.9, 
26.0, 22.6, 10.6. HRMS (ESI) m/z [M+H]+ for C23H26ClN2O5: 445.1530, found: 445.1539. tR = 
2.73 min, 98.0%. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-(trifluoromethyl)benzyl)-1H-imidazol-2-
yl)ethyl)benzoate (43). 25 mg (21% yield), white amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.65 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.02 (s, 1H), 
6.79 (s, 1H), 6.57 (d, J = 7.8 Hz, 1H), 6.39 (s, 1H), 5.25 (s, 2H), 3.85 (s, 3H), 3.50 – 3.41 (m, 2H), 
2.93 – 2.79 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.7, 162.1, 158.0, 148.1, 141.5, 
135.0, 132.6, 128.0, 127.6, 126.9, 126.3 (q, J = 5.6 Hz), 125.2, 123.0, 120.2, 114.7, 105.9, 102.5, 
52.5, 45.9, 30.9, 25.8. HRMS (ESI) m/z [M+H]+ for C21H19ClF3N2O4: 455.0985, found: 455.0979. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(2-methoxy-4-methylbenzyl)-1H-imidazol-2-
yl)ethyl)benzoate (44). 45 mg (40% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.28 (d, J = 2.1 Hz, 1H), 6.94 (d, J = 7.6 Hz, 1H), 6.85 (d, J = 2.1 Hz, 1H), 6.76 (d, J = 
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7.3 Hz, 1H), 6.69 (s, 1H), 6.56 (s, 1H), 4.81 (s, 2H), 3.99 (s, 3H), 3.74 (s, 3H), 3.63 (t, J = 7.4 Hz, 
2H), 3.44 (t, J = 7.4 Hz, 2H), 2.34 (s, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 169.9, 162.0, 
157.1, 151.4, 145.7, 142.0, 140.1, 130.0, 129.5, 121.7, 121.6, 120.5, 118.6, 112.1, 111.9, 55.4, 
54.2, 46.6, 30.5, 29.7, 24.0, 21.8. HRMS (ESI) m/z [M+H]+ for C22H24ClN2O5: 431.1374, found: 
431.1370.  
 
5-Chlorofuran-2-carbaldehyde (45) 5-nitrofuran-2-carbaldehyde (730 mg, 5.1 mmol) was 
stirred in conc. HCl (40 mL) at 40˚C for 15 h. The reaction was poured into H2O (80 mL) and 
extracted with EtOAc (3 x 50 mL). The organic layers were combined, dried (Na2SO4), and 
concentrated. The residue was purified via flash chromatography (SiO2, 1:4 EtOAc:Hexanes) to 
provide the title compound. 266 mg (40% yield), yellow oil. 1H NMR (400 MHz, CDCl3) δ 9.53 
(s, 1H), 7.23 (d, J = 3.6 Hz, 1H), 6.42 (d, J = 3.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 176.4, 
152.0, 144.2, 122.7, 109.8. HRMS (ESI) m/z [M+H]+ for C5H4ClO2: 130.9900, found: 130.9900. 
General procedure for oxime formation. NH2OH•HCl (3 equiv.) and NaOAc (3 equiv.) were 
added to a stirred solution of aromatic aldehydes (1 equiv.) in MeOH (0.2 M) and stirred for 8 h 
at rt. The reaction was quenched with the addition of H2O (20 mL) and EtOAc (20 mL). The 
organic layer was washed with H2O (2 x 20 mL), separated, dried (Na2SO4), and concentrated. The 
residue was purified via flash chromatography (1:10 EtOAc:Hexanes to 1:3 EtOAc:Hexanes) to 






5-Chlorofuran-2-carbaldehyde oxime (46a) 225 mg (75% yield) as a white amorphous solid, 
1:1 mixture of isomers. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.46 (s, 1H), 7.35 (d, J = 3.5 
Hz, 1H), 6.61 (d, J = 3.4 Hz, 1H), 6.36 (d, J = 3.5 Hz, 1H), 6.26 (d, J = 3.4 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 146.4, 144.4, 139.5, 139.1, 135.9, 121.2, 114.7, 109.8, 109.4, 108.5. HRMS 
(ESI) m/z [M+H]+ for C5H5ClNO2: 146.0009, found: 146.0003. 
 
Thiazole-2-carbaldehyde oxime (46b) 510 mg (91% yield), white amorphous solid. 1H NMR 
(400 MHz, CDCl3) δ 8.37 (s, 1H), 7.86 (d, J = 3.2 Hz, 1H), 7.33 (dd, J = 3.3, 0.9 Hz, 1H). 
13C 
NMR (126 MHz, CDCl3) δ 144.7, 143.2, 142.3, 140.7, 123.5, 120.0. HRMS (ESI) m/z [M+H]
+ for 
C4H5N2OS: 129.0123, found: 129.0124. 
 
5-Methylthiophene-2-carbaldehyde oxime (46c) 491 mg (76% yield), white amorphous solid. 
1H NMR (500 MHz, CDCl3) δ 7.62 (s, 1H), 7.21 (d, J = 3.7 Hz, 1H), 6.77 (dd, J = 3.6, 1.1 Hz, 
1H), 2.53 (d, J = 1.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 146.8, 141.5, 132.3, 128.9, 124.8, 




3-Vinylthiophene-2-carbaldehyde oxime (46d) 407 mg (95% yield), white amorphous solid, 2:1 
mixture of isomers. 1H NMR (400 MHz, CDCl3) δ 8.45 (s, 1H), 8.36 (s, 2H), 7.92 (s, 2H), 7.87 (s, 
1H), 7.30 (d, J = 5.3 Hz, 2H), 7.25 (d, J = 5.4 Hz, 2H), 7.20 (d, J = 5.3 Hz, 1H), 7.01 (d, J = 5.4 
Hz, 2H), 6.84 (dd, J = 17.4, 10.9 Hz, 1H), 5.65 (d, J = 17.3 Hz, 1H), 5.38 (d, J = 11.0 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 144.4, 143.7, 140.8, 130.7, 130.3, 130.2, 128.1, 127.5, 127.1, 125.6, 
116.9, 113.9. HRMS (ESI) m/z [M+H]+ for C7H8NOS: 154.0327, found: 154.0331. 
 
3-Vinylfuran-2-carboxaldehyde oxime (46e) 105 mg (48% yield), white amorphous solid. 1H 
NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 7.40 (d, J = 1.6 Hz, 1H), 6.76 (dd, J = 17.4, 10.9 Hz, 1H), 
6.62 (d, J = 1.9 Hz, 1H), 5.59 (dd, J = 17.5, 1.2 Hz, 1H), 5.32 (dd, J = 10.8, 1.2 Hz, 1H). 13C NMR 
(126 MHz, CDCl3) δ 144.3, 143.0, 139.6, 126.5, 125.4, 116.6, 108.9. HRMS (ESI) m/z [M+H]
+ 
for C7H8NO2: 138.0555, found: 138.0549. 
 
5-(Bromomethyl)isoxazole (47) N-bromosuccinimide (2.14 g, 12 mmol, 1 equiv.) and benzoyl 
peroxide (290 mg, 1.2 mmol, 0.1 equiv.) were added to a stirred solution of 5-methylisoxazole (1 
g, 12 mmol, 1 equiv.) in CCl4 (50 mL). The reaction was heated to 80˚C for 5 h then concentrated. 
The resulting residue was redissolved in EtOAc (30 mL) and washed with H2O (3 x 20 mL). The 
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organic layer was separated, dried (Na2SO4), and concentrated. The residue was purified via flash 
chromatography (SiO2, 1:10 EtOAc:Hexanes to 3:10 EtOAc:Hexanes) to provide the title 
compound. 725 mg (38% yield) as a colorless oil.  1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 1.6 
Hz, 1H), 6.33 (d, J = 1.7 Hz, 1H), 4.49 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 166.9, 150.6, 103.1, 
18.3. MS (EI) m/z [M]+ for C4H4BrNO: 160.9, found: 161.0; [M-Br]
+ for C4H4NO: 82.0, found 
82.0. 
 
3,5-Dimethylfuran-2-carboxylic acid (48) A solution of 3-methylfuran-2-carboxylic acid (1 g, 
8 mmol, 1 equiv.) in THF (3 mL) was added to a stirred solution of LDA (1 M in THF, 16 mmol, 
2.1 equiv.) at -78˚C and stirred at this temperature for 15 min followed by the addition of 
iodomethane (1 mL, 16 mmol, 2 equiv.). The reaction was stirred for an additional 15 min at -78˚C 
before removal of the ice bath and slowly warming to room temperature. The reaction was 
quenched with the addition of saturated NH4Cl (50 mL). The organic layer was separated and the 
aqueous layer was extracted with EtOAc (2 x 40 mL). The organic layers were combined, dried 
(Na2SO4), and concentrated. The residue was purified via flash chromatography (SiO2, 3:10 
EtOAc:Hexanes to 3:5 EtOAc:Hexanes) to provide the title compound. 774 mg (69% yield) as a 
white amorphous solid.  1H NMR (400 MHz, CDCl3) δ 12.35 (br, s, 1H), 6.00 (s, 1H), 2.31 (s, 
3H), 2.30 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 164.4, 157.0, 138.0, 135.3, 112.4, 14.0, 11.8. 






(3,5-Dimethylfuran-2-yl)methanol (49a) 575 mg (82% yield), colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 5.80 (s, 1H), 4.52 (s, 2H), 2.24 (s, 3H), 1.99 (s, 3H), 1.62 (br, s, 1H). 
13C NMR (126 
MHz, CDCl3) δ 145.2, 124.2, 115.3, 109.0, 61.4, 13.6, 9.7. MS (EI) m/z [M+H]
+ for C7H11O2: 
127.1, found 127.1. 
 
(3-Chlorothiophen-2-yl)methanol (49b) 240 mg (36% yield), yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.25 (dd, J = 5.4, 1.1 Hz, 1H), 6.90 (dd, J = 5.4, 1.1 Hz, 1H), 4.81 (dd, J = 6.1, 1.3 Hz, 
2H), 2.04 (br s, 1H). 13C NMR (126 MHz, CDCl3) δ 136.0, 127.8, 124.6, 123.0, 57.6. MS (EI) m/z 
[M]+ for C5H5ClOS: 148.0, found 148.0. 
 
(4-Chlorothiophen-2-yl)methanol (49c) 165 mg (25% yield), yellow oil. 1H NMR (400 MHz, 
CDCl3) δ 7.05 (s, 1H), 6.88 (s, 1H), 4.77 (d, J = 5.8 Hz, 2H), 1.92 (br s, 1H). 
13C NMR (126 MHz, 
CDCl3) δ 144.7, 125.5, 124.8, 119.9, 60.1. MS (EI) m/z [M]
+ for C5H5ClOS: 148.0, found: 148.0; 







(50) 40 mg (41% yield), off white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 
1H 
NMR (500 MHz, CDCl3-MeOD) δ 7.30 (d, J = 1.6 Hz, 1H), 7.20 (s, 1H), 6.84 (dd, J = 2.7, 1.4 
Hz, 1H), 6.78 (d, J = 1.4 Hz, 1H), 6.36 (d, J = 2.0 Hz, 1H), 6.15 (d, J = 1.9 Hz, 1H), 4.80 (s, 2H), 
3.78 (d, J = 1.9 Hz, 3H), 3.39 (tt, J = 8.9, 2.5 Hz, 2H), 2.95 – 2.80 (m, 2H). δ  13CNMR (125 MHz, 
CDCl3, MeOD): 170.8, 161.8, 158.1, 147.3, 144.1, 141.6, 141.6, 140.1, 126.7, 121.0, 119.6, 114.7, 
109.4, 106.2, 102.5, 52.4, 41.0, 30.8, 26.1. HRMS (ESI) m/z [M + H]+  for C18H18ClN2O5: 
377.0904, found: 377.0905. 
 
Methyl 3-chloro-2-(2-(1-(furan-2-ylmethyl)-1H-imidazol-2-yl)ethyl)-4,6-dihydroxybenzoate 
(51) 44 mg (45% yield), off white amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 7.31 
(dt, J = 2.4, 1.2 Hz, 1H), 6.87 (dd, J = 2.4, 1.4 Hz, 1H), 6.83 (d, J = 1.5 Hz, 1H), 6.40 (d, J = 1.8 
Hz, 1H), 6.26 (dt, J = 3.5, 1.7 Hz, 1H), 6.18 (d, J = 3.3 Hz, 1H), 4.94 (d, J = 1.6 Hz, 2H), 3.82 (d, 
J = 1.9 Hz, 3H), 3.46 (ddd, J = 10.2, 6.1, 2.0 Hz, 2H), 2.95 (ddd, J = 9.8, 5.9, 1.5 Hz, 2H). 13CNMR 
(125 MHz, CDCl3, MeOD) δ 170.9, 162.0, 158.2, 149.1, 147.4, 143.2, 141.8, 126.9, 119.7, 114.8, 
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110.6, 108.8, 106.2, 102.6, 52.6, 42.6, 30.8, 26.1. HRMS (ESI) m/z [M + H]+ for C18H18ClN2O5: 
377.0904, found: 377.0911. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-((5-methylfuran-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)benzoate (52) 46 mg (46% yield), off white amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 6.87 (d, J = 1.4 Hz, 1H), 6.84 (d, J = 1.4 Hz, 1H), 6.41 (s, 1H), 6.08 (d, J = 3.1 Hz, 1H), 
5.84 (dd, J = 3.0, 1.2 Hz, 1H), 4.88 (s, 2H), 3.84 (s, 3H), 3.49-3.42 (m, 2H), 3.08-2.93 (m, 2H), 
2.18 (d, J = 1.0 Hz, 3H). 13CNMR (125 MHz, CDCl3, MeOD): 171.0, 162.2, 158.3, 153.1, 147.3, 
147.1, 141.9, 126.7, 119.7, 114.9, 109.7, 106.5, 106.1, 102.6, 52.6, 42.7, 30.9, 26.2, 13.5. HRMS 
(ESI) m/z [M+H]+ for C19H20ClN2O5: 391.1061, found: 391.1066. tR = 3.05 min, 95.1%. 
 
Methyl 3-chloro-2-(2-(1-((5-chlorofuran-2-yl)methyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (53) 50 mg (47% yield), white amorphous solid. ( 1H NMR (400 MHz, CDCl3, 
MeOD) δ 6.91 (s, 2H), 6.31 (s, 1H), 6.23 (d, J = 3.4 Hz, 1H), 5.98 (d, J = 3.3 Hz, 1H), 4.87 (s, 
2H), 3.73 (s, 3H), 3.37 – 3.27 (m, 2H), 2.99 (t, J = 7.9 Hz, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 173.9, 165.0, 161.9, 151.1, 150.7, 143.8, 141.6, 124.6, 118.5, 116.3, 111.3 (2C), 106.8 
95 
 
(2C), 56.4, 46.9, 34.1, 29.1. HRMS (ESI) m/z [M+H]+ for C18H17Cl2N2O5: 411.0515, found: 
411.0527. tR = 4.15 min, 95.5%. 
 
Methyl 3-chloro-2-(2-(1-((3,5-dimethylfuran-2-yl)methyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (54). 36 mg (25% yield), off white amorphous solid. 1H NMR (400 MHz, 
CDCl3, MeOD) δ 7.28 (d, J = 2.0 Hz, 1H), 6.92 (s, 1H), 6.44 (s, 1H), 5.77 (s, 1H), 4.80 (s, 2H), 
3.89 (s, 3H), 3.59 – 3.48 (m, 2H), 3.37 (t, J = 7.1 Hz, 2H), 2.11 (s, 3H), 1.92 (s, 3H). 13C NMR 
(126 MHz, CDCl3, MeOD) δ 169.9, 162.0, 157.1, 151.4, 145.7, 140.1, 130.0, 121.6, 120.5, 118.9, 
118.6, 112.1, 111.9, 55.4, 54.2, 46.6, 30.5, 29.7, 24.0, 21.8. HRMS (ESI) m/z [M+H]+ for 
C20H22ClN2O5: 405.1217, found: 405.1210. tR = 3.24 min, 95.5%. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(thiophen-2-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (55) 37 mg (37% yield), yellow amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.23 (dd, J = 5.1, 1.3 Hz, 1H), 6.95 (d, J = 1.5 Hz, 1H), 6.92 (dd, J = 5.1, 3.5 Hz, 1H), 
6.87 (dd, J = 3.5, 1.9 Hz, 2H), 6.43 (s, 1H), 5.17 (d, J = 0.9 Hz, 2H), 3.84 (s, 3H), 3.56 -3.44 (m, 
2H), 3.01-2.92 (m, 2H). 13CNMR (125 MHz, CDCl3, MeOD) δ 170.9, 162.1, 158.2, 147.3, 141.7, 
138.5, 127.2, 126.9, 126.4, 126.2, 119.7, 114.9, 106.2, 102.7, 52.6, 44.7, 30.9, 26.2. HRMS (ESI) 
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m/z [M+H]+ for C18H18ClN2O4S:
 393.0676, found: 393.0674. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(thiophen-3-ylmethyl)-1H-imidazol-2-
yl)ethyl)benzoate (56). 28 mg (27% yield), yellow amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.25 (d, J = 4.8 Hz, 1H), 6.98 – 6.92 (m, 2H), 6.83 (d, J = 1.5 Hz, 1H), 6.81 – 6.78 (m, 
1H), 6.37 (s, 1H), 4.97 (s, 2H), 3.79 (s, 3H), 3.43 – 3.37 (m, 2H), 2.95 – 2.88 (m, 2H). 13C NMR 
(126 MHz, CDCl3, MeOD) δ 174.5, 165.7, 162.0, 151.1, 145.0, 140.3, 131.3, 130.0, 129.4, 126.7, 
124.0, 118.6, 110.2, 106.5, 56.4, 49.3, 34.5, 29.7. HRMS (ESI) m/z [M+H]+ for C18H18ClN2O4S: 
393.0676, found: 393.0693. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-((5-methylthiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)benzoate (57). 23 mg (22% yield), off white amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.34 (d, J = 1.8 Hz, 1H), 7.02 – 6.96 (m, 1H), 6.79 (d, J = 4.1 Hz, 1H), 6.60 (d, J = 2.7 
Hz, 1H), 6.48 (s, 1H), 5.03 (s, 2H), 3.95 (s, 3H), 3.58 (t, J = 7.2 Hz, 2H), 3.39 (t, J = 7.2 Hz, 2H), 
2.41 (s, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 169.8, 161.9, 158.2, 145.6, 138.8, 131.1, 
129.1 (2C), 125.6 (2C), 120.6, 119.1, 106.3, 103.5, 53.2, 46.0, 30.1, 24.2 15.3. HRMS (ESI) m/z 





dihydroxybenzoate (58). 20 mg (18% yield), yellow amorphous solid. 1H NMR (500 MHz, CDCl3, 
MeOD) δ 6.95 (s, 1H), 6.87 (s, 1H), 6.68 (d, J = 3.5 Hz, 1H), 6.63 (d, J = 3.5 Hz, 1H), 6.37 (s, 
1H), 5.03 (s, 2H), 3.81 (s, 3H), 3.47 – 3.37 (m, 2H), 3.02 – 2.92 (m, 2H). 13C NMR (126 MHz, 
CDCl3, MeOD) δ 174.3, 165.6, 162.0, 150.9, 144.7, 140.2, 134.9, 130.2, 130.1, 129.4, 123.7, 
118.6, 110.3, 106.7, 56.5, 48.8, 34.5, 29.6. HRMS (ESI) m/z [M+H]+ for C18H17Cl2N2O4S: 
427.0286, found: 427.0292. 
 
Methyl 3-chloro-2-(2-(1-((4-chlorothiophen-2-yl)methyl)-1H-imidazol-2-yl)ethyl)-4,6-
dihydroxybenzoate (59). 23 mg (21% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 6.97 (s, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 6.67 (s, 1H), 6.38 (s, 1H), 5.07 (s, 2H), 3.81 (s, 
3H), 3.45 – 3.39 (m, 2H), 2.88 (t, J = 8.2 Hz, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.6, 
161.8, 158.1, 147.3, 141.5, 139.6, 127.3, 126.2, 125.1, 120.1, 119.5, 114.7, 106.0, 102.5, 52.4, 





dihydroxybenzoate (60). 17 mg (15% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.21 (dd, J = 5.9, 2.3 Hz, 1H), 6.90 (d, J = 2.1 Hz, 1H), 6.86 (dt, J = 5.2, 1.8 Hz, 2H), 
6.41 (s, 0H), 5.09 (s, 0H), 3.84 (s, 2H), 3.54 – 3.45 (m, 2H), 2.96 (dd, J = 11.9, 5.4 Hz, 3H). 13C 
NMR (126 MHz, CDCl3, MeOD) δ 170.8, 162.1, 158.0, 147.2, 141.7, 131.3, 127.9, 127.3, 125.2, 
124.2, 119.3, 114.8, 106.0, 102.6, 52.5, 42.0, 30.8, 26.2. HRMS (ESI) m/z [M+H]+ for 
C18H16Cl2N2O4S: 427.0286, found: 427.0278. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(isoxazol-5-ylmethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(61). 15 mg (15% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 8.17 (s, 1H), 
6.96 (s, 1H), 6.89 (s, 1H), 6.42 (s, 1H), 6.04 (s, 1H), 5.17 (s, 2H), 3.88 (s, 3H), 3.50 – 3.41 (m, 
2H), 2.97 – 2.89 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.6, 166.3, 158.0, 150.4, 
147.6, 141.5, 127.8, 119.7, 114.6, 106.1, 102.6, 102.5, 102.1, 52.6, 41.2, 30.9, 26.0. HRMS (ESI) 





(62). 41 mg (40% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, MeOD) δ 7.72 (d, J = 
3.2 Hz, 1H), 7.30 (d, J = 3.3 Hz, 1H), 6.99 (s, 1H), 6.95 (s, 1H), 6.43 (s, 1H), 5.35 (s, 2H), 3.87 (s, 
3H), 3.51 – 3.46 (m, 2H), 2.98 – 2.91 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.7, 
165.8, 162.1, 157.9, 147.6, 143.1, 141.6, 127.8, 120.3, 119.8, 114.7, 106.0, 102.6, 52.6, 46.8, 30.8, 
26.1. HRMS (ESI) m/z [M+H]+ for C17H17ClN3O4S: 394.0628, found: 394.0630. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-((3-vinylthiophen-2-yl)methyl)-1H-imidazol-2-
yl)ethyl)benzoate (63). 35 mg (32% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.19 (d, J = 5.3 Hz, 1H), 7.15 (d, J = 5.3 Hz, 1H), 7.01 (s, 1H), 6.77 (s, 1H), 6.58 (dd, J 
= 17.3, 10.9 Hz, 1H), 6.45 (s, 1H), 5.56 (d, J = 17.3 Hz, 1H), 5.31 (d, J = 11.0 Hz, 1H), 5.11 (s, 
2H), 3.87 (s, 3H), 3.58 – 3.49 (m, 2H), 3.07 (t, J = 7.8 Hz, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 170.9, 163.2, 156.1, 142.8, 140.7, 139.8, 138.5, 130.5, 128.7, 128.5, 126.7, 126.5, 126.0, 
113.9, 106.7, 102.6, 52.6, 38.4, 34.0, 32.5. HRMS (ESI) m/z [M+H]+ for C20H20ClN2O4S: 





yl)ethyl)benzoate (64). 35 mg (33% yield), off white amorphous solid 1H NMR (400 MHz, CDCl3, 
MeOD) δ 7.30 (d, J = 2.0 Hz, 1H), 6.84 (d, J = 1.8 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 6.49 (s, 1H), 
6.48 – 6.41 (m, 1H), 5.50 (d, J = 17.3 Hz, 1H), 5.26 (d, J = 11.0 Hz, 1H), 4.94 (s, 2H), 3.91 (s, 
3H), 3.59 (t, J = 7.6 Hz, 2H), 3.22 (t, J = 7.7 Hz, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 
170.4, 162.1, 158.0, 146.6, 143.6 (2C), 124.5 (2C), 123.7, 119.9 (2C), 116.6, 114.8, 108.3 (2C), 




dihydroxybenzoate (65). 43 mg (39% yield), tan amorphous solid. 1H NMR (500 MHz, CDCl3, 
MeOD) δ 7.16 (d, J = 5.2 Hz, 1H), 6.91 (d, J = 1.4 Hz, 1H), 6.86 (d, J = 5.2 Hz, 1H), 6.73 (d, J = 
1.5 Hz, 1H), 6.45 (s, 1H), 5.04 (s, 2H), 3.86 (s, 3H), 3.56 – 3.50 (m, 2H), 3.00 – 2.95 (m, 2H), 2.53 
(q, J = 7.6 Hz, 2H), 1.12 (t, J = 7.6 Hz, 3H). 13C NMR (126 MHz, CDCl3, MeOD) δ 170.8, 162.2, 
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157.9, 147.1, 142.2, 141.8, 130.8, 128.7, 127.0, 124.6, 119.1, 114.7, 106.0, 102.6, 52.6, 42.3, 30.8, 
26.3, 21.5, 14.9. HRMS (ESI) m/z [M+H]+ for C20H22ClN2O4S: 421.0989, found: 421.0995. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-2-ylmethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(66). 15 mg (15% yield), tan amorphous solid. 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 5.0 Hz, 
1H), 7.68 (td, J = 7.7, 1.9 Hz, 1H), 7.13 (d, J = 1.5 Hz, 1H), 6.99 (d, J = 1.6 Hz, 1H), 6.89 (d, J = 
7.9 Hz, 1H), 6.51 (s, 0H), 5.23 (s, 1H), 3.89 (s, 1H), 3.52 (t, J = 7.9 Hz, 2H), 3.05 (t, J = 8.0 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 170.5, 162.8, 157.7, 150.0 (2C), 147.4, 137.5 (3C), 123.4, 
121.1, 120.7, 114.6, 106.0, 103.2, 52.9, 51.5, 30.6, 25.4. HRMS (ESI) m/z [M–H]- for 
C19H18ClN3O4: 386.0908, found: 386.0899. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-3-ylmethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(67). 25 mg (25% yield), yellow amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 8.44 (d, 
J = 4.3 Hz, 1H), 8.30 (s, 1H), 7.32 (d, J = 6.0 Hz, 1H), 7.31 – 7.24 (m, 1H), 6.98 (s, 1H), 6.83 (s, 
1H), 6.38 (s, 1H), 5.06 (s, 2H), 3.83 (s, 3H), 3.48 – 3.37 (m, 2H), 2.90 – 2.84 (m, 2H). 13C NMR 
(126 MHz, CDCl3, MeOD) δ 174.4, 165.7, 162.0, 152.9, 152.8, 151.5, 145.2, 138.9, 136.3, 131.1, 
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128.1, 123.8, 118.6, 110.1, 106.5, 56.4, 50.8, 34.7, 30.0. HRMS (ESI) m/z [M–H]- C19H18ClN3O4: 
386.0908, found: 386.0903. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(1-(pyridin-4-ylmethyl)-1H-imidazol-2-yl)ethyl)benzoate 
(68). 32 mg (30% yield), yellow amorphous solid. 1H NMR (500 MHz, CDCl3, MeOD) δ 8.44 – 
8.29 (m, 2H), 6.95 (d, J = 1.4 Hz, 1H), 6.88 – 6.82 (m, 2H), 6.81 (d, J = 1.5 Hz, 1H), 6.30 (s, 1H), 
5.03 (s, 2H), 3.78 (s, 3H), 3.40 – 3.28 (m, 2H), 2.78 – 2.71 (m, 2H). 13C NMR (126 MHz, CDCl3, 
MeOD) δ 170.4, 161.5, 157.9, 149.6 (2C), 147.8, 146.4, 141.1, 127.4, 121.3 (2C), 120.2, 114.5, 




yl)ethyl)benzoate (69). 45 mg (45% yield), white amorphous solid. 1H NMR (500 MHz, CDCl3, 
MeOD) δ 9.09 (s, 1H), 8.46 (s, 2H), 7.05 (s, 1H), 6.92 (s, 1H), 6.40 (s, 1H), 5.12 (s, 2H), 3.86 (s, 
3H), 3.52 – 3.36 (m, 2H), 3.00 – 2.79 (m, 2H). 13C NMR (126 MHz, CDCl3, MeOD) δ 174.1, 
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165.4, 161.9, 159.5, 159.4, 159.4, 151.4, 144.7, 134.1, 130.8, 123.8, 118.5, 110.4, 106.7, 56.5, 
48.8, 34.7, 29.8. HRMS (ESI) m/z [M–H]- C18H17ClN4O4: 387.0860, found: 387.0861. 
Fluorescence polarization. Assay was performed in 96-well format in black, flat bottom plates 
(Santa Cruz Biotechnology) with a final volume of 100µL. 25µL of assay buffer (20 mM HEPES, 
pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% 
NP-40), 25µL of assay buffer containing 6nM FITC-GDA (fluorescent tracer, stock in DMSO and 
diluted in assay buffer), and 50µL of assay buffer containing 10nM of either Grp94, Hsp90α, or 
Hsp90β were added to each well. Compounds were tested in triplicate wells (1% DMSO final 
concentration). For each plate wells containing buffer only (background), tracer in buffer only 
(low polarization control), and protein and tracer in buffer with 1% DMSO (high polarization 
control) were included. Plates were incubated at 4˚C with rocking for 24h. Polarization values (in 
mP units) was measured at 37˚C with an excitation filter at 485nm and an emission filter at 528nm. 
Polarization values were correlated to % tracer bound and compound concentrations. The apparent 
Kd of compounds of interest is defined as the concentration at which the tracer was 50% displaced 
by the inhibitor. 
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3. Second Generation Grp94-selective Inhibitors Provide Opportunities for 
the Inhibition of Metastatic Cancer 
Introduction 
The 90 kDa heat shock protein (Hsp90) family is responsible for the maturation of nascent 
polypeptides and the re-maturation of denatured proteins. Hsp90 has gained considerable interest 
as a therapeutic target, because Hsp90-dependent proteins, clients, are directly associated with all 
ten hallmarks of cancer.1-2 Therefore, inhibition of Hsp90 results in simultaneous disruption of 
multiple oncogenic pathways that are essential to cancer progression via a single molecular target. 
Seventeen small molecule Hsp90 inhibitors have progressed into clinical trials for the treatment of 
various forms of cancer.3-4 Unfortunately, these inhibitors have produced various toxicities that 
have dampened enthusiasm for Hsp90 as a therapeutic target.5-6 All of these clinical candidates are 
pan-Hsp90 inhibitors and target all four Hsp90 isoforms with similar affinity, which has been 
suggested to cause some on-target toxicities, such as cardiotoxicity, gastrointestinal toxicity, and 
ocular toxicity.7 In addition to these toxicities, pan-Hsp90 inhibition induces the pro-survival heat 
shock response (HSR).8 The HSR induces the expression of various heat shock proteins, including 
Hsp90, which results in significant dosing and scheduling issues in the clinic. Therefore, 
alternative approaches toward Hsp90 inhibition are needed to overcome the potential liabilities 
associated with pan-Hsp90 inhibition.  
One approach that has gained considerable interest in recent years is the development of Hsp90 
isoform-selective inhibitors.7, 9-12 The Hsp90 protein family is composed of four isoforms: Hsp90α 
and Hsp90β reside in the cytosol, TRAP1 is localized to the mitochondria, and Grp94 is found in 
the endoplasmic reticulum. Grp94 is responsible for the maturation and trafficking of proteins 
associated with cell signaling and motility.13 Some Grp94-dependent proteins have been identified 
109 
 
and include some Toll-like receptors, select integrins, IGF-I and -II, LRP6, and mutant myocilin.13-
16 Consequently, Grp94 has been implicated for the treatment of disease states that include 
metastatic cancer (integrins), glaucoma (mutant myocilin), multiple myeloma (LRP6), and 
hepatocellular carcinoma (reliance upon a functional ER chaperone system).10, 14-15, 17 While Grp94 
is essential during embryonic development, it is non-essential in developed organisms.18 
Therefore, Grp94 inhibition could provide a therapeutic opportunity that exhibits fewer toxic 
liabilities than pan-Hsp90 inhibition for the treatment of some diseases (e.g. glaucoma). In 
contrast, some disease states rely more heavily upon a functional ER chaperone system, such as 
multiple myeloma and hepatocellular carcinoma, wherein Grp94 knockouts decrease the viability 
of these cancers, highlighting Grp94 as a potential target for these cancers (discussed further in 
Chapter 4). The development of Hsp90 isoform-selective inhibitors is hindered by >85% identity 
within the N-terminal ATP-binding site of all four isoforms, which poses a significant challenge 
to the rational design of Hsp90 isoform-selective inhibitors.19-21  
Second Generation Grp94-selective Inhibitor Design 
The nucleotide binding site of Grp94 is most unique among the four isoforms, due to a five 
amino acid insertion into its primary sequence which results in secondary binding pockets that can 
be exploited for selective inhibition. The first Grp94-selective inhibitor was developed via 
incorporation of a cis-amide bioisostere into the RDA scaffold (1, Figure 3.1) to predispose the 
side chain into the Grp94-exclusive S1 sub-pocket, ultimately leading to the development of BnIm 
(2, Figure 3.1), which manifested ~12-fold selectivity via a fluorescence polarization assay.22 
Subsequent structure-activity relationship studies on the benzyl side chain of 2 resulted in the 
development of KUNG29 (3), which exhibited improved affinity and selectivity for Grp94 as 
compared to 2 (Figure 3.1).10 Interestingly, substitutions at the 2-position of the benzyl side chain 
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(3-5) manifested the greatest Grp94-selectivity (Figure 3.1), and suggested that projection of the 
side chain into this region could improve selectivity. Analysis of the co-crystal structure of 
KUNG38 bound to Grp94 suggested that modification of the cis-amide bioisostere (imidazole) 
could orient the side chain to mimic substitutions present in 3-5 and increase both selectivity and 
affinity. 
Replacement of the first generation imidazole with a phenyl ring was hypothesized to serve 
multiple purposes: 1) The larger 6-membered ring would reduce the angle between the benzyl side 
chain and the resorcinol moiety (Figure 3.2a) and mimic the binding mode of 3-5 to improve 
selectivity; 2) Removal of the polar nitrogen atoms within the imidazole ring could improve 
interactions with the more hydrophobic binding site present in Grp94 (Figure 3.2b);23 and 3) The 
phenyl ring could provide a synthetic handle to identify substituents that interact with polar 
residues at the solvent exposed region without participation in the extensive hydrogen bond 
network present in Hsp90 (Figure 3.2c). The ortho-substituted phenyl derivative, 6, reduced the 
 
Figure 3.1. First generation Grp94-selective inhibitors.  
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angle between the resorcinol moiety and the benzyl side chain (~72˚ ~60˚), which can mimic 2-
substitutions on the benzyl side chain of the first generation Grp94 inhibitors and potentially 
improve Grp94 selectivity. Alternatively, the meta-substituted phenyl derivative 7 increased the 
angle between these two substituents (~72˚  ~120˚), which should reduce Grp94 affinity and 
selectivity due to steric limitations that result from the backbone carbonyl of Asn162. Herein, the 
 
Figure 3.2. Rational design for second generation Grp94-selective inhibitors. (a) Replacement of the cis-amide 
linker to decrease (6) and increase (7) the angle between the benzylic side chain and the resorcinol moiety. (b) 
The water mediated hydrogen bonding network in Hsp90 (right, PDBID: 2FXS) is much more extensive than that 
of Grp94 (left, PDBID: 2GFD, trans-RDA omitted for clarity). (c) 6 docked into Grp94 (PDBID: 5IN9) 
demonstrating that polar residues are present in the region which the linker is proposed to bind can be utilized to 
increase affinity for Grp94. 
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synthesis and biological evaluation of Grp94-selective inhibitors with replacements for the cis-
amide bioisostere linker is reported. 
Synthesis and Biochemical Evaluation of Second Generation Grp94-selective 
Inhibitors 
Synthesis of the designed analogues, 6 and 7, was envisioned to occur via a Heck coupling 
between aryl bromide 8 and 2- or 3-benzylstyrene (9a and 9b, respectively), followed by 
hydrogenolysis of the benzyl ethers and concomitant reduction of the alkene. This synthetic route 
allowed for late-stage diversification and provided access to various analogues in a succinct 
manner (Scheme 3.1). Aryl bromide 8 was synthesized from 1-bromo-3,5-dimethoxybenzene in 6 
steps, 28% overall yield, and required only one chromatographic separation. The methyl ethers of 
Scheme 3.1. Synthesis 2nd Generation Grp94-Selective Inhibitors of 6 and 7. 
 
Conditions: (a) Py HCl, 220˚C; (b) BnBr, K2CO3, DMF; (c) AgOTf, 1,1-dichloromethyl methyl ether, DCM, -
78˚C; (d) NaClO2, NaH2PO4, 2-methyl-2-butene/tBuOH/H2O; (e) LiOH, Me2SO4, THF; (f) SO2Cl2, THF, <-30˚C; 




1-bromo-3,5-dimethoxybenzene were cleaved via pyridinium hydrochloride, which provided the 
free phenols after an acidic workup. The phenols were subsequently converted to the benzyl ethers 
(11) upon treatment with benzyl bromide and potassium carbonate. Silver-promoted formylation 
of 11 and subsequent Pinnick oxidation yielded benzoic acid 12.24 Conversion of 12 to the 
corresponding methyl ester was achieved upon exposure to dimethyl sulfate followed by 
regioselective chlorination upon reaction with sulfuryl chloride at -30˚C, which provided the 
desired resorcinol 8 (Scheme 3.1).25 Synthesis of 9a and 9b commenced via a palladium-catalyzed 
cross coupling reaction between commercially available 2- and 3-formylphenyl boronic acid and 
benzyl bromide to provide the corresponding 2- and 3-benzylbenzaldehydes (13a and 13b, 
respectively). Subsequent Wittig olefination afforded the 2- and 3-benzylstyrenes (9a and 9b, 
respectively), which were then subjected to Heck olefination conditions with aryl bromide 8.26 
Hydrogenolysis of the benzyl ethers and reduction of the olefin under a hydrogen atmosphere 
provided the desired analogues 6 and 7 (Scheme 3.1).  











1.15 ± 0.1 13.1 ± 1.1 12 
6 
 
0.63 ± 0.03 20.7 ± 0.5 32 
7 
 
10.4 ± 0.2 >100a >10 




Compounds 6 and 7 were evaluated via a fluorescence polarization assay to determine Grp94 
affinity and selectivity.27 As seen in Table 3.1, 6 produced an apparent Kd of 0.63 µM along with 
32-fold selectivity for Grp94 over Hsp90α, which represented ~2-fold improvement over 2. In 
contrast, 7 exhibited a significant reduction in both affinity and selectivity (apparent Kd = 10.4 µM 
and >10-fold selective) for Grp94. These data suggested that reduction of the angle between the 
resorcinol moiety and the benzyl side chain was beneficial for Grp94 affinity and selectivity. 
Therefore, structure-activity relationship studies were performed on the phenyl linker of 6 to probe 
interactions between the phenyl ring and polar residues surrounding this linker.  
As seen in Figure 3.2c, the linker was proposed to bind adjacent to polar residues (Glu158 and 
Asn162) at the solvent exposed region of the binding pocket. Therefore, hydrogen bond donors 
and acceptors were incorporated onto the linker to improve Grp94 affinity. In addition, a pyridine 
ring (in lieu of the phenyl linker) was included to investigate the electronic nature of the linker. 
Scheme 3.2. Synthesis of 16-24 possessing hydrogen bond donating and accepting group substituted linkers. 
Conditions: (a) BnBr, Pd(PPh3)4, K2CO3; (b) MePh3P+Br-, nBuLi; (c) Potassium benzyltrifluoroborate, Pd(OAc)2, 
RuPhos, K3PO4; (d) BnBr, K2CO3; (e) 9c-9k, Pd(OAc)2, triethanolamine; (f) H2, Pd/C. 
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Both 9c and 9d were synthesized using similar conditions to 9a and 9b as outlined in Scheme 3.1. 
As shown in Scheme 3.2, commercially available aryl bromides 14a-d and 15a-c were subjected 
to a palladium-catalyzed cross coupling reaction with potassium benzyltrifluoroborate, RuPhos, 
and palladium (II) acetate to provide benzaldehydes 13e-k. Conversion of benzaldehydes 13e-k to 
the corresponding styrenes 9c-k was achieved via a Wittig reaction with 
methyltriphenylphosphonium bromide and n-butyllithium. The corresponding alkenes were then 
subjected to a Heck reaction with 8, followed by simultaneous cleavage of the benzyl ethers and 
reduction of the alkene via hydrogen gas and palladium on carbon to provide analogues 16-24.  
Under hydrogenation conditions, the nitro group was also reduced to the corresponding aniline 
(19 and 20) and hydrogenolysis of the benzyl ethers present on the linker ring produced the free 
phenols, 22-24. 
Data obtained via a fluorescence polarization assay with these compounds (Table 3.2) 
suggested that incorporation of hydrogen bond acceptors (16-18) did not significantly improve 
affinity (apparent Kd’s = 0.45-0.73 µM). However, hydrogen bond donors (19, 20, 22-24) did 
improve Grp94 affinity and these compounds exhibited apparent Kd values between 0.24-0.54 
µM. Unfortunately, both hydrogen bond acceptors and donors produced a significant loss in Grp94 
selectivity. Of these analogues, 18 manifested the highest selectivity (19-fold), which was 
considerably less than analogue 6 (32-fold selective). Replacement of the phenyl ring with a 
pyridine linker (21) substantially increased affinity (apparent Kd = 0.18 µM) as compared to 6; 
however this substitution also produced high affinity for Hsp90α (0.16 µM) and resulted in no 

















0.63 ± 0.03 20.7 ± 0.5 32 
16 
 
0.45 ± 0.04 2.2 ± 0.2 5 
17 
 
0.68 ± 0.04 2.6 ± 0.6 4 
18 
 
0.73 ± 0.1 13.7 ± 1.4 19 
19 
 
0.28 ± 0.04 1.0 ± 0.1 4 
20 
 
0.24 ± 0.04 0.34 ± 0.07 n/a 
21 
 
0.18 ± 0.01 0.16 ± 0.02 n/a 
22 
 












0.33 ± 0.01 0.92 ± 0.03 3 
24 
 
0.54 ± 0.02 2.0 ± 0.2 4 
Apparent Kd values are the average of two independent experiments ± SEM. n/a = non-selective 
Due to the low selectivity produced by 16-24, additional structure-activity relationship studies 
were sought to improve both Grp94 selectivity and affinity. 16-24 were synthesized to contain the 
benzyl side chain of 2 to rapidly evaluate modifications about the linker as the side chain of 2 was 
previously optimized to achieve >40-fold Grp94-selectivity (see Figure 3.1). Incorporation of the 
Grp94-selective 2-ethoxy- and 2-methoxybenzyl side chains (3 and 4) to analogues with a phenyl 
linker were proposed to further increase Grp94 selectivity. Synthesis of 25 and 26 was achieved 
through a route similar to that utilized to construct 6 (Scheme 3.3). Upon their preparation, these 
Scheme 3.3. Synthesis of side chain substituted analogues 25-31. 
 
Conditions: (a) Pd(PPh3)4, K2CO3, benzyl bromides; (b) MePh3P+Br-, nBuLi; (c) Pd(dppf)Cl2, K3PO4, 4-
fluorobenzylboronic acid pinacol ester; (d) Pd(OAc)2, 9l-9r, triethanolamine; (e) H2, Pd/C. 
118 
 
analogues were evaluated via fluorescence polarization, and demonstrated low affinity (apparent 
Kd = 6.1 µM and 7.8 µM, respectively, Table 3.3 ). The loss in affinity exhibited by 25 (compared 
to 3) suggests the phenyl linker does not bind in a similar manner compared to the first generation 
imidazole-linked inhibitors. Therefore, a chloride scan was performed to identify an optimal side 
chain for the phenyl-linked analogues. Synthesis of 27-29 was performed in a manner similar to 
that used for 25 (Scheme 3.3). Once prepared, these analogues were evaluated for Grp94 affinity 
and selectivity via the fluorescence polarization assay, and as shown in Table 3.3, 27 and 29 
manifested >18- and >24-fold selectivity for Grp94, respectively. However, this gain in selectivity 
was accompanied by ~10-fold reduction in Grp94 affinity as compared to 6, which suggests a 
potential steric clash between the chloride-substituted side chains and the hydrophobic pocket of 
Grp94. Due to the size difference between the hydrogen of 6 and the chloride of 29, a fluoride was 
incorporated into the 4-position of the side chain to reduce detrimental steric interactions. 
Gratifyingly, 30 produced an apparent Kd of 0.54 µM and was 73-fold selective for Grp94. The 
smaller fluoride substitution (compared to the chloride of 29) appears to minimize steric 
interactions with the hydrophobic pocket and provide a small increase in Grp94 affinity as 
compared to 6.  























6.1 ± 0.3 >100a >16 
26 
 
7.8 ± 0.4 >100a >13 
27 
 
5.5 ± 0.1 >100a >18 
28 
 
11.9 ± 1.8 44.6 ± 2.0 4 
29 
 
4.2 ± 0.7 >100a 24 
30 
 
0.54 ± 0.05 39.2 ± 2.7 73 
31 
 
0.36 ± 0.02 0.46 ± 0.03 n/a 
a 100 µM was the highest concentration tested. Apparent Kd values are the average of two independent experiments ± 
SEM. n/a = non-selective 
Efforts to combine the high affinity produced by the linker of 21 and increased selectivity 
exhibited by the side chain 30 were pursued in the form of 31. Synthesis of 31 was accomplished 
via a palladium-catalyzed cross coupling reaction between 14d and 4-fluorobenzylboronic acid 
pinacol ester (32)28 to provide aryl aldehyde 13r, which was then converted to the corresponding 
styrene 9r. A Heck coupling reaction between 9r and 8 followed by hydrogenolysis of the benzyl 
ethers and reduction of the alkene provided 31 (Scheme 3.3). Evaluation of 31 against Grp94 and 
Hsp90α via fluorescence polarization gave apparent Kd values of 0.36 µM and 0.46 µM, 
respectively. Ultimately, the 4-fluoro side chain produced ~2-fold loss in Grp94 affinity (compared 
to 21) and a complete loss of selectivity. These data suggest the pyridine linker oriented the side 
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chain towards the solvent exposed region of the binding pocket in order to avoid repulsive 
interactions between the pyridine nitrogen and the hydrophobic S1 sub-pocket of Grp94.  
Crystallization of 6, 21, and 30 with Grp94 Provides Rationale for Increased 
Selectivity 
Crystal structures of the Grp94 N-terminal domain in complex with 6, 21, and 30 revealed 
binding modes that can explain differences in their selectivity and affinity profiles, as well as the 
binding interactions for similar compounds within this series (Figure 3.3a, c, and e). The 
resorcinol ring was anchored within the N-terminal ATP-binding site through direct interactions 
with Asp149 and Thr245, and a hydrogen bonding network with water molecules (Figure 3.3b, d, 
and f).10, 23 Interestingly, 6 and 30 were best modeled via two partially occupied binding modes. 
The first, termed “benzyl in”, aligns with the previously observed binding mode of the first 
generation Grp94-selective inhibitor, KUNG38 (PDBID: 5IN9), wherein the benzylic side chain 
is oriented towards the Grp94-exclusive S1 sub-pocket.10 When crystallized with 6, Grp94 loop 
residues 167-170 which make up a portion of the aforementioned unique binding region, appeared 
disordered, suggesting that interactions between this loop and the unsubstituted terminal benzene 
ring of 6 were not stabilizing (Figure 3.3a). Alternatively, when crystallized with 30, the main 




interactions mediated by the fluoride substituent stabilized these residues, leading to slightly 
improved Grp94 binding affinity (Figure 3.3c). The second binding mode, termed “benzyl out”, 
positioned the benzyl side chain in the solvent-exposed region of the Grp94 binding pocket. The 
phenyl linker of 6 is rotated ~180˚ in this conformation compared to the “benzyl in” conformation, 
 
Figure 3.3. Crystal structures of 6 (a and b, PDBID: 6AOM), 30 (c and d, PDBID: 6AOL), and 21 (e and f) 
bound to Grp94. (a, c, e) Surface representation of nucleotide binding pocket of Grp94 occupied by 6 (a), 30 
(c), and 21 (e) which are shown as ball and stick. Alternate conformations of 6 and 30 are indicated by off-
shade coloration. Arrow in (c) indicates loop stabilized at the mouth of the binding pocket through hydrophobic 
interactions with fluorine substituent of 30. (b, d, f) Hydrogen-bond-mediated protein-inhibitor interactions 






which orients the terminal benzene ring into the vicinity of the ε-NH2 of Lys114, suggesting a 
stabilized cation-π interaction (Figure 3.3b); direct confirmation of such an interaction is limited 
by the partial occupancy of 6 in this orientation, but appears likely. Alternatively, the phenyl linker 
of 30 only rotated ~90˚ and did not appear to orient the terminal benzene ring into position to form 
this interaction (Figure 3.3d). Since Lys114 is conserved amongst Hsp90 isoforms (Lys44 
cytosolic Hsp90s), interactions with this residue will likely affect selectivity. In sum, the improved 
selectivity of 30 appears to result from decreased affinity for Hsp90 rather than a significant 
improvement in affinity for Grp94. Conversely, non-selective inhibitors, like 21, appear to favor 
the binding mode in which Lys114/Lys44 forms a cation-π interaction. When crystallized with 
Grp94, 21 occupied only one conformation, which was similar to the “benzyl out” conformation 
(Figure 3.3f), and form a cation-π interaction with Lys114, providing some rationale for the 
increased affinity and non-selective binding profile of this inhibitor. 
Integrins are Dependent on Grp94 for their Maturation and Trafficking to the Cell 
Surface 
Integrins are essential to cellular adhesion and the activation of migration/invasion through 
promoting interactions between the intracellular actin cytoskeleton and the extracellular matrix.29 
Activation of integrin signaling promotes initiation of intracellular signaling pathways that alter 
gene expression, cell cycle regulation, and actin dynamics, ultimately resulting in cellular 
migration and invasion away from the primary tumor to form metastatic lesions.30 Grp94 
overexpression has been correlated with tumor aggressiveness and metastatic potential resulting 
in poor prognoses for patients with increased Grp94 expression.31 Therefore, Grp94-selective 
inhibitors were evaluated for their ability to decrease the migration of aggressive cancer cell lines 
in a model of metastatic cancer. BnIm, KUNG29, KUNG38 (see Figure 3.1), and 30 were 
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evaluated for their ability to decrease cell migration of the metastatic breast cancer cell line, MDA-
MB-231. 
Evaluation of Grp94-selective inhibitors in a wound healing scratch assay was used to 
determine the potential of Grp94 inhibitors as anti-metastatic agents. The first Grp94-selective 
inhibitor, BnIm, reduced cell migration against this cell line and led to 73% closure of the wound 
at 10µM after 24 h (Figure 3.4). First generation Grp94-selective inhibitors, KUNG29 and 
KUNG38, exhibited similar effects (70% and 73%, respectively), but at 20-fold lower 
concentrations (0.5 µM).10 Lastly, treatment with 30 resulted in only 40% wound closure at 0.5 
µM (Figure 3.4). These anti-migratory activities occurred at concentrations well below the anti-
proliferative activities of these compounds which, together, demonstrated that Grp94-selective 
inhibition results in an anti-migratory effect that is not due to decreased proliferation.  
Based on these results, 30 was evaluated in other aggressive cancer cell lines to determine if 
Grp94-selective inhibition could be applicable to multiple types of cancer. As seen in Figure 3.5, 
30 demonstrated a dose-dependent decrease in cell migration against aggressive prostate (PC3-
MM2) and melanoma (SK-MEL-28) cell lines. PC3-MM2 cells were similarly susceptible to 
Grp94-selective inhibition as MDA-MB-231; however, SK-MEL-28 cells demonstrated a reduced 
 
Figure 3.4. Grp94-selective inhibition reduces cellular migration of a metastatic breast cancer cell line (MDA-
MB-231) after 24 h. Scale bar = 100 µm. 
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susceptibility to Grp94 inhibition after 24 h which suggests that Grp94-dependent integrins are not 
the major contributor to cellular migration for this cell line. Together, these data suggest that 
Grp94-selective inhibition represents a new opportunity to inhibit cellular migration of multiple 
aggressive cell lines.  
Increased integrin expression has been positively correlated with increased metastatic 
aggressiveness for lung squamous cell carcinoma, and therefore, Grp94 inhibition could reduce 
the metastatic potential of this cancer.32-33 Grp94-selective inhibition with 30 was evaluated against 
a non-metastatic lung cancer cell line (A549) and demonstrated an anti-migratory effect at 0.5 µM; 
however this effect was reduced when compared to the highly metastatic breast, prostate, and 
melanoma cancers described above as a consequence of the non-aggressive nature of the A549 
cell line (Figure 3.5). The limited efficacy of Grp94 inhibition in this non-aggressive cancer 
 
Figure 3.5. Compound 30 inhibits the migration of multiple aggressive cancer cell lines. *Due to the non-
aggressive nature of the A549 cell line, the wound only closed 84% in vehicle treated cells. Data for inhibitor 
treated cells was normalized to the vehicle control = 100%. 
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suggests that the efficacy of Grp94-selective inhibition correlates directly with the aggressiveness 
nature of a cancer due to Grp94 overexpression in metastatic cancers. 
 Grp94-selective Inhibition Results in the Degradation of Integrin α2 
The integrin α2 subunit is dependent upon Grp94 for its maturation and trafficking to the cell 
surface.34 Integrin α2 is found as a heterodimer with the β1 integrin subunit and is responsible for 
binding collagen in the extracellular matrix, which promotes cancer metastasis and invasion.35-36 
Increased expression of integrin α2β1 has been reported in both primary and metastatic tissue 
samples of melanoma from patients, suggesting this cancer utilizes Grp94-dependent integrins to 
facilitate migration.37 As shown in Figure 3.6a, treatment with first and second generation Grp94-
 
Figure 3.6.  Western blot analysis for the Grp94-dependent client protein Integrin α2 after treatment with Grp94-
selective inhibitors. (a) MDA-MB-231 breast cancer cell line and (b) PC3-MM2 (prostate), SK-MEL-28 




selective inhibitors induced the degradation of integrin α2 in the metastatic breast cancer cell line, 
MDA-MB-231. Compound 30 demonstrated integrin α2 degradation against other aggressive cell 
lines (PC3-MM2 and SK-MEL-28). Treatment with 30 also induced the degradation of integrin 
α2 in the non-aggressive lung cancer cell line A549; however, this effect was not observed until 5 
µM, which correlated with the diminished anti-migratory activity exhibited against this cell line 
(Figure 3.6b). Importantly, treatment with Grp94-selective inhibitors did not induce the 
degradation of Akt, a cytosolic Hsp90-dependent protein, nor did it induce Hsp70 levels. This 
result contrasts the natural product pan-Hsp90 inhibitor geldanamycin (G, Figure 3.6), which 
induced the degradation of Akt and increased the levels of Hsp70 in all cell lines. These data 
demonstrate that these inhibitors selectively target Grp94 and induce the degradation of Grp94-
specific client proteins without decreasing the levels of proteins that depend upon the cytosolic 
Hsp90 isoforms. 
 Conclusions & Future Directions 
Incorporation of a phenyl linker, in lieu of the imidazole ring of BnIm, reduced the angle 
between the resorcinol moiety and the benzyl side chain and led to the identification of 6, which 
manifests 0.64 µM Grp94 affinity and 32-fold Grp94 selectivity. Substitutions about the phenyl 
linker provided compounds with improved affinity; however, in all cases this improved affinity 
was accompanied by a loss in selectivity. Subsequent modification to the side chain revealed 
alternative binding modes between the first and second generation of Grp94-selective inhibitors. 
Structure-activity relationship studies on the side chain of 6 ultimately led to the discovery of 30, 
which manifests 0.54 µM affinity and 73-fold selectivity for Grp94 versus other Hsp90 isoforms. 
Evaluation of first generation Grp94-selective inhibitors BnIm, KUNG29 and KUNG38, as well 
as the second generation Grp94-selective inhibitor 30 in a wound healing scratch assay against 
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aggressive and metastatic cancers (MDA-MB-231, PC3-MM2, and SK-MEL-28) revealed that 
Grp94-selective inhibition decreased the migratory capabilities of these cells at 500 nM and 
induced the degradation of the Grp94-dependent protein, integrin α2. When combined, these data 
suggest that Grp94 inhibition may provide a suitable therapeutic option to reduce the 
migration/metastasis of many aggressive cancers. Further analysis of these Grp94-selective 
inhibitors against other aggressive types of cancer would be beneficial to expand the utility of this 
method for reducing cancer cell migration.  
One common trait shared among both first and second generation Grp94-selective inhibitors is 
that when crystallized with Grp94, they generally adopt multiple conformations within the N-
terminal ATP-binding site as a result of the rotational flexibility associated with the ethylene 
moiety between the resorcinol ring and the linker ring. Therefore, prevention of this flexibility will 
be beneficial during the development of more selective inhibitors. Furthermore, these inhibitors 
could utilize the S2 sub-pocket to gain additional selectivity for Grp94, as modifications to the 
resorcinol ring would project into the S2 sub-pocket. It is not well understood if occupation of both 
sub-pockets could provide an additive effect for Grp94-selective inhibition or if these pockets are 
mutually exclusive. The evaluation of such inhibitors would provide a better understanding of the 
structural requirements for Grp94 selectivity. 
Experimental Section 
Chemistry General. 1H NMR were recorded at 400 (Bruker AVIIIHD 400 MHz NMR with a 
broadband X-channel detect gradient probe) or 500 MHz (Avance AVIII 500 MHz spectrometer 
with a dual carbon/proton cryoprobe), 19F NMR were recorded at 376 MHz (Bruker AVIIIHD 400 
MHz NMR equipped with a multinuclear broadband fluorine observe probe), and 13C NMR were 
recorded at 125 MHz (Bruker AVIII spectrometer equipped with a cryogenically cooled carbon 
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observe probe); chemical shifts are reported in δ (ppm) relative to the internal standard (CDCl3, 
7.26 ppm for 1H and 77.2 for 13C). HRMS spectra were recorded with a LCT Premier with ESI 
ionization. All biologically tested compounds were determined to be >95% pure. TLC analysis 
was performed on glass backed silica gel plates and visualized by UV light. All solvents were 
reagent grade and used without further purification. Synthesis and characterization of compounds 
is provided in the supplemental information. 
Synthetic Procedures 
 
Methyl 4,6-bis(benzyloxy)-2-bromo-3-chlorobenzoate (8). 1-bromo-3,5-dimethoxybenzene 
(5g, 23 mmol, 1 equiv.) was added to a round bottom flask containing pyridinium hydrochloride 
(20 g, 173 mmol, 7.5 equiv.). The mixture was heated to 220 ˚C for 3h and poured in water (100 
mL), diluted with EtOAc (200 mL). The aqueous layer was made acidic via the addition of 3N 
HCl (100 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL). The organic layers 
were combined, dried over anhydrous Na2SO4, and concentrated and used as obtained. The residue 
was diluted in DMF (50 mL) followed by the addition of K2CO3 (11 g) and BnBr (4 mL). The 
mixture was stirred at rt for 14 h at which point water (200 mL) and EtOAc (300 mL) were added. 
The organic layer was washed with water (5 x 150 mL), brine (1 x 100 mL), dried over anhydrous 
Na2SO4, and concentrated to provide 11 as a white amorphous solid which was used without 
further purification. 11 was dissolved in dry DCM (150 mL) followed by the addition of AgOTf 
(12.6 g). The mixture was cooled to -78 ˚C and 1,1-dichloromethylmethyl ether (4.4 mL) was 
added dropwise over 5 min. The reaction mixture was stirred at -78 ˚C for 30 min followed by 
removal from the cold bath and quenched with sat’d NaHCO3 (150 mL). The mixture was stirred 
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for 1 h at rt the filtered through a pad of celite. The aqueous layer was extracted with DCM (2 x 
100 mL). The organic layers were combined, dried over Na2SO4, and concentrated. The residue 
obtained was used without further purification. The residue was dissolved in a mixture of tBuOH:2-
methyl-2-butene-water (2:2:1) followed by the addition of NaClO2 (2.4 g) and NaH2PO4 (4.7 g). 
The reaction was stirred at rt for 14 h and quenched with sat’d NaH2PO4 (100 mL). The aqueous 
layer was extracted with EtOAc (3 x 100 mL). The organic layers were combined, dried, and 
concentrated to provide crude 12, which was used without further purification. 12 was dissolved 
in THF (200 mL) followed by the addition of LiOH (0.7 g) and Me2SO4 (1.5 mL) and stirred at 50 
˚C for 8 h (no starting material remaining). Sat’d NH4Cl (200 mL) was added to the reaction 
mixture and stirred at 50 ˚C for 1 h, then cooled to rt, and the aqueous layer was extracted with 
EtOAc (3 x 100 mL). The organic layers were combined, dried, and concentrated. The resultant 
residue was dissolved in THF (150 mL) and cooled to -40 ˚C followed by the addition of SO2Cl2 
dropwise over 15 min (temperature maintained < -30 ˚C during addition). The reaction was stirred 
at -40 ˚C for 30 min and quenched with sat’d NH4Cl and extracted with Et2O (3 x 100 mL). The 
organic layers were combined, dried, and concentrated. The residue was purified via flash 
chromatography (SiO2, 15% EtOAc in Hexanes) to provide 8 was an off white amorphous solid 
(3 g, 28%). 1H NMR (400 MHz, CDCl3) δ 7.38-7.34 (m, 7H), 7.32 – 7.28 (m, H), 6.51 (s, 1H), 
5.08 (s, 2H), 5.02 (s, 2H), 3.91 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 166.3, 156.1, 155.0, 135.8, 
135.6, 128.9 (2C), 128.8 (2C), 128.5, 128.4, 127.1 (2C), 127.0 (2C), 121.4, 121.0, 117.0, 99.6, 
71.5, 71.3, 53.0. HRMS [M+H]+ for C22H19BrClO4 461.0155, found 461.0143. 
General Procedure for the synthesis of 13a-13d, 13l-13q 
A microwave vial was charged with 2- or 3-formylphenyl boronic acids (10a-d, 1 equiv.), 
tetrakis(triphenylphosphine)palladium(0) (0.025 equiv.), benzyl bromide (13a-13d) or substituted 
130 
 
benzyl bromide (13l-13q) (1 equiv.) and sealed with a disposable Teflon lined cap. The tube was 
evacuated and purged with argon (3x) followed by the addition of THF (0.2 M) and 2M K2CO3 (3 
equiv.). The reaction mixture was heated to 95 ˚C for 12 h, cooled to rt, and diluted with Et2O (10 
mL) and water (15 mL). The aqueous layer was extracted with Et2O (3 x 10 mL). The organic 
layers were combined, dried, and concentrated. The resulting residue was purified via flash 
chromatography (SiO2, 1:9 EtOAc:Hexanes) to provide the desired benzaldehydes (13a-13d, 13l-
13q). 
 
2-Benzylbenzaldehyde (13a). Clear oil (220 mg, 67%). 1H NMR (400 MHz, CDCl3) δ 10.26 (s, 
1H), 7.87 (dd, J = 7.7, 1.5 Hz, 1H), 7.53 (td, J = 7.5, 1.5 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.29 – 
7.24 (m, 3H), 7.23 – 7.17 (m, 1H), 7.15 (d, J = 7.6 Hz, 2H), 4.46 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 192.8, 143.4, 140.7, 134.3, 134.3, 132.4, 132.1, 129.2 (2C), 129.0 (2C), 127.4, 126.7, 
38.4. HRMS (ESI) [M+H]+ for C14H13O 197.0966, found 197.0976 
 
3-Benzylbenzaldehyde (13b). Clear oil (165 mg, 50%) 1H NMR (400 MHz, CDCl3) δ 9.98 (s, 1H), 
8.01 – 7.91 (m, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.49 – 7.36 (m, 2H), 7.31 (ddd, J = 7.8, 6.5, 1.9 Hz, 
2H), 7.20 (dd, J = 7.7, 6.1 Hz, 3H), 4.06 (d, J = 6.1 Hz, 2H). HRMS (ESI) [M+H]+ for C14H13O 




2-Benzyl-5-methoxybenzaldehyde (13c). Clear oil (230 mg, 73%). 1H NMR (400 MHz, CDCl3) 
δ 10.22 (s, 1H), 7.37 (d, J = 2.9 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.11 – 7.04 
(m, 3H), 4.34 (s, 2H), 3.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.6, 158.4, 140.6, 135.3, 
134.5, 132.8, 128.5 (2C), 128.4 (2C), 126.1, 120.8, 113.9, 55.4, 36.9. HRMS (ESI) [M+Na]+ for 
C15H14O2Na 249.0892, found 249.0889 
 
2-Benzyl-4-methoxybenzaldehyde (13d). Clear oil (470 mg, 75%). 1H NMR (400 MHz, CDCl3) 
δ 10.13 (s, 1H), 7.85 (d, J = 8.5 Hz, 1H), 7.29 (d, J = 7.3 Hz, 2H), 7.21 (dd, J = 17.3, 7.4 Hz, 3H), 
6.91 (dd, J = 8.6, 2.5 Hz, 1H), 6.75 (d, J = 2.5 Hz, 1H), 4.45 (s, 2H), 3.86 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 191.0, 164.0, 145.7, 140.1, 135.1, 128.9, 128.7, 127.7, 126.4, 117.3, 111.9, 108.6, 
100.8, 55.6, 38.3. HRMS (ESI) [M+H]+ for C15H15O2 227.1072, found 227.1062 
 
2-(2-Ethoxybenzyl)benzaldehyde (13l). Clear oil (275 mg, 43%) 1H NMR (400 MHz, CDCl3) δ 
10.38 (s, 1H), 7.88 (dd, J = 7.7, 1.5 Hz, 1H), 7.49 (td, J = 7.5, 1.5 Hz, 1H), 7.42 – 7.33 (m, 1H), 
7.31 – 7.25 (m, 2H), 7.18 (td, J = 7.8, 1.8 Hz, 1H), 7.04 – 6.92 (m, 1H), 6.90 – 6.80 (m, 2H), 4.41 
(s, 2H), 4.03 (q, J = 7.0 Hz, 2H), 1.36 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 192.9, 
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156.7, 144.0, 134.4, 134.2, 131.8, 130.5, 130.4, 129.3, 128.1, 127.0, 120.8, 111.5, 63.9, 32.2, 15.2. 
HRMS (ESI) [M+H]+ for C16H17O2 241.1229, found 241.1226 
 
2-(2-Methoxybenzyl)benzaldehyde (13m). clear oil (230 mg, 51%) 1H NMR (400 MHz, CDCl3) 
δ 10.36 (s, 1H), 7.88 (dd, J = 7.7, 1.4 Hz, 1H), 7.53 – 7.46 (m, 1H), 7.37 (t, J = 7.5 Hz, 1H), 7.25 
– 7.16 (m, 2H), 6.94 (dd, J = 7.4, 1.6 Hz, 1H), 6.91 – 6.82 (m, 2H), 4.40 (s, 2H), 3.81 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 192.3, 156.8, 143.2, 133.9, 133.7, 131.2, 130.1, 129.9, 128.6, 127.6, 
126.5, 120.5, 110.1, 55.1, 31.7. HRMS (ESI) [M+H]+ for C15H15O 227.1076, found 227.1072 
 
2-(2-Chlorobenzyl)benzaldehyde (13n). yellow oil (160 mg, 35%) 1H NMR (400 MHz, CDCl3) 
δ 10.23 (s, 1H), 7.89 (dd, J = 7.7, 1.5 Hz, 1H), 7.53 (ddd, J = 15.1, 8.1, 1.6 Hz, 2H), 7.46 – 7.38 
(m, 2H), 7.20 – 7.10 (m, 3H), 7.02 (td, J = 8.5, 8.0, 7.0 Hz, 1H), 6.94 (dd, J = 7.2, 2.1 Hz, 1H), 
4.56 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 192.4, 141.4, 136.9, 133.9, 132.3, 130.9, 130.6, 129.4, 




2-(3-Chlorobenzyl)benzaldehyde (13o). yellow oil (100 mg, 22%) 1H NMR (400 MHz, CDCl3) 
δ 10.19 (s, 1H), 7.86 (dd, J = 7.6, 1.5 Hz, 1H), 7.55 (td, J = 7.5, 1.6 Hz, 1H), 7.45 (td, J = 7.6, 1.2 
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Hz, 1H), 7.30 – 7.24 (m, 1H), 7.23 – 7.15 (m, 2H), 7.12 (d, J = 1.9 Hz, 1H), 7.07 – 7.01 (m, 1H), 
4.43 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 192.7, 142.4, 142.0, 134.5, 134.1, 134.0, 133.3, 131.9, 
129.9, 129.0, 127.4, 127.2, 126.6, 37.9. HRMS (ESI) [M+H]+ for C14H12ClO 231.0577, found 
231.0574. 
 
2-(4-Chlorobenzyl)benzaldehyde (13p). yellow oil (145 mg, 31%) 1H NMR (400 MHz, CDCl3) 
δ 10.19 (s, 1H), 7.85 (dd, J = 7.6, 1.5 Hz, 1H), 7.54 (td, J = 7.5, 1.6 Hz, 1H), 7.45 (dd, J = 7.5, 1.2 
Hz, 1H), 7.26 (d, J = 1.7 Hz, 1H), 7.25 – 7.23 (m, 2H), 7.08 (d, J = 8.4 Hz, 2H), 4.42 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 192.7, 142.4, 138.9, 134.1, 134.0, 133.3, 132.2, 131.8, 130.3 (2C), 
128.8 (2C), 127.4, 37.7. HRMS (ESI) [M+Na]+ for C14H12ClO 253.0396, found 253.0387. 
 
 
2-(4-Fluorobenzyl)benzaldehyde (13q). yellow oil (320 mg, 75%) 1H NMR (400 MHz, CDCl3) 
δ 10.21 (s, 1H), 7.85 (dd, J = 7.6, 1.5 Hz, 1H), 7.54 (td, J = 7.5, 1.6 Hz, 1H), 7.44 (td, J = 7.5, 1.2 
Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 7.11 (dd, J = 8.6, 5.5 Hz, 2H), 6.96 (t, J = 8.7 Hz, 2H), 4.42 (s, 
2H). 19F NMR (376 MHz, CDCl3) δ -117.0 (s, 1F). 
13C NMR (126 MHz, CDCl3) δ 192.7, 142.9, 
134.1, 133.0, 131.9, 131.7, 131.2, 130.4, 130.3, 127.3, 122.1, 115.5, 115.4, 37.5. HRMS (ESI) 
[M+H]+ for C14H12FO 215.0872, found 215.0880. 
General procedure for the synthesis of 13e-13h 
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A microwave vial was charged with aryl bromides (14a-d, 1 equiv.), potassium 
benzyltrifluoroborate (1.5 equiv.), palladium (II) acetate (0.08 equiv.), RuPhos (0.17 equiv.), and 
K3PO4 (5.2 equiv.). The tube was sealed with a disposable Teflon lined lid and evacuate and purged 
with argon (3x) followed by the addition of mixture of toluene:water (5:1, 0.1 M). The reaction 
mixture was heated to 115 ˚C for 16 h, cooled to rt, and diluted with water (10 mL) and EtOAc 
(20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL) and the organic layers were 
combined, dried, and concentrated. The resulting residue was purified via flash chromatography 
(SiO2, 1:5 EtOAc:Hexanes) to provide the desired benzaldehydes (13e-13h). 
 
2-Benzyl-3-methoxybenzaldehyde (13e). clear oil (110 mg, 70%) 1H NMR (400 MHz, CDCl3) 
δ 10.30 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.28 – 7.19 (m, 2H), 7.15 (d, J = 
7.1 Hz, 4H), 4.50 (s, 2H), 3.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 192.3, 157.9, 140.5, 134.9, 
131.5, 128.2, 128.2, 127.6, 125.8, 122.8, 121.3, 116.8, 115.9, 55.8, 29.4. HRMS (ESI) [M+Na]+ 
for C15H15O2 249.0892, found 249.0890. 
 
2-Benzyl-5-nitrobenzaldehyde (13f). yellow oil (180 mg, 32%) 1H NMR (400 MHz, CDCl3) δ 
10.31 (s, 1H), 8.71 (d, J = 2.5 Hz, 1H), 8.34 (dd, J = 8.4, 2.5 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 
7.34 – 7.28 (m, 2H), 7.27 – 7.21 (m, 1H), 7.13 (dd, J = 6.9, 1.8 Hz, 2H), 4.54 (s, 2H). 13C NMR 
(126 MHz, CDCl3) δ 190.1, 150.0, 138.6, 134.7, 133.0, 129.1 (2C), 128.9 (2C), 127.9, 127.1 (2C), 





2-Benzyl-4-nitrobenzaldehyde (13g). yellow oil (245 mg, 58%) 1H NMR (400 MHz, CDCl3) δ 
10.37 (s, 1H), 8.23 (dd, J = 8.5, 2.1 Hz, 1H), 8.13 (s, 1H), 8.05 (d, J = 8.4 Hz, 1H), 7.32 (t, J = 7.5 
Hz, 2H), 7.26 (d, J = 4.7 Hz, 2H), 7.14 (d, J = 7.5 Hz, 2H), 4.53 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 190.3, 150.4, 144.7, 138.4, 137.7, 132.3, 128.9, 128.6, 126.9, 126.3, 121.8, 37.7. HRMS 
(ESI) [M+H]+ for C14H12NO3 242.0817, found 242.0825. 
 
2-Benzylnicotinaldehyde (13h). clear oil (145 mg, 68%) 1H NMR (400 MHz, CDCl3) δ 10.34 
(s, 1H), 8.77 (dd, J = 4.8, 1.7 Hz, 1H), 8.14 (dt, J = 7.9, 1.5 Hz, 1H), 7.37 (dd, J = 7.8, 4.9 Hz, 1H), 
7.31 – 7.16 (m, 5H), 4.60 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 190.8, 162.1, 153.5, 138.8, 138.3, 
129.3, 128.6 (2C), 128.5 (2C), 126.5, 122.2, 40.9. HRMS (ESI) [M+H]+ for C13H12NO 198.0919, 
found 198.0928. 
General procedure for the synthesis of 13i-13k. 
Benzyl bromide (1.1 equiv.) was added to a stirred solution of 15a-15c (1 equiv.) and K2CO3 
(2.5 equiv.) in DMF (0.3 M). The reaction was stirred at rt for 13 h followed by the addition of 
water (30 mL) and EtOAc (40 mL). The organic layer was washed with water (5 x 30 mL) and 
brine (1 x 20 mL), dried, and concentrated. The resulting residue was passed through a filter 
column (SiO2, 1:3 EtOAc:Hexanes) and used as obtained. The residue (1 equiv.) was dissolved in 
toluene (5 mL) and transferred to a microwave vial that was charged with potassium 
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benzyltrifluoroborate (1.5 equiv.), palladium (II) acetate (0.08 equiv.), RuPhos (0.17 equiv.), and 
K3PO4 (5.2 equiv.). The tube was sealed with a disposable Teflon lined lid and the solvent sparged 
with argon (10 min) followed by the addition of water (0.5 mL). The reaction mixture was heated 
to 115 ˚C for 16 h, cooled to rt, and diluted with water (10 mL) and EtOAc (20 mL). The aqueous 
layer was extracted with EtOAc (2 x 20 mL) and the organic layers were combined, dried, and 
concentrated. The resulting residue was purified via flash chromatography (SiO2, 1:5 
EtOAc:Hexanes) to provide the desired benzaldehydes (13i-13j). 
 
2-Benzyl-5-(benzyloxy)benzaldehyde (13i). clear oil (195 mg, 32%) 1H NMR (400 MHz, 
CDCl3) δ 10.24 (d, J = 1.6 Hz, 1H), 7.48 (q, J = 1.9 Hz, 1H), 7.47 – 7.38 (m, 5H), 7.35 (td, J = 6.8, 
1.7 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.19 (t, J = 7.0 Hz, 3H), 7.16 – 7.11 (m, 2H), 5.11 (s, 2H), 4.38 
(s, 2H). 13C NMR (126 MHz, CDCl3) δ 191.6, 157.6, 140.6, 136.3, 135.6, 134.5, 132.9, 130.0, 
128.6, 128.6, 128.5, 128.1, 127.4, 126.1, 123.6, 122.1, 121.5, 115.1, 113.1, 70.1, 37.0. HRMS 
(ESI) [M+H]+ for C21H19O2 303.1385, found 303.1395 
 
2-Benzyl-4-(benzyloxy)benzaldehyde (13j). clear oil (400 mg, 66%) 1H NMR (400 MHz, 
CDCl3) δ 10.11 (s, 1H), 7.82 (d, J = 8.6 Hz, 1H), 7.43 – 7.33 (m, 5H), 7.31 – 7.27 (m, 2H), 7.23 – 
7.17 (m, 1H), 7.17 – 7.13 (m, 2H), 6.96 (dd, J = 8.6, 2.6 Hz, 1H), 6.80 (d, J = 2.5 Hz, 1H), 5.09 (s, 
2H), 4.42 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 190.8, 162.8, 145.6, 139.8, 135.8, 134.9, 128.7 
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(2C), 128.6 (2C), 128.5 (2C), 128.2, 127.5, 127.5 (2C), 126.2, 117.7, 112.6, 70.0, 38.1. HRMS 
(ESI) [M+H]+ for C21H19O2 303.1385, found 303.1400 
 
2-Benzyl-3-(benzyloxy)benzaldehyde (13k). clear oil (350 mg, 58%) 1H NMR (400 MHz, 
CDCl3) δ 10.32 (s, 1H), 7.54 – 7.47 (m, 2H), 7.37 – 7.31 (m, 3H), 7.29 – 7.25 (m, 2H), 7.23 – 7.20 
(m, 2H), 7.19 – 7.10 (m, 4H), 5.10 (s, 2H), 4.55 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 192.8, 
157.5, 141.0, 136.9, 135.6, 132.5, 129.1, 128.9, 128.9, 128.7, 128.6, 128.4, 128.1, 127.9, 127.7, 
127.4, 126.3, 123.6, 117.8, 71.0, 30.1. HRMS (ESI) [M+Na]+ for C21H18O2 325.1205, found 
325.1205. 
General procedure for the synthesis of 9a-9r. 
n-butyllithium (2.5 M in hexanes, 1.3 equiv.) was added dropwise to a stirred solution of 
methytriphenylphosphonium bromide (1.5 equiv.) in dry THF (0.1M) at 0 ˚C. The mixture was 
stirred for 15 min before the addition of 13a-13r (1 eq. in 2 mL THF). The reaction was stirred at 
rt for 8 h at which point water was added dropwise and the aqueous layer was extracted with EtOAc 
(2 x 10 mL). The combined organic layers were dried, concentrated, and purified via flash 
chromatography (SiO2, 1:9 EtOAc:Hexanes) to provide the desired styrenes, 9a-9r.  
 
1-Benzyl-2-vinylbenzene (9a). clear oil (197 mg, 90%) 1H NMR (400 MHz, CDCl3) δ 7.56 – 
7.52 (m, 1H), 7.32 – 7.22 (m, 4H), 7.22 – 7.17 (m, 1H), 7.13 (d, J = 7.5 Hz, 3H), 6.95 (dd, J = 
17.4, 11.0 Hz, 1H), 5.64 (d, J = 17.2 Hz, 1H), 5.26 (dd, J = 10.9, 1.6 Hz, 1H), 4.09 (s, 2H). 13C 
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NMR (126 MHz, CDCl3) δ 141.0, 138.1, 137.4, 135.1, 130.8, 129.0 (2C), 128.8 (2C), 128.3, 127.1, 
126.4, 126.3, 116.2, 39.4. HRMS (ESI)  [M]+ for C15H14 194.1096, found 194.1104. 
 
1-Benzyl-3-vinylbenzene (9b). clear oil (142 mg, 87%) 1H NMR (400 MHz, CDCl3) δ 7.38 – 
7.30 (m, 2H), 7.28 (d, J = 7.5 Hz, 2H), 7.24 (d, J = 2.5 Hz, 2H), 7.22 – 7.17 (m, 3H), 7.12 – 7.06 
(m, 1H), 6.69 (dd, J = 17.6, 10.9 Hz, 1H), 5.72 (d, J = 17.6 Hz, 1H), 5.24 (s, 1H), 3.98 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 137.2, 129.3 (2C), 129.0, 128.9, 128.8 (2C), 128.8, 128.7, 127.3, 126.5, 
126.3, 124.4, 114.2, 42.3. HRMS (ESI) [M+H]+ for C15H14 194.1096, found 194.1093. 
 
1-Benzyl-4-methoxy-2-vinylbenzene (9c). clear oil (217 mg, 95%) 1H NMR (400 MHz, CDCl3) 
δ 7.30 – 7.22 (m, 3H), 7.17 (t, J = 7.3 Hz, 1H), 7.14 – 7.03 (m, 4H), 6.90 (dd, J = 17.3, 10.9 Hz, 
1H), 6.80 (dd, J = 8.4, 2.7 Hz, 1H), 5.63 (dd, J = 17.3, 1.3 Hz, 1H), 5.24 (dd, J = 10.9, 1.3 Hz, 1H), 
4.01 (s, 2H), 3.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 158.2, 140.9, 137.9, 134.6, 131.4, 130.1, 
128.4 (2C), 128.3 (2C), 125.8, 115.7, 113.4, 110.9, 55.2, 38.0. MS (ESI) m/z [M+H]+ for C16H17O 
225.1279, found 225.1285. 
 
2-Benzyl-1-methoxy-3-vinylbenzene (9e). clear oil (84 mg, 77%) 1H NMR (400 MHz, CDCl3) 
δ 7.29 – 7.20 (m, 3H), 7.18 (d, J = 1.3 Hz, 1H), 7.14 (t, J = 7.0 Hz, 3H), 6.95 (dd, J = 17.4, 11.0 
Hz, 1H), 6.86 (d, J = 8.1 Hz, 1H), 5.64 (dd, J = 17.3, 1.5 Hz, 1H), 5.26 (dd, J = 11.0, 1.5 Hz, 1H), 
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4.14 (s, 2H), 3.80 (d, J = 1.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 157.6, 140.8, 138.4, 134.8, 
128.1, 128.1, 127.7, 127.1, 126.4, 125.4, 118.2, 116.1, 110.6, 109.7, 55.6, 31.0. HRMS (ESI) 
[M+Na]+ for C16H16O 247.1094, found 247.1090. 
 
1-Benzyl-4-nitro-2-vinylbenzene (9f). yellow oil (157 mg, 88%) 1H NMR (400 MHz, CDCl3) δ 
8.37 (d, J = 2.4 Hz, 1H), 8.05 (dd, J = 8.4, 2.5 Hz, 1H), 7.35 – 7.18 (m, 4H), 7.13 – 7.08 (m, 2H), 
6.94 (dd, J = 17.3, 11.0 Hz, 1H), 5.80 (dd, J = 17.3, 0.9 Hz, 1H), 5.45 (dd, J = 11.0, 0.9 Hz, 1H), 
4.13 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 147.4, 145.5, 139.1, 138.9, 133.2, 131.6, 129.2 (2C), 
129.1 (2C), 127.0, 122.7, 121.4, 119.3, 39.3. HRMS (ESI) m/z [M+H]+ for C15H14NO2 242.0817, 
found 242.0824. 
 
2-Benzyl-4-nitro-1-vinylbenzene (9g). yellow oil (230 mg, 95%) 1H NMR (400 MHz, CDCl3) 
δ 8.09 (dd, J = 8.6, 2.3 Hz, 1H), 8.01 (d, J = 2.3 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.35 – 7.19 (m, 
3H), 7.11 (d, J = 7.4 Hz, 2H), 6.96 (dd, J = 17.3, 11.0 Hz, 1H), 5.79 (d, J = 17.4 Hz, 1H), 5.48 (d, 
J = 11.0 Hz, 1H), 4.14 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 147.6, 143.9, 139.7, 139.2, 133.5, 
129.2 (2C), 129.0 (2C), 127.2, 127.0, 125.8, 122.3, 120.3, 39.3. HRMS (ESI) m/z [M+H]+ for 




2-Benzyl-3-vinylpyridine (9h). yellow oil (97 mg, 68%) 1H NMR (400 MHz, CDCl3) δ 8.50 
(dd, J = 4.8, 1.6 Hz, 1H), 7.77 (dd, J = 7.8, 1.6 Hz, 1H), 7.34 – 7.13 (m, 6H), 6.94 (dd, J = 17.4, 
11.0 Hz, 1H), 5.64 (d, J = 17.3 Hz, 1H), 5.35 (d, J = 10.9 Hz, 1H), 4.27 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 157.3, 148.4, 139.2, 133.5, 133.0, 132.2, 128.5 (2C), 128.3 (2C), 126.0, 121.9, 
117.5, 41.7. HRMS (ESI) [M+H]+ for C14H14N 196.1126, found 196.1132 
 
1-Benzyl-4-(benzyloxy)-2-vinylbenzene (9i). clear oil (163 mg, 84%) 1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J = 8.6 Hz, 1H), 7.42 – 7.35 (m, 4H), 7.35 – 7.25 (m, 3H), 7.24 – 7.17 (m, 1H), 
7.15 – 7.10 (m, 2H), 6.92 – 6.84 (m, 2H), 6.74 (d, J = 2.6 Hz, 1H), 5.53 (dd, J = 17.4, 1.4 Hz, 1H), 
5.15 (dd, J = 10.9, 1.4 Hz, 1H), 5.03 (s, 2H), 4.03 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 158.3, 
140.2, 139.2, 136.8, 133.8, 129.8, 128.6 (2C), 128.5 (2C), 128.3 (2C), 127.8, 127.4 (2C), 126.9, 
125.9, 116.5, 113.8, 112.9, 69.8, 39.0. HRMS (ESI) [M+Na]+ for C22H20O 323.1412, found 
323.1419. 
 
2-Benzyl-4-(benzyloxy)-1-vinylbenzene (9j). clear oil (372 mg, 94%) 1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J = 8.6 Hz, 1H), 7.43 – 7.35 (m, 4H), 7.34 – 7.30 (m, 1H), 7.29 – 7.23 (m, 3H), 
7.23 – 7.16 (m, 1H), 7.15 – 7.10 (m, 2H), 6.96 – 6.83 (m, 2H), 6.74 (d, J = 2.6 Hz, 1H), 5.53 (dd, 
J = 17.4, 1.4 Hz, 1H), 5.15 (dd, J = 10.9, 1.4 Hz, 1H), 5.03 (s, 2H), 4.03 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 158.9, 140.7, 139.7, 137.3, 134.4, 130.3, 129.1 (2C), 129.0 (2C), 128.8 (2C), 
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128.3, 127.9 (2C), 127.4, 126.4, 117.1, 114.3, 113.4, 70.3, 39.5. HRMS (ESI) [M+H]+ for C22H21O 
301.1592, found 301.1607. 
 
2-Benzyl-1-(benzyloxy)-3-vinylbenzene (9k). clear oil (322 mg, 93%) 1H NMR (400 MHz, 
CDCl3) δ 7.44 – 7.29 (m, 2H), 7.27 – 7.20 (m, 2H), 7.18 – 7.09 (m, 4H), 7.07 (t, J = 6.9 Hz, 3H), 
6.91 (dd, J = 17.3, 10.9 Hz, 1H), 6.81 (dd, J = 7.0, 2.2 Hz, 1H), 5.56 (dd, J = 17.3, 1.4 Hz, 1H), 
5.19 (dd, J = 11.0, 1.4 Hz, 1H), 4.97 (s, 2H), 4.10 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 156.9, 
141.1, 138.9, 137.32, 135.1, 128.7, 128.7, 128.5, 128.5, 128.3, 127.8, 127.7, 127.4, 127.3, 127.2, 
127.1, 125.7, 118.7, 116.5, 111.3, 70.3, 31.6. HRMS (ESI) [M+H]+ for C22H21O 301.1592, found 
301.1581. 
 
1-Ethoxy-2-(2-vinylbenzyl)benzene (9l). clear oil (249 mg, 91%) 1H NMR (400 MHz, CDCl3) 
δ 7.54 (dd, J = 7.0, 2.2 Hz, 1H), 7.23 – 7.19 (m, 1H), 7.19 – 7.11 (m, 3H), 6.98 (dd, J = 17.5, 11.1 
Hz, 1H), 6.90 – 6.78 (m, 3H), 5.63 (dd, J = 17.4, 1.5 Hz, 1H), 5.23 (dd, J = 11.0, 1.5 Hz, 1H), 4.06 
(dd, J = 13.6, 6.6 Hz, 4H), 1.41 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 156.4, 137.7, 
137.0, 134.8, 130.4, 129.7, 129.1, 127.6, 127.0, 126.3, 125.4, 120.1, 115.1, 110.8, 63.4, 32.7, 14.8. 






1-Methoxy-2-(2-vinylbenzyl)benzene (9m). clear oil (197 mg, 86%) 1H NMR (400 MHz, 
CDCl3) δ 7.54 (dd, J = 7.1, 1.9 Hz, 1H), 7.24 – 7.15 (m, 3H), 7.13 – 7.06 (m, 1H), 6.95 (dd, J = 
17.4, 11.0 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.83 (d, J = 4.6 Hz, 2H), 5.64 (dd, J = 17.4, 1.4 Hz, 
1H), 5.23 (dt, J = 11.0, 1.2 Hz, 1H), 4.03 (s, 2H), 3.85 (d, J = 1.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 157.5, 138.0, 137.5, 135.2, 130.8, 130.2, 129.3, 128.2, 127.6, 126.9, 126.0, 120.8, 115.7, 
110.3, 55.7, 33.1. HRMS (ESI) [M+H]+ for C16H17O 225.1279, found 225.1280. 
 
1-Chloro-2-(2-vinylbenzyl)benzene (9n). yellow oil (147 mg, 93%) 1H NMR (400 MHz, 
CDCl3) δ 7.56 (dd, J = 7.5, 1.6 Hz, 1H), 7.40 (dd, J = 7.5, 1.7 Hz, 1H), 7.30 – 7.20 (m, 2H), 7.14 
(pd, J = 7.4, 1.8 Hz, 2H), 7.05 (dd, J = 7.5, 1.6 Hz, 1H), 6.91 – 6.81 (m, 2H), 5.65 (dd, J = 17.3, 
1.3 Hz, 1H), 5.26 (dd, J = 11.0, 1.4 Hz, 1H), 4.15 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 138.0, 
137.1, 136.2, 134.3, 133.9, 130.3, 130.1, 129.2, 127.9, 127.4, 126.8, 126.7, 125.8, 115.9, 36.3. 
HRMS (ESI) [M]+ for C15H13Cl 228.0706, found 228.0712. 
 
1-(3-Chlorobenzyl)-2-vinylbenzene (9o). yellow oil (78 mg, 79%) 1H NMR (400 MHz, CDCl3) 
δ 7.53 (dd, J = 7.0, 2.1 Hz, 1H), 7.27 – 7.20 (m, 4H), 7.11 (dd, J = 6.9, 2.1 Hz, 1H), 7.07 – 7.02 
(m, 2H), 6.88 (dd, J = 17.3, 10.9 Hz, 1H), 5.63 (dd, J = 17.4, 1.4 Hz, 1H), 5.25 (dd, J = 11.0, 1.3 
Hz, 1H), 4.03 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 142.6, 136.9, 136.7, 134.3, 134.1, 130.3, 
143 
 
129.5, 128.6, 127.9, 126.9, 126.7, 126.1, 126.0, 116.0, 38.5. HRMS (ESI) m/z [M]+ for C15H13Cl 
228.0706, found 228.0697. 
 
1-(4-Chlorobenzyl)-2-vinylbenzene (9p). yellow oil (99 mg, 68%) 1H NMR (400 MHz, CDCl3) 
δ 7.54 (dd, J = 7.0, 2.2 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.24 – 7.15 (m, 2H), 7.13 – 7.10 (m, 2H), 
7.02 – 6.97 (m, 1H), 6.89 (dd, J = 17.3, 11.0 Hz, 1H), 5.64 (dd, J = 17.3, 1.3 Hz, 1H), 5.27 (dd, J 
= 11.0, 1.3 Hz, 1H), 4.04 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 139.4, 137.6, 137.4, 134.8, 132.1, 
130.8, 130.3 (2C), 128.9 (2C), 128.4, 127.4, 126.4, 116.5, 38.8. HRMS [M]+ for C15H13Cl 
228.0706, found 228.0703. 
 
1-(4-Fluorobenzyl)-2-vinylbenzene (9q). clear oil (291 mg, 92%) 1H NMR (400 MHz, CDCl3) 
δ 7.57 – 7.50 (m, 1H), 7.29 – 7.20 (m, 2H), 7.15 – 7.03 (m, 3H), 6.99 – 6.86 (m, 3H), 5.63 (dd, J 
= 17.4, 1.4 Hz, 1H), 5.25 (dd, J = 11.0, 1.4 Hz, 1H), 4.04 (s, 2H). 19F NMR (376 MHz, CDCl3) δ 
-117.5 (s, 1F). 13C NMR (126 MHz, CDCl3) δ 138.0, 137.4, 136.6, 136.6, 134.9, 130.7, 130.4, 







2-(4-Fluorobenzyl)-3-vinylpyridine (9r). A microwave vial was charged with 14d (250 mg, 1.3 
mmol, 1 equiv.), 4-fluorobenzylboronicacid pinacol ester (317 mg, 1.3 mmol, 1 equiv.), [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (49 mg, 0.07 mmol, 0.05 equiv.), and 
K3PO4 (560 mg, 4 mmol, 3 equiv.) and capped with a Teflon lined lid. The vial was evacuated and 
purged with argon (3x) and then dioxane (15 mL) was added. The reaction mixture was heated to 
90 ˚C for 14 h, cooled to rt, and diluted with EtOAc (40 mL) and water (15 mL). The aqueous 
layer was extracted with EtOAc (2 x 20 mL). The combined organic layers were dried, 
concentrated and purified via through a filter column (SiO2, 1:2 EtOAc:Hexanes) and used as 
obtained. The residue was added to a stirred solution of n-butyl lithium (1.5 equiv.) and 
methyltriphenylphosphonium bromide (1.3 equiv.) at 0 ˚C. The reaction was stirred for 8 h at rt 
and quenched with water (10 mL). The aqueous phase was extracted with EtOAc (2 x 15 mL). The 
combined organic layers were dried, concentrated, and purified via flash chromatography (SiO2, 
1:3 EtOAc:Hexanes) to provide 9r as a clear oil (73 mg, 26%). 1H NMR (400 MHz, CDCl3) δ 8.51 
– 8.46 (m, 1H), 7.82 – 7.72 (m, 1H), 7.16 (ddd, J = 15.5, 8.1, 5.1 Hz, 3H), 6.92 (dt, J = 18.4, 9.7 
Hz, 3H), 5.65 (d, J = 17.3 Hz, 1H), 5.36 (d, J = 11.0 Hz, 1H), 4.22 (s, 2H). 19F NMR (376 MHz, 
CDCl3) δ -117.2 (s, 1F). 
13C NMR (126 MHz, CDCl3) δ 162.8, 160.8, 157.5, 149.0, 135.3, 134.1, 
133.4, 130.4, 130.3, 122.5, 118.3, 115.7, 115.5, 41.3. HRMS (ESI) [M+H]+ for C14H13FN 
214.1032, found 214.1036. 
General procedure for the synthesis of 6-7 and 16-31. 
A microwave vial was charged with 8 (200 mg, 2 equiv.), 9a-9r (1 eq.), and palladium (II) 
acetate (5 mg, 0.1 equiv.). The tube was sealed with a Teflon lined lid, evacuated and purged with 
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argon (3x). Triethanolamine (0.8 mL) was added and the reaction was stirred at 115 ˚C for 12 h. 
The reaction was cooled, partitioned between Et2O (30 mL) and water (10 mL). The aqueous layer 
was extracted with Et2O (3 x 20 mL). The organic layers were combined, dried, and concentrated. 
The residue was passed through a filter column (SiO2, 1:1 EtOAc:Hexanes) and concentrated. The 
residue was dissolved in EtOAc (15 mL), evacuated and purged with argon (3x) before the addition 
of 10% Pd/C (25 mg). The reaction was then stirred under a hydrogen atmosphere (balloon) for 14 
h. The reaction mixture was passed through a pad of celite and washed with DCM and 
concentrated. The residue was purified by flash chromatography (SiO2, 1:2 EtOAc:Hexanes) to 
provide the desired analogues 6-7 and 16-31. 
 
Methyl 2-(2-benzylphenethyl)-3-chloro-4,6-dihydroxybenzoate (6). White amorphous solid (45 
mg, 52%). 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.31 – 7.22 (m, 2H), 7.20 (q, J = 4.5, 2.8 
Hz, 4H), 7.11 (d, J = 7.6 Hz, 3H), 6.58 (s, 1H), 6.05 (s, 1H), 4.11 (s, 2H), 3.91 (d, J = 1.0 Hz, 3H), 
3.42 – 3.34 (m, 2H), 2.91 – 2.80 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.8, 163.1, 156.0, 
142.6, 140.6, 139.7, 138.3, 130.4, 129.0, 128.6, 128.3, 126.6, 126.4, 125.9, 113.7, 106.6, 102.5, 





Methyl 2-(3-benzylphenethyl)-3-chloro-4,6-dihydroxybenzoate (7). White amorphous solid (57 
mg, 66%) 1H NMR (400 MHz, CDCl3) δ 11.45 (s, 1H), 7.36 – 7.26 (m, 3H), 7.22 (t, J = 7.5 Hz, 
3H), 7.09 (t, J = 8.1 Hz, 2H), 7.03 (s, 1H), 6.57 (s, 1H), 6.06 (s, 1H), 4.00 (s, 2H), 3.83 (s, 3H), 
3.38 – 3.30 (m, 2H), 2.87 – 2.70 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.9, 163.1, 156.1, 
142.6, 141.7, 141.3, 140.9, 128.9 (2C), 128.7, 128.5, 128.4 (2C), 126.7, 126.0, 125.9, 113.6, 106.5, 
102.4, 52.3, 41.8, 35.4, 35.0. HRMS (ESI) [M+H]+ for C23H22ClO4 397.1207, found 397.1230. 
 
Methyl 2-(2-benzyl-5-methoxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (16). White 
amorphous solid (25 mg, 27%) 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.24 (s, 2H), 7.17 (t, 
J = 7.2 Hz, 1H), 7.09 (d, J = 7.6 Hz, 2H), 7.03 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 2.7 Hz, 1H), 6.74 
(dd, J = 8.3, 2.7 Hz, 1H), 6.57 (s, 1H), 6.05 (s, 1H), 4.04 (s, 2H), 3.91 (d, J = 1.0 Hz, 3H), 3.81 (s, 
3H), 3.41 – 3.33 (m, 2H), 2.85 – 2.74 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.3, 163.5, 158.6, 
156.5, 143.1, 141.5, 141.5, 131.9, 131.1, 129.0 (2C), 128.8 (2C), 126.3, 115.6, 114.2, 111.5, 107.1, 





Methyl 2-(2-benzyl-4-methoxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (17). White 
amorphous solid (83 mg, 90%) 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.26 (d, J = 1.2 Hz, 
1H), 7.19 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 7.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 1H), 6.66 (s, 1H), 6.57 
(s, 1H), 6.04 (s, 1H), 4.08 (s, 2H), 3.91 (s, 3H), 3.76 (s, 3H), 3.39 – 3.32 (m, 2H), 2.81 (d, J = 8.7 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 163.5, 158.5, 156.5, 143.2, 140.9, 140.1, 132.4, 130.5, 
129.1 (2C), 128.9 (2C), 126.5, 116.5 (2C), 114.2, 112.2, 107.1, 103.0, 55.6, 53.0, 39.0, 34.7, 32.2. 
HRMS (ESI) [M+Na]+ for C24H23ClO5 449.1132, found 449.1128. 
 
Methyl 2-(2-benzyl-3-methoxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (18). White 
amorphous solid (57 mg, 64%) 1H NMR (400 MHz, CDCl3) δ 11.43 (d, J = 11.6 Hz, 1H), 7.25 – 
7.18 (m, 2H), 7.15 – 7.11 (m, 1H), 7.08 (d, J = 7.6 Hz, 2H), 6.93 (d, J = 7.6 Hz, 1H), 6.88 – 6.77 
(m, 2H), 6.56 (d, J = 1.1 Hz, 1H), 4.18 (s, 2H), 3.89 (s, 3H), 3.78 (s, 3H), 3.39 – 3.28 (m, 2H), 2.85 
(dd, J = 10.7, 6.0 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 171.3, 163.5, 156.5, 142.9, 134.1, 131.0, 
130.7, 128.4, 127.6, 127.6, 127.1, 125.4, 124.5, 123.5, 114.3, 111.7, 111.3, 107.2, 103.0, 69.9, 




Methyl 2-(5-amino-2-benzylphenethyl)-3-chloro-4,6-dihydroxybenzoate (19). Tan amorphous 
solid (41 mg, 46%). 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.31 – 7.25 (m, 2H), 7.23 – 7.17 
(m, 1H), 7.15 – 7.10 (m, 3H), 6.71 (dd, J = 8.2, 2.8 Hz, 1H), 6.57 (s, 1H), 6.54 (d, J = 2.7 Hz, 1H), 
6.07 (s, 1H), 4.05 (s, 2H), 3.91 (s, 3H), 3.41 – 3.30 (m, 2H), 2.84 – 2.73 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 170.8, 163.0, 156.0, 153.8, 142.7, 140.2, 140.0, 131.9, 130.2, 128.7 (2C), 128.4 
(2C), 126.0, 116.9, 113.4, 106.6, 102.5, 52.5, 38.3, 34.1, 31.7. HRMS (ESI) [M+H]+ for 
C23H23ClNO4 412.1316, found 412.1303. 
 
 
Methyl 2-(4-amino-2-benzylphenethyl)-3-chloro-4,6-dihydroxybenzoate (20). Tan amorphous 
solid (38 mg, 43%). 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.19 (m, 2H), 7.17 – 7.13 (m, 1H), 7.09 
(d, J = 7.7 Hz, 2H), 7.05 (d, J = 7.9 Hz, 1H), 6.56 (dd, J = 8.2, 2.5 Hz, 1H), 6.41 (dd, J = 4.9, 1.9 
Hz, 2H), 4.00 (s, 2H), 3.86 (s, 3H), 3.34 – 3.22 (m, 2H), 2.75 – 2.67 (m, 2H), 2.63 (br s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 171.5, 162.6, 157.9, 144.6, 143.6, 141.2, 139.8, 130.9, 130.4, 129.1, 
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129.1, 128.7, 128.7, 126.2, 117.7, 114.9, 114.2, 106.3, 102.4, 52.7, 38.7, 34.6, 32.1. HRMS (ESI) 
[M+H]+ for C23H23ClNO4 412.1316, found 412.1302. 
 
Methyl 2-(2-(2-benzylpyridin-3-yl)ethyl)-3-chloro-4,6-dihydroxybenzoate (21). White 
amorphous solid (81 mg, 94%). 1H NMR (400 MHz, CDCl3) δ 11.34 (s, 1H), 8.49 (d, J = 4.9 Hz, 
1H), 7.51 (d, J = 7.7 Hz, 1H), 7.23 (d, J = 7.2 Hz, 2H), 7.19 – 7.13 (m, 4H), 6.58 (d, J = 1.1 Hz, 
1H), 6.40 (s, 1H), 4.30 (s, 2H), 3.86 (d, J = 1.0 Hz, 3H), 3.50 – 3.35 (m, 2H), 3.04 – 2.83 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 170.8, 163.3, 158.5, 156.5, 147.5, 142.2, 139.5, 137.1, 135.1, 128.7 
(2C), 128.6 (2C), 126.4, 122.1, 114.1, 106.7, 103.0, 52.7, 41.3, 33.4, 31.8. HRMS (ESI) [M+H]+ 
for C22H21ClNO4 398.1159, found 398.1154. 
 
Methyl 2-(2-benzyl-5-hydroxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (22). White 
amorphous solid (42 mg, 47%). 1H NMR (400 MHz, CDCl3) δ 11.37 (s, 1H), 7.24 (s, 2H), 7.18 
(d, J = 7.3 Hz, 1H), 7.09 (d, J = 7.5 Hz, 2H), 6.97 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 
6.66 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 6.04 (s, 1H), 4.02 (s, 2H), 3.90 (s, 3H), 3.40 – 3.32 (m, 2H), 
2.86 – 2.73 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.2, 163.5, 156.5, 154.5, 143.0, 141.8, 
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141.5, 132.0, 131.2, 129.0 (2C), 128.8 (2C), 126.4, 116.2, 113.7, 107.1, 103.0, 53.0, 38.1, 34.1, 
32.8. HRMS (ESI) [M+H]+ for C23H22ClO5 413.1156, found 413.1150. 
 
Methyl 2-(2-benzyl-4-hydroxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (23). White 
amorphous solid (38 mg, 42%). 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.27 (d, J = 8.4 Hz, 
2H), 7.22 – 7.17 (m, 1H), 7.16 – 7.11 (m, 3H), 6.71 (dd, J = 8.2, 2.8 Hz, 1H), 6.57 (s, 1H), 6.54 
(d, J = 2.7 Hz, 1H), 6.07 (s, 1H), 4.05 (s, 2H), 3.91 (s, 3H), 3.40 – 3.32 (m, 2H), 2.87 – 2.73 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 171.3, 163.5, 156.5, 154.4, 143.2, 140.7, 140.5, 132.4, 130.7, 
129.2 (2C), 128.9 (2C), 126.6, 117.4, 113.9, 107.1, 103.0, 53.0, 38.8, 34.6, 32.2. HRMS (ESI) 
[M+H]+ for C23H22ClO5 413.1156, found 413.1175. 
 
Methyl 2-(2-benzyl-3-hydroxyphenethyl)-3-chloro-4,6-dihydroxybenzoate (24). White 
amorphous solid (25 mg, 28%) 1H NMR (400 MHz, CDCl3) δ 11.40 (s, 1H), 7.24 (d, J = 0.9 Hz, 
2H), 7.18 (d, J = 7.9 Hz, 1H), 7.14 (dd, J = 7.9, 1.5 Hz, 3H), 6.95 – 6.91 (m, 1H), 6.74 (d, J = 1.2 
Hz, 1H), 6.56 (s, 1H), 6.03 (s, 1H), 4.62 (s, 1H), 4.19 (s, 2H), 3.89 (s, 3H), 3.39 – 3.26 (m, 2H), 
2.93 – 2.79 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.1, 163.3, 156.3, 154.4, 142.8, 142.0, 
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139.9, 128.8 (2C), 128.1 (2C), 127.7, 126.4, 124.9, 122.0, 114.0, 114.0, 106.8, 102.8, 52.7, 34.4, 
33.0, 31.5. HRMS (ESI) [M]+ for C23H21ClO5 412.1078, found 412.1073. 
 
Methyl 3-chloro-2-(2-(2-ethoxybenzyl)phenethyl)-4,6-dihydroxybenzoate (25). Tan amorphous 
solid (61 mg, 64%). 1H NMR (400 MHz, CDCl3) δ 11.46 (s, 1H), 7.29 (dd, J = 7.6, 1.6 Hz, 2H), 
7.22 (td, J = 7.4, 1.6 Hz, 1H), 7.17 (td, J = 7.7, 2.2 Hz, 2H), 7.09 (dd, J = 7.5, 1.5 Hz, 1H), 6.90 – 
6.80 (m, 3H), 6.57 (s, 1H), 6.04 (d, J = 1.2 Hz, 1H), 4.09 (s, 2H), 4.03 (q, J = 7.0 Hz, 2H), 3.93 (s, 
3H), 3.40 – 3.30 (m, 2H), 2.94 – 2.72 (m, 2H), 1.35 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 171.0, 163.1, 156.5, 156.0, 142.9, 139.9, 138.3, 130.2, 129.6, 129.2, 128.9, 127.1, 126.3, 
126.3, 120.1, 113.8, 110.7, 106.5, 102.4, 63.3, 52.5, 34.0, 32.5, 32.4, 14.8. HRMS (ESI) [M+H]+ 
for C25H26ClO5 441.1469, found 441.1449. 
 
Methyl 3-chloro-4,6-dihydroxy-2-(2-(2-methoxybenzyl)phenethyl)benzoate (26). White 
amorphous solid (52 mg, 56%). 1H NMR (400 MHz, CDCl3) δ 11.50 (s, 1H), 7.31 (d, J = 7.5 Hz, 
1H), 7.25 (d, J = 6.0 Hz, 1H), 7.20 (q, J = 8.3, 7.3 Hz, 2H), 7.09 (d, J = 7.5 Hz, 1H), 6.89 (d, J = 
8.2 Hz, 1H), 6.86 – 6.81 (m, 2H), 6.58 (s, 1H), 6.12 (s, 1H), 4.10 (s, 2H), 3.95 (s, 3H), 3.83 (s, 
3H), 3.45 – 3.29 (m, 2H), 2.97 – 2.69 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 171.5, 163.5, 157.6, 
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156.6, 143.3, 140.4, 138.6, 130.7, 130.0, 129.6, 129.5, 127.7, 126.8, 126.8, 120.8, 114.3, 110.3, 
107.0, 102.9, 55.6, 52.9, 34.5, 32.9, 32.7. HRMS (ESI) [M+Na]+ for C24H23ClO5 449.1132, found 
449.1124. 
 
Methyl 3-chloro-2-(2-(2-chlorobenzyl)phenethyl)-4,6-dihydroxybenzoate (27). Clear oil (27 
mg, 29%). 1H NMR (400 MHz, CDCl3) δ 11.41 (s, 1H), 7.40 (dd, J = 7.6, 1.7 Hz, 1H), 7.33 (dd, J 
= 7.6, 1.6 Hz, 1H), 7.30 – 7.24 (m, 1H), 7.22 – 7.09 (m, 3H), 7.01 (dd, J = 7.6, 1.3 Hz, 1H), 6.88 
– 6.80 (m, 1H), 6.57 (s, 1H), 6.06 (s, 1H), 4.20 (s, 2H), 3.96 (s, 3H), 3.41 – 3.30 (m, 2H), 2.91 – 
2.72 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.8, 163.0, 156.1, 142.5, 140.0, 138.3, 136.7, 
134.1, 130.1, 130.1, 129.2, 129.2, 127.5, 126.8, 126.7, 126.6, 113.8, 106.5, 102.5, 52.5, 36.0, 
334.0, 32.4. HRMS (ESI) [M+H]+ for C23H21Cl2O4 431.0817, found 431.0836. 
 
Methyl 3-chloro-2-(2-(3-chlorobenzyl)phenethyl)-4,6-dihydroxybenzoate (28). Clear oil (35 
mg, 37%). 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 7.28 (dd, J = 3.0, 1.8 Hz, 1H), 7.25 – 7.21 
(m, 1H), 7.20 – 7.16 (m, 2H), 7.10 (dd, J = 7.4, 1.5 Hz, 1H), 7.07 (dt, J = 1.8, 1.0 Hz, 1H), 7.02 – 
6.97 (m, 1H), 6.58 (s, 1H), 6.08 (d, J = 5.2 Hz, 2H), 4.08 (s, 2H), 3.93 (s, 3H), 3.43 – 3.31 (m, 2H), 
2.91 – 2.74 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 170.7, 163.0, 156.1, 142.7, 142.5, 139.6, 
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137.4, 134.2, 130.5, 129.6, 129.1, 128.6, 126.9, 126.7, 126.6, 126.2, 113.7, 106.6, 102.6, 52.5, 
38.0, 33.8, 32.3. HRMS (ESI) [M+H]+ for C23H20Cl2O4 431.0817, found 431.0835. 
 
Methyl 3-chloro-2-(2-(4-chlorobenzyl)phenethyl)-4,6-dihydroxybenzoate (29). Clear oil (25 
mg, 27%). 1H NMR (400 MHz, CDCl3) δ 11.37 (s, 1H), 7.30 – 7.26 (m, 2H), 7.23 (d, J = 8.4 Hz, 
2H), 7.21 – 7.16 (m, 1H), 7.16 – 7.07 (m, 2H), 7.07 – 7.00 (m, 2H), 6.58 (s, 1H), 6.07 (s, 1H), 4.07 
(s, 2H), 3.92 (s, 3H), 3.44 – 3.34 (m, 2H), 2.90 – 2.76 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
170.7, 163.0, 156.0, 142.5, 139.6, 139.1, 137.8, 130.4, 129.8, 129.1, 129.0, 128.6, 128.4, 128.3, 
126.8, 126.5, 125.9, 106.6, 102.6, 52.5, 37.7, 33.9, 32.3. HRMS (ESI) [M+H]+ for C23H21Cl2O4 
431.0817, found 431.0814. 
 
Methyl 3-chloro-2-(2-(4-fluorobenzyl)phenethyl)-4,6-dihydroxybenzoate (30). White 
amorphous solid (44 mg, 49%). 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 7.29 (dd, J = 7.5, 1.9 
Hz, 1H), 7.24 – 7.16 (m, 2H), 7.13 – 7.02 (m, 3H), 6.99 – 6.92 (m, 2H), 6.58 (s, 1H), 6.07 (s, 1H), 
4.07 (s, 2H), 3.92 (s, 3H), 3.41 – 3.35 (m, 2H), 2.90 – 2.78 (m, 2H). 19F NMR (376 MHz, CDCl3) 
δ -117.4 (s, 1F). 13C NMR (126 MHz, CDCl3) δ 170.7, 163.0, 162.2 (d, J = 244.0 Hz), 156.0, 
154 
 
142.5, 139.6, 138.2, 136.2, 136.2, 130.3, 129.9, 129.1, 126.7, 126.5, 115.2, 115.0, 113.7, 106.6, 
102.5, 52.5, 37.5, 33.8, 32.3. HRMS (ESI) [M+H] for C23H21ClFO4 415.1112, found 415.1103. 
 
Methyl 3-chloro-2-(2-(2-(4-fluorobenzyl)pyridin-3-yl)ethyl)-4,6-dihydroxybenzoate (31). Clear 
oil (37 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 8.42 (t, J = 4.2 Hz, 1H), 7.54 (dd, J = 7.6, 1.6 Hz, 
1H), 7.17 (dd, J = 7.7, 4.9 Hz, 1H), 7.09 (t, J = 6.6 Hz, 2H), 6.90 (td, J = 8.6, 2.0 Hz, 2H), 6.47 (d, 
J = 3.9 Hz, 1H), 4.24 (s, 2H), 3.86 (s, 3H), 3.42 – 3.29 (m, 2H), 2.92 – 2.77 (m, 2H). 19F NMR 
(376 MHz, CDCl3) δ -117.03 (s, 1F). 
13C NMR (126 MHz, CDCl3) δ 170.6, 163.2, 162.6 (d, J = 
244 Hz), 156.7, 142.0, 130.1 (2C), 130.1 (2C), 122.3, 115.5 (2C), 115.4 (2C), 114.2, 106.7, 103.1 
(2C), 52.7, 33.4, 31.7, 29.9. HRMS (ESI) [M+H]+ for C22H20ClFNO4 416.1065, found 416.1050. 
Fluorescence Polarization. The assay was performed in 96-well black, flat-bottom plates with 
a final volume of 100 µL. 25 µL of assay buffer (20 mM HEPES, pH 7.3, 50 mM KCl, 5 mM 
MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% NP-40) were added, followed 
by 25 µL of assay buffer containing 6 nM FITC-GDA (fluorescent tracer, stock in DMSO, diluted 
in assay buffer) and 50 µL of assay buffer containing 10 nM of either Grp94 or Hsp90α were added 
to each well. For each plate, wells containing buffer only (background), tracer in buffer only (low 
polarization control) and protein, tracer, and 1% DMSO (final concentration, high polarization 
control) were included. Compounds were then added with a final concentration of DMSO = 1%. 
Plates were incubated at 4 ˚C with rocking for 24 h. Polarization values (in mP units) were 
measured at 37 ˚C with an excitation filter at 485 nm and an emission filter at 528 nm. Polarization 
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values were correlated to % tracer bound and compound concentrations. The concentration at 
which the tracer was 50% displaced by compound of interested were calculated and reported as 
apparent Kd’s. 
Docking Studies. The Surlfex-Docking module in Sybyl v8.0 was used for docking studies 
using the crystal structure of KUNG38 bound to Grp94 (PDBID: 5IN9). Pymol was used for 
visualization of the results. 
Cell Culture. MDA-MB-231, PC3-MM2, SK-MEL-28, and A549 cells were grown in a water 
jacketed incubator at 37 ̊ C with 5% CO2 in DMEM (MDA-MB-231 and PC3-MM2), EMEM (SK-
MEL-28) or F-12K (A549) media supplemented with 10% FBS and 1% penicillin/streptomycin.  
Anti-proliferation. cells were counted via Trypan blue exclusion and seeded in 96-well plates 
at 2,000 cells/0.1 mL/well then returned to the incubator for 24 h. Compounds or vehicle were 
administered in DMSO (1% DMSO final concentration) and the plates were placed back in the 
incubator. After 72 h, the % viable cells were determined using the MTS/PMS cell proliferation 
kit (Promega) per the manufacturer’s instructions. Cells treated with vehicle were normalized to 
100% viable and compound treated wells were adjusted accordingly. GI50 values were calculated 
via GraphPad Prism and reported as the average of 2 or more independent experiments ± SEM. 
Wound Healing Scratch Assay. Cells were counted via Trypan blue exclusion and seeded in 
12-well plates at 200,000 cells/mL/well and returned to the incubator for 24 h. Scratches were 
made with a 0.1-10 µL pipette tip, then cells were washed with PBS and fresh media was added. 
Compound or DMSO control were then added (0.25% DMSO final concentration) and 0 h pictures 
taken with a camera-mounted Olympus IX-71 microscope (10X objective). Plates were returned 
to the incubator until 24 h pictures were taken. Images were processed and % migration determined 
via ImageJ. All experiments were performed in quadruplicate.  
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Western Blot Analysis. Cells were counted via Trypan blue exclusion and were seeded at 
100,000 cells/mL in 10 cm dishes and placed back in the incubator for 24 h. Compounds or vehicle 
were dosed (0.25% DMSO final concentration) and incubated together for 24 h. Cells were 
harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease 
inhibitors (Roche) according the manufacturer’s instructions. Cell lysates were obtained by 
centrifugation at 15,000 rpm for 10 min at 4 ˚C. Protein concentrations were determined using the 
Pierce BCA assay kit following the manufacturer’s instructions. Equal amounts of protein were 
separated via gel electrophoresis under reducing conditions (10% acrylamide gels) then transferred 
to PVDF membranes and immunoblotted with the corresponding primary antibodies. Membranes 
were then incubated with the correct HRP-labeled secondary antibody, developed with a 
chemiluminescent substrate, and visualized. 
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4. Resorcinol-based Grp94-selective Inhibitors Exhibit Activity against 
Multiple Myeloma 
Introduction 
The 90kDa heat shock proteins (Hsp90) are responsible for the maturation of more than 300 
nascent polypeptides into their biologically active conformations as well as the re-maturation of 
denatured proteins.1-3 Many protein substrates dependent upon Hsp90 are associated with signaling 
pathways that are commonly hijacked during malignant transformation, including Her2, Akt, and 
Raf. In fact, Hsp90-dependent client proteins are represented in all ten hallmarks of cancer.4-5 
Consequently, Hsp90 inhibition provides a combinatorial attack against cancer via a single 
molecular target. Hsp90 is a homodimeric protein and each monomer contains: An N-terminal 
ATP-binding motif, a middle domain that is important for protein-protein interactions, and a C-
terminal dimerization domain.6 Binding and hydrolysis of ATP at the N-terminus provides the 
requisite source of energy for client protein folding, but inhibition or disruption of this process 
results in ubiquitination of the substrate which signals its degradation via the proteasome.  
Seventeen small molecule, ATP-competitive N-terminal inhibitors have been introduced into 
clinical trials for the treatment of various types of cancer.7-9 Unfortunately, these trials have 
revealed cardiotoxicity, hepatotoxicity, ocular toxicity, hypoglycemia, and/or limited efficacy as 
a single agent in many cases.10 In addition, all of these inhibitors induce the pro-survival heat shock 
response (HSR), in which the heat shock proteins (Hsp90, Hsp70, Hsp27, etc.) are upregulated at 
the same concentrations required for client protein degradation, requiring patients to receive 
increasingly higher doses that push the patient toward the maximum tolerated dose and toxicity. 
These detriments have produced concerns about Hsp90 as a therapeutic target and support the need 
for alternative strategies of Hsp90 inhibition.  
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The Hsp90 family of chaperones is comprised of four isoforms: Hsp90α and Hsp90β reside in 
the cytosol, TRAP1 is localized to the mitochondria, and Grp94 is found in the endoplasmic 
reticulum. All of the Hsp90 clinical candidates are pan-Hsp90 inhibitors and manifest similar 
affinity against all four Hsp90 isoforms. Each Hsp90 isoform appears to play a distinct role in 
cancer progression, and therefore, targeting a specific isoform may induce the degradation of a 
smaller subset of client proteins and reduce the liabilities associated with pan-Hsp90 inhibition. 
All four Hsp90 isoforms share high identity within their N-terminal ATP-binding site, hindering 
the development of Hsp90 isoform-selective inhibitors.11-13 The most unique isoform is Grp94, 
which contains a five amino acid insertion into its primary sequence that results in a unique 
secondary binding pocket within the ATP-binding site.  
Grp94 is the ER resident isoform of the Hsp90 protein family and is responsible for the 
maturation and trafficking of proteins associated with cell signaling and cellular adhesion.14 Grp94 
plays a key role in the maturation and intracellular trafficking of integrins as well as maintenance 
of cell polarity.15 Other Grp94-dependent client proteins include Her2, LRP6, IGF-I and –II, Toll-
like receptors, integrins, and mutant myocilin.16-19 Due to the dependency of integrins on Grp94 
for their maturation and trafficking to the cell surface, Grp94-selective inhibitors may represent a 
non-toxic method to inhibit cancer metastasis.20-22 Inhibition of Grp94 has also been implicated in 
other diseases, such as myocilin-associated open angle glaucoma.23-25 Since Grp94 is only essential 
during embryonic development, Grp94 may represent a non-toxic target that can be inhibited to 
treat these diseases while reducing the liabilities associated with pan-Hsp90 inhibitors. 
Conversely, some cancers exhibit an increased dependence upon a functional ER and the ER 
chaperone system for survival due to increased metabolic rate (hepatocellular carcinoma) or the 
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unfolded protein response as a result of elevated ER stress (multiple myeloma), and these 
circumstances render Grp94 inhibition as a potential strategy to combat these cancers.23-24  
Rationale of Resorcinol-based Grp94-selective inhibitor that utilize the S2 sub-pocket 
As a consequence of the five amino acid insertion into its primary sequence, the Grp94 N-
terminal ATP-binding pocket contains a unique hydrophobic pocket, which can be divided into 
two distinct sub-pockets that are not present in other isoforms. Sub-pocket 1 (S1) is located near 
the solvent-exposed region of the binding pocket, but it is hydrophobic in nature and surrounded 
by Ile166, Ala167, Phe195, Val197, and Tyr200. The corresponding residues in cytosolic Hsp90s 
(Hsp90α and Hsp90β) are similar, but access to this region is blocked by Asn92 and Lys90. The 
S1 sub-pocket has been utilized previously for the development of Grp94-selective inhibitors, as 
evidenced by the rational design of BnIm and its subsequent analogue, KUNG38 (Figure 4.1a).21, 
26-27 These resorcinol-based inhibitors orient the benzylic side chain into the S1 sub-pocket to 
Figure 4.1. Grp94-selective scaffolds utilize different sub-pockets to gain selectivity. (a) Structure of KUNG38 
and its interaction with the S1 sub-pocket of Grp94. (b) Structure of PU-H54 and its interaction with the S2 sub-
pocket of Grp94. (c) Overlay of KUNG38 (green, PDBID: 5IN9) and PU-H54 (blue, PDBID: 3O2F) co-crystal 
structures demonstrating the different binding modes between two Grp94-selective scaffolds. Red arrows 
indicate helix reorganization upon ligand binding resulting in Phe199 moving to allow access to S2 sub-pocket. 
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impart selectivity for Grp94 (Figure 4.1c). Recently, a small library of purine-based inhibitors was 
screened for Grp94-inhibition which identified PU-H54 as a Grp94-selective inhibitor (Figure 
4.1b).17, 28 The co-crystal structure of PU-H54 bound to Grp94 identified a second Grp94-exclusive 
sub-pocket (S2) near the adenine binding region of the N-terminal ATP-binding pocket (Figure 
4.1c). The S2 sub-pocket results from rotation of Phe199 in Grp94 (red arrow, Figure 4.1c) as helices 
1, 4, and 5 reorganize upon ligand binding (red arrow, Figure 4.1c). Surprisingly, access to the S2 
sub-pocket is obstructed in the crystal structure of KUNG38 bound to Grp94. To date, no 
resorcinol-based inhibitor has been shown to bind the S2 sub-pocket in order to gain Grp94 
selectivity. Therefore, resorcinol-based inhibitors were designed to selectively interact with the S2 
sub-pocket in an effort to identify the optimal sub-pocket for the development of Grp94-selective 
inhibitors.  
Design, Synthesis, and Biochemical Evaluation of Resorcinol-based Grp94-selective 
inhibitors 
The resorcinol containing isoindoline 1 was chosen as a starting point to probe the S2 sub-pocket 
of Grp94 (Figure 4.2a) because it contains the resorcinolic pharmacophore present in the pan-
Hsp90 inhibitor AT13387, which remains under clinical investigation.29-30 As shown in Figure 
4.2b, an overlay of 1 docked to both Grp94 and Hsp90α provides insight into the development of 
Grp94-selective inhibitors. The 5-position of the resorcinol ring projects directly toward the 
hydrophobic S2 sub-pocket that is surrounded by Leu104, Phe199, Ala202, Val211, Trp223, and 
Leu249 (Figure 4.2c). The Hsp90α binding site possesses a pocket that extends towards the 
solvent exposed region of the ATP-binding pocket (Site-1, Figure 4.2d), which has been utilized 
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previously to develop pan-Hsp90inhibitors. The S2 sub-pocket extends deeper into the protein and 
away from the solvent exposed region compared to Site-1. In order to transform 1 into a Grp94-
selective inhibitor, substitutions at the 5-position must exhibit a preference for interacting with the 
S2 sub-pocket of Grp94 versus Site-1 of Hsp90α (Figure 4.2b). Molecular modeling studies 
suggested that direct attachment of an aryl group to the 5-position of the resorcinol ring (3) would 
produce detrimental steric interactions with the S2 sub-pocket. However, it appeared that a single 
atom linker could alleviate this steric clash and, instead, produce compounds that selectively 
interact with the S2 sub-pocket to exhibit Grp94 selectivity. Molecules that connect a phenyl 
(proposed to bind to the S2 sub-pocket) and resorcinol ring via a sulfur atom (4) or methylene 
 
Figure 4.2. Grp94-selective inhibitor design. (a) Structure of 1. (b) Proposed binding model of 1 in Hsp90α (green) 
and Grp94 (blue). PDBIDs: 3O2F (Grp94), 3O2I (Hsp90α). Br = light blue (c) Key hydrophobic residues 
comprising the S2 sub-pocket of Grp94. (d) Key hydrophobic residues comprising Site-1 of Hsp90α. Isoindoline 
ring omitted for clarity. 
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group (5) were proposed. In addition, a ring-constrained nitrogen-linked analogue (6) was also 
sought to limit rotation about the linker moiety, while projecting the aromatic ring into the S2 sub-
pocket for selective inhibition of Grp94.  
Synthesis of the proposed analogues began via the preparation of 2 following literature 
procedures.31 Subsequent treatment of 2 with boron tribromide afforded resorcinol 1. Compounds 
3-6 were prepared via palladium-catalyzed cross-coupling reactions between 2 and the 
corresponding coupling partners (3a-6a). Resorcinol 3 was synthesized via a Suzuki cross-
coupling reaction with phenyl boronic acid (3a), followed by cleavage of the benzyl ethers upon 
exposure to boron tribromide. Coupling of 2 with thiophenol (4a) was achieved via the enlistment 
of tris(dibenzylideneacetone)dipalladium(0), sodium tert-butoxide, and XPhos to provide the 
corresponding thioether, which was then exposed to boron tribromide to provide 4. Coupling of 
potassium benzyltrifluoroborate (5a) with 2 was performed using palladium (II) acetate, RuPhos, 
and potassium phosphate tribasic followed by cleavage of the benzyl ethers to afford 5. Coupling 
of indoline (6a) with resorcinol ring 2 was achieved via a palladium-catalyzed cross-coupling 
reaction followed by cleavage of the benzyl ethers to yield 6 (Scheme 4.1).  
Scheme 4.1. Synthesis of compounds 3-6. 
 
Conditions: (a) 3a, Pd(dppf)Cl2, Toluene/EtOH; (b) 4a, Pd2(dba)3, NaOtBu, XPhos, Toluene; (c) 5a, Pd(OAc)2, 
RuPhos, K3PO4, Toluene; (d) 6a, Pd2(dba)3, RuPhos, NaOtBu, Toluene; (e) BBr3, DCM. 
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Upon their preparation, compounds 1 and 3-6 were evaluated in a fluorescence polarization 
assay to measure their affinity for both Grp94 and Hsp90α.32 The results from these studies are 
summarized in Table 4.1. The parent compound, 1, demonstrated good affinity but no selectivity 
between Grp94 and Hps90α, which was expected due to the bromide substitution not projecting 
into the S2 sub-pocket of Grp94 or Site-1 of Hsp90α. As predicted by modeling, direct attachment 
of an aryl appendage to the resorcinol ring was detrimental, as evidenced by 3 which did not 
produce any measurable affinity up to 100 µM against both Grp94 and Hsp90α. However, 
incorporation of a linker (4 and 5) proved that the S2 sub-pocket could be exploited with the 
resorcinol scaffold to gain Grp94 selectivity with these analogues, resulting in 2- or 4-fold 
selectivity for Grp94, respectively. Thioether 4 and methylene analogue 5 exhibited excellent 
affinities of 13 nM and 15 nM for Grp94, respectively. However, the low selectivity exhibited by 
Table 4.1. Evaluation of compounds 1 and 3 – 6 via fluorescence polarization against Grp94 and Hsp90α. 
 
Entry R Grp94 (µM) Hsp90α(µM) 
Fold Grp94 
Selective 
1 -Br 0.02 ± 0.005 0.025 ± 0.007 n/a 
3 
 
>100 >100 n/a 
4 
 
0.013 ± 0.002 0.026 ± 0.002 2 
5 
 
0.015 ± 0.003 0.066 ± 0.006 4 
6 
 
9.89 ± 1.1 >50 5 
Data are the average of at least two independent experiments ± SEM. n/a = non-selective 
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these analogues suggested that rotation about the linker produced similar affinities for Hsp90α. 
Therefore, reduction of the rotational freedom about the linker atom was pursued via the 
incorporation of an indoline ring (6), which produced 5-fold selectivity. However, this selectivity 
was accompanied by a significant loss of affinity for Grp94 with an apparent Kd of 9.9 µM. 
 Compounds containing sulfur and methylene linkers (4 and 5) also produced low selectivity 
for Grp94, but maintained good affinity. Lack of selectivity for these analogues was not too 
surprising, as rotation about the linker atoms could project the phenyl ring into either the S2 sub-
pocket of Grp94 or Site-1 of Hsp90α (Figure 4.3). Similar rotational freedom has been observed 
for the sulfide linked purine-based Grp94-selective inhibitors that target the S2 sub-pocket of 
Scheme 4.2. Synthesis of sulfide-containing analogues 10 – 14. 
 
Conditions: (a) Pd2(dba)3, XPhos, 7a-11a, NaOtBu, Toluene; (b) BBr3, DCM 
 
Figure 4.3. Proposed binding mode of 4. (a) Grp94 (blue) and (b) Hsp90α (green). 
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Grp94; however these purine-based inhibitors appear to possess some preference for binding the 
S2 sub-pocket for reasons that remain unclear. In an effort to improve the selectivity profile of 
these inhibitors, substitutions on the aryl side chain of 4 and 6 were explored.  
Analysis of the crystal structures of Hsp90α and Grp94 indicated that both Site-1 of Hsp90α and 
the S2 sub-pocket of Grp94 are comprised of similar, hydrophobic amino acid residues, but these 
residues orient differently around the aryl side chain of these inhibitors (Figure 4.3). Furthermore, 
the S2 sub-pocket of Grp94 appears to be sterically less demanding compared to Site-1 of Hsp90α. 
Therefore, it was proposed that these subtle differences could be exploited to improve Grp94 
selectivity by the introduction of substituents onto the aryl side chain. Selection of substituents 
Table 4.2. Evaluation of 7 – 11 in a fluorescence polarization assay against Grp94 and Hsp90α. 
 





0.013 ± 0.002 0.026 ± 0.002 2 
7 
 
0.029 ± 0.004 0.065 ± 0.01 2 
8 
 
0.034 ± 0.002 0.037 ± 0.002 n/a 
9 
 
0.07 ± 0.002 0.052 ± 0.007 n/a 
10 
 
0.03 ± 0.002 0.07 ± 0.002 2 
11 
 
0.029 ± 0.001 0.031 ± 0.002 n/a 
Data are the average of at least two independent experiments ± SEM. n/a = non-selective. 
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was guided by docking studies and prior structure-activity relationship studies observed for the 
purine-based Grp94-selective inhibitors, due to the potential for overlapping binding modes.28, 33  
Compounds 7 – 9 , which contain electron donating groups at the 2’-, 3’-, and 4’-positions were 
considered (Scheme 4.2) as well as dimethyl (10 and 11) substituents on the aryl side chain as 
mechanisms to reduce affinity for the smaller Site-1 binding region. The 2’-methyl group was 
hypothesized to produce detrimental steric interactions with the smaller Site-1 of Hsp90α and 
produce favorable interactions with the larger and more hydrophobic residues present in the S2 
sub-pocket of Grp94. 7 – 11 were prepared via the synthetic route described for 4, but instead, 
utilized coupling partners 7a – 11a, followed by cleavage of the benzyl ethers with boron 
tribromide to provide the desired analogues. 
Once synthesized, 7 – 11 were evaluated for affinity and selectivity via a fluorescence 
polarization assay, which provided information regarding the binding modes for these analogues 
(Table 4.2). While these substitutions provided compounds with excellent affinity for Grp94 (Kds 
<70 nM), many of these analogues did not exhibit the anticipated selectivity for Grp94 (eg, 8, 9, 
and 11). Lack of selectivity is likely due to Site-1 of Hsp90α possessing a higher degree of 
flexibility than originally suspected and observed via docking studies. Alteration of the electronic 
nature of the phenyl ring did not improve selectivity, as neither electron donating (8) nor electron 
neutral (11) substitutions provided enhanced selectivity. Additionally, the low selectivity exhibited 
by analogues 10 and 11 (2-fold and non-selective, respectively) suggests the aryl side chains of 
these resorcinol-based Grp94-selective inhibitors orients differently than the aryl side chains of 
the previously reported purine-based Grp94-selective inhibitors. Substitutions similar to 10 and 11 
in the purine-scaffold exhibited high selectivity for Grp94 over the cytosolic Hsp90 isoforms. 
Therefore, these resorcinol-based Grp94 inhibitors resulted in new structure-activity relationships. 
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Due to poor selectivity manifested by the analogues containing a sulfide linker (7 – 11), 
attention turned toward modification of 6 to improve selectivity for Grp94. Compounds 7 and 10 
possess substitutions at the 2’- and 4’-positions and were the only analogues that demonstrated 
Grp94-selectivity, suggesting that these modifications are necessary to improve selectivity. 
Therefore, 12 and 13 were sought to elucidate substituents that could further enhance Grp94 
selectivity versus other Hsp90 isoforms. These analogues were synthesized via a palladium-
catalyzed cross-coupling reaction between boronic acid pinacol ester 2a and 2-chloro- or 4-
chlorobenzyl bromide (12a and 13a, respectively), followed by treatment with boron tribromide 
to ultimately produce 12 and 13 (Scheme 4.3).  
Evaluation of these analogues via a fluorescence polarization assay revealed 13 to manifest 5-
fold selectivity for Grp94 and improved affinity as compared to sulfide analogues 7 – 11, whereas 
12 exhibited a similar affinity and selectivity profile to the sulfide analogues (Table 4.3). Due to 
the difference in size between the sulfur atom and the methylene group, substitutions at the 4’-
position did not exhibit similar affinities or selectivity profiles (e.g. 9 versus 13). Consequently, 
substitutions at the 4’-position were further explored and ultimately led to the identification of 14 
Scheme 4.3. Synthesis of methylene-linked analogues 12 – 15. 
 




and 15. It was determined that increasing the size of the substituent from chloro (13) to methyl 
(14) reduced selectivity and a 3-fold decrease in affinity, as compared to 13. In contrast, decreasing 
the size to a fluorine (15), led to ~10-fold selectivity for Grp94 and <10 nM affinity and warranted 
further evaluation in cellular models of Grp94-dependent processes.  
Evaluation of Grp94-selective inhibitors against Multiple Myeloma 
ER chaperones are upregulated in multiple myeloma as a consequence of the unfolded protein 
response that leads to plasma cell differentiation and pathogenesis.33 Grp94 is critical for the 
development of multiple myeloma and its genetic deletion led to inhibition of cell growth.24 Li and 
coworkers demonstrated this phenomenon to occur through loss of the canonical Wnt signaling 
pathway. LRP6, a Frizzled co-receptor, was identified as a Grp94-specific client, and genetic 
Table 4.3. Evaluation of 12 – 15 in a fluorescence polarization assay against Grp94 and Hsp90α. 
 





0.015 ± 0.003 0.066 ± 0.006 4 
12 
 
0.06 ± 0.01 0.20 ± 0.01 3 
13 
 
0.013 ± 0.004 0.06 ± 0.01 5 
14 
 
0.04 ± 0.001 0.04 ± 0.002 n/a 
15 
 
0.008 ± 0.001 0.077 ± 0.004 10 
Data are the average of at least two independent experiments ± SEM. n/a = non-selective 
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knockdown of Grp94 led to degradation of LRP6 and reduction of Wnt signaling, ultimately 
leading to cell death via activation of caspase 9. Consequently, these Grp94-selective inhibitors 
were evaluated for their ability to decrease the proliferation of multiple myeloma cells.  
 
Table 4.4. Evaluation of resorcinol-based inhibitors against the multiple myeloma cell line, RPMI8226. 
 
Entry R GI50 (µM) RPMI8226 
Geldanamycin n/a 0.003 ± 0.0006 






3.7 ± 0.8 
11 
 
1.9 ± 0.2 
13 
 
3.0 ± 0.4 
14 
 
2.7 ± 0.4 
15 
 
1.4 ± 0.1 
Data are the average of at least two independent experiments ± SEM 
Grp94-selective inhibitors (5, 13, 15), non-selective inhibitors (11, 14), and an inactive control 
(3) were evaluated for anti-proliferative activity against a multiple myeloma cell line (RPMI8226) 
as summarized in  
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Table 4.4. In general, compounds that demonstrated affinity via fluorescence polarization 
exhibited low micromolar GI50 values against these cells. The Grp94-selective inhibitor 15 
exhibited a GI50 value of 1.4 µM and was selected for further evaluation via western blot analysis 
of RPMI8226 cell lysates. As predicted via Grp94 KD studies, treatment with 15 demonstrated 
reduction of LRP6 levels (Figure 4.4), and this effect was seen at concentrations that mirrored cell 
viability, linking Grp94 inhibition to cell viability. Analysis of downstream Wnt signaling 
demonstrated that survivin, an anti-apoptotic protein, was degraded in a dose-dependent manner, 
which suggested that 15 activated apoptosis through decreased Wnt signaling. Importantly, 
degradation of Akt, a cytosolic Hsp90 isoform-dependent client protein, was not observed until 
the highest concentration. Similarly, induction of Hsp70, a hallmark of the pro-survival HSR and 
pan-Hsp90 inhibition, was not observed until the highest concentration. This result contrasted the 
natural product pan-Hsp90 inhibitor, geldanamycin (G), which induced Hsp70 levels at low 
concentrations. Together, these data suggest that 15 manifests Grp94-selective inhibition in cells 
and represents a new scaffold for future development. 
 
Figure 4.4. Western blot analysis of RPMI8226 cell lysates after treatment with 15. G = geldanamycin (a natural 
product, pan-Hsp90 inhibitor, 0.5 µM) and D = DMSO (vehicle control, 0.1% final concentration).  
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Conclusions & Future Directions 
Recently, Grp94-selective inhibition has emerged as a therapeutic target for the treatment of 
glaucoma, multiple myeloma, and metastatic cancer. Therefore, the development of new Grp94-
selective scaffolds is highly desirable. In this study, a resorcinol-based, non-selective Hsp90 
inhibitory scaffold was modified through a rational, structure-based drug design approach to probe 
an exclusive S2 sub-pocket present in Grp94, which had not been previously accessed with the 
resorcinol class of Hsp90 inhibitors. Structure-activity relationship studies resulted in the Grp94-
selective inhibitor 15, which manifested low nanomolar affinity and ~10-fold selectivity for Grp94 
via fluorescence polarization. This work demonstrates that the S2 sub-pocket of Grp94 can be 
utilized to develop inhibitors that are selective for Grp94. Compound 15 also demonstrated a low 
micromolar GI50 value against the multiple myeloma cell line, RPMI8226. Further analysis via 
western blot demonstrated that treatment of multiple myeloma cells with 15 induced degradation 
of the Grp94-specfic client protein LRP6, without the degradation of the cytosolic Hsp90-
dependent client protein Akt, demonstrating that 15 selectively inhibited Grp94 within cells. In 
addition, compound 15 did not induce the HSR at concentrations similar to those needed to degrade 
LRP6, which contrasts the pan-Hsp90 inhibitors in the clinic. These data suggest that Grp94-
selective inhibition could provide an attractive therapeutic option for the treatment of multiple 
myeloma. Based on the success of converting the non-selective inhibitor 1 into a Grp94-selective 
inhibitor that takes advantage of the Grp94-exclusive S2 sub-pocket, a structure-based approach 
to modify other resorcinol-based pan-Hsp90 inhibitors could lead to more efficacious Grp94-




Chemistry General. 1H NMR were recorded at 400 (Bruker AVIIIHD 400 MHz NMR with a 
broadband X-channel detect gradient probe) or 500 MHz (Avance AVIII 500 MHz spectrometer 
with a dual carbon/proton cryoprobe), 19F NMR were recorded at 376 MHz (Bruker AVIIIHD 400 
MHz NMR equipped with a multinuclear broadband fluorine observe probe), and 13C NMR were 
recorded at 125 MHz (Bruker AVIII spectrometer equipped with a cryogenically cooled carbon 
observe probe); chemical shifts are reported in δ (ppm) relative to the internal standard (CDCl3, 
7.26 ppm). HRMS spectra were recorded with a LCT Premier with ESI ionization. All biologically 
tested compounds were determined to be >95% pure via 1H and 13C NMR. TLC analysis was 
performed on glass backed silica gel plates and visualized by UV light. All solvents were reagent 
grade and used without further purification. 
 
(4,6-Dihydroxy-[1,1'-biphenyl]-3-yl)(isoindolin-2-yl)methanone (3). A microwave vial was 
charged with 2 (100 mg, 0.19 mmol, 1 equiv.), phenyl boronic acid (549 mg, 0.39 mmol, 2.0 
equiv.), and [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium (27 mg, 0.038 mmol, 0.2 
equiv.). The tube was sealed with a cap lined with a disposable Teflon septum. The tube was 
evacuated and purged with nitrogen (3 times), before the addition of a solvent mixture of toluene 
(1.0 mL), ethanol (1.0 mL), and saturated sodium bicarbonate solution (1.0 mL) by syringe. The 
resulting mixture was heated at 80 °C for 14 h, cooled to rt, and filtered through a small pad of 
celite (elution with ethyl acetate). Solvent was removed and the residue purified by flash 
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chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the corresponding 5-substituted product, 
which was used further as obtained, and taken in dichloromethane (2 mL), cooled to 0 °C before 
the addition of 1 M solution of boron tribromide (0.5 mL). The resulting mixture was stirred for 6 
h, quenched with saturated sodium bicarbonate solution (5 mL) and extracted with 
dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated sodium 
chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  The 
residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the desired 
product 3 as white amorphous solid (31 mg, 49 %). 1H NMR (500 MHz, CDCl3) δ 11.67 (s, 1H), 
7.57 (s, 1H), 7.56 – 7.41 (m, 5H), 7.34 – 7.28 (m, 4H), 6.63 (s, 1H), 5.78 (s, 1H), 5.11 (s, 4H). 13C 
NMR (125 MHz, CDCl3) δ 170.7, 162.6, 156.8, 136.6, 136.0 (2), 130.4, 129.7 (4), 128.1 (3), 128.0, 
122.8, 119.7, 110.4, 104.5, 55.2, 53.4. HRMS (ESI-) m/z [M-H+] calcd for C21H16NO3, 330.1130, 
found 330.1124.  
 
(2,4-Dihydroxy-5-(phenylthio)phenyl)(isoindolin-2-yl)methanone (4). A microwave vial was 
charged with 2 (100 mg, 0.19 mmol, 1 equiv.), thiophenol (0.02 mL, 0.19 mmol, 1.0 equiv.), 
Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 equiv.), 1,1′-Ferrocenediyl-
bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and diisopropyethylamine (0.04 mL, 
0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with a disposable Teflon septum. 
The tube was evacuated and purged with nitrogen (3 times), before the addition of toluene (4.0 
mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, cooled to rt, and filtered 
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through a small pad of celite (elution with ethyl acetate). Solvent was removed and the residue 
passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give the corresponding 5-
substituted product, which was used further as obtained, and taken in dichloromethane (5 mL), 
cooled to 0 °C before the addition of 1 M solution of boron tribromide (0.8 mL). The resulting 
mixture was stirred for 6 h, quenched with water (5 mL) and extracted with dichloromethane (2 × 
10 mL). The combined organic layers were washed with saturated sodium chloride solution (15 
mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  The residue purified with 
flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the desired product 4 as yellow 
amorphous solid (43 mg, 62 %). 1H NMR (400 MHz, CDCl3) δ 12.09 (s, 1H), 7.91 (s, 1H), 7.29 
(dd, J = 9.7, 2.4 Hz, 5H), 7.18 (t, J = 7.3 Hz, 1H), 7.11 – 7.05 (m, 2H), 6.76 (s, 1H), 6.71 (s, 1H), 
5.07 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 169.9, 165.5, 161.2, 137.7 (2C), 136.3, 129.5 (2C), 
128.1, 126.4 (2C), 126.4 (2C), 122.7, 111.2 (2C), 105.9, 104.2 (2C), 77.4 (2C). HRMS (ESI) 
[M+H]+ for C21H18NO3S: 364.1007, found 364.0996. 
 
(5-Benzyl-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (5). A microwave vial was charged 
with 2 (100 mg, 0.19 mmol, 1 equiv.), potassium benzyltrifluoroborate (60 mg, 0.3 mmol, 1.5 
equiv.), RuPhos (15 mg, 0.03 mmol, 0.17 equiv.), palladium (II) acetate (3 mg, 0.015 mmol, 0.08 
equiv.), and potassium phosphate tribasic (215 mg, 1 mmol, 5.2 equiv.). The tube was sealed with 
a cap lined with a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 
times), before the addition of toluene (1.7 mL) and water (0.3 mL) by syringe. The resulting 
mixture was heated at 115 °C for 16 h, cooled to rt, and filtered through a small pad of celite 
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(elution with ethyl acetate). Solvent was removed and the residue purified through a filter column 
(SiO2, 1:3 ethyl acetate/hexanes) to give the corresponding 5-substituted product, which was used 
further as obtained, and taken in dichloromethane (5 mL), cooled to 0 °C before the addition of 1 
M solution of boron tribromide (0.7 mL). The resulting mixture was stirred for 6 h, quenched with 
water (5 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers were 
washed with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, 
filtered, and concentrated.  The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 5 as white amorphous solid (37 mg, 56 %). 1H NMR 
(400 MHz, CDCl3) δ 11.71 (s, 1H), 7.36 (dd, J = 8.5, 6.7 Hz, 2H), 7.32 – 7.26 (m, 5H), 7.24 (d, J 
= 9.4 Hz, 3H), 6.43 (s, 1H), 4.91 (br s, 4H), 3.97 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 170.4, 
161.4, 157.4, 139.8, 130.8, 130.5, 129.0 (2C), 128.7 (2C), 128.6 (2C), 127.6, 126.4, 122.4, 117.9, 
109.3, 103.8 (2C), 68.1, 38.6, 35.1. HRMS (ESI) [M+H]+ for C22H20NO3: 346.1143, found: 
346.1146. 
 
(2,4-Dihydroxy-5-(indolin-1-yl)phenyl)(isoindolin-2-yl)methanone (6). A microwave vial was 
charged with 2 (150 mg, 0.36 mmol, 1 equiv.), indoline (0.06 mL, 0.55 mmol, 1.5 equiv.), RuPhos 
(15 mg, 0.03 mmol, 0.09 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.033 mmol, 
0.09 equiv.), and sodium tert-butoxide (55 mg, 0.55 mmol, 1.5 equiv.). The tube was sealed with 
a cap lined with a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 
times), before the addition of toluene (3 mL) by syringe. The resulting mixture was heated at 115 
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°C for 16 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). 
Solvent was removed and the residue purified through a filter column (SiO2, 1:3 ethyl 
acetate/hexanes) to give the corresponding 5-substituted product, which was used further as 
obtained, and taken in dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution 
of boron tribromide (0.4 mL). The resulting mixture was stirred for 6 h, quenched with water (5 
mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layers were washed 
with saturated sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, 
and concentrated.  The residue purified with flash chromatography (SiO2, 1:2 ethyl 
acetate/hexanes) to give the desired product 6 as white amorphous solid (19 mg, 14 %). 1H NMR 
(400 MHz, CDCl3) δ 7.50 (s, 1H), 7.32 – 7.27 (m, 3H), 7.24 (d, J = 7.6 Hz, 2H), 7.10 (td, J = 7.7, 
1.2 Hz, 1H), 6.86 (td, J = 7.4, 1.0 Hz, 1H), 6.69 (s, 1H), 6.39 (d, J = 7.9 Hz, 1H), 4.99 (s, 4H), 3.67 
(s, 2H), 3.20 (t, J = 8.1 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 170.3, 163.0, 161.3, 157.7, 155.9, 
151.5, 130.5, 128.8, 128.3, 127.5, 125.3, 124.9, 124.1, 122.9, 121.3, 120.8, 120.1, 109.6, 103.4, 
56.8, 53.4, 29.6, 29.1. HRMS (ESI) [M+Na]+ for C23H20N2O3Na: 395.1372, found: 395.1383. 
 
(2,4-Dihydroxy-5-((2-hydroxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (7). A 
microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 2-methoxythiophenol (0.02 
mL, 0.19 mmol, 1.0 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 
equiv.), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and 
diisopropyethylamine (0.04 mL, 0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
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the addition of toluene (4.0 mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give 
the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.8 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the 
desired product 7 as yellow amorphous solid (69 mg, 92 %). 1H NMR (400 MHz, CDCl3) δ 7.70 
(s, 1H), 7.35 – 7.27 (m, 3H), 7.26 (m, 3H), 6.98 (dd, J = 8.1, 1.3 Hz, 1H), 6.91 (td, J = 7.5, 1.2 Hz, 
1H), 6.59 (s, 1H), 4.96 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 169.6, 163.7, 159.6, 155.3, 134.9 
(2C), 133.6 (2C), 130.5 (2C), 127.8, 122.5, 121.5 (2C), 120.2, 115.7, 110.6, 108.9, 104.0, 60.4 
(2C). HRMS (ESI) [M+H]+ for C21H18NO4S: 380.0957, found 380.0976. 
 
(2,4-Dihydroxy-5-((3-methoxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (8). A 
microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 3-methoxythiophenol (0.03 
mL, 0.19 mmol, 1.0 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 
equiv.), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and 
diisopropyethylamine (0.04 mL, 0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
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the addition of toluene (4.0 mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give 
the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(1.0 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the 
desired product 8 as yellow amorphous solid (68 mg, 94 %). 1H NMR (400 MHz, CDCl3) δ 7.71 
(d, J = 1.3 Hz, 1H), 7.26 (m, 4H), 7.07 (td, J = 8.0, 1.3 Hz, 1H), 6.67 – 6.63 (m, 1H), 6.61 – 6.58 
(m, 1H), 6.57 (d, J = 1.3 Hz, 1H), 6.50 (q, J = 1.8 Hz, 1H), 4.96 (s, 4H), 2.79 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 169.4, 162.5, 160.7, 157.4, 137.4 (2C), 136.8 (2C), 129.9 (2C), 127.6, 122.4, 
118.1 (2C), 113.3, 113.2, 111.5, 107.2, 103.4, 66.8, 55.1, 53.1. HRMS (ESI) [M]+ for C22H19NO4S: 
393.1035, found: 393.1041. 
 
 
(2,4-Dihydroxy-5-((4-hydroxyphenyl)thio)phenyl)(isoindolin-2-yl)methanone (9). A 
microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 4-methoxythiophenol (0.03 
mL, 0.19 mmol, 1.0 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 
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equiv.), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and 
diisopropyethylamine (0.04 mL, 0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
the addition of toluene (4.0 mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give 
the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(1.0 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the 
desired product 9 as yellow amorphous solid (53 mg, 74 %). 1H NMR (400 MHz, CDCl3) δ 11.95 
(s, 1H), 7.87 (s, 1H), 7.30 (m, 4H), 7.07 (s, 2H), 6.83 (s, 1H), 6.77 (d, J = 8.7 Hz, 2H), 6.67 (s, 
1H), 5.06 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 170.2, 165.2, 161.0, 155.3, 137.4 (2C), 129.8 
(2C), 128.3, 127.0, 123.0, 118.0, 116.9 (2C), 111.3 (2C), 108.3, 104.3 (2C), 60.9 (2C). HRMS 
(ESI) [M]+ for C21H17NO4S 379.0878, found: 379.0876. 
 
(5-((2,4-Dimethylphenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (10). A 
microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 2,4-dimethylthiophenol (0.03 
mL, 0.19 mmol, 1.0 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 
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equiv.), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and 
diisopropyethylamine (0.04 mL, 0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
the addition of toluene (4.0 mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give 
the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.8 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the 
desired product 10 as yellow amorphous solid (43 mg, 58 %). 1H NMR (400 MHz, CDCl3) δ 12.06 
(s, 1H), 7.83 (s, 1H), 7.31 (m, 4H), 7.03 (m, 1H), 6.89 (dd, J = 8.0, 1.9 Hz, 1H), 6.70 (s, 1H), 6.69 
(s, 1H), 6.62 (d, J = 8.0 Hz, 1H), 5.05 (s, 4H), 2.43 (s, 3H), 2.28 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.6, 164.9, 160.8, 137.2 (2C), 135.9, 135.2, 131.5, 131.3 (2C), 127.7, 127.5 (2C), 
125.6, 122.4, 111.0, 105.7, 103.9 (2C), 55.4, 53.5, 20.7, 19.8. HRMS (ESI) [M+H]+ for 
C23H22NO3S: 392.1320, found: 392.1336. 
 
(5-((2,5-Dimethylphenyl)thio)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (11). A 
microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 2,5-dimethylthiophenol (0.03 
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mL, 0.19 mmol, 1.0 equiv.), Tris(dibenzylideneacetone)dipalladium(0) (90 mg, 0.01 mmol, 0.05 
equiv.), 1,1′-Ferrocenediyl-bis(diphenylphosphine) (110 mg, 0.02 mmol, 0.1 equiv.), and 
diisopropyethylamine (0.04 mL, 0.21 mmol, 1.1 equiv.). The tube was sealed with a cap lined with 
a disposable Teflon septum. The tube was evacuated and purged with nitrogen (3 times), before 
the addition of toluene (4.0 mL) by syringe. The resulting mixture was heated at 115 °C for 14 h, 
cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent was 
removed and the residue passed through a filter column (SiO2, 1:3 ethyl acetate/hexanes) to give 
the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (5 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.8 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) to give the 
desired product 11 as yellow amorphous solid (48 mg, 65 %). 1H NMR (400 MHz, CDCl3) δ 12.08 
(s, 1H), 7.84 (s, 1H), 7.31 (dt, J = 6.5, 3.6 Hz, 3H), 7.08 (d, J = 7.6 Hz, 1H), 6.95 – 6.89 (m, 1H), 
6.72 (m, 2H), 6.53 – 6.47 (m, 1H), 5.06 (s, 4H), 2.42 (s, 3H), 2.20 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.9, 165.2, 161.2, 137.6 (2C), 136.9, 135.0, 132.3, 130.5 (2C), 128.0, 126.9, 125.7, 
122.7, 111.3, 105.5, 104.2 (2C), 55.7, 53.8, 21.3, 19.6. HRMS (ESI) [M+H]+ for C23H22NO3S: 





yl)methanone (2a). A microwave vial was charged with 2 (100 mg, 0.19 mmol, 1 equiv.), 
bis(pinacolato)diboron (74 mg, 0.29 mmol, 1.5 equiv.), Tris(dibenzylideneacetone)dipalladium(0) 
(9 mg, 0.01 mmol, 0.05 equiv.), tricylcohexylphosphine (7 mg, 0.02 mg, 0.12 equiv.), and 
potassium acetate (29 mg, 0.29 mmol, 1.5 equiv.). The tube was sealed with a cap lined with a 
disposable Teflong septum. The tube was evacuated and purged with nitrogen (3 times) before the 
addition of dioxane (2 mL) by syringe. The resulting mixture was heated to 115 °C for 16 h, cooled 
to rt, and filtered through a small pad of celite (elution with EtOAc). The solvent was removed and 
the residue purified by flash chromatography (SiO2, 3:10 EtOAc:Hexanes) to afford 2a as a gold 
oil (73 mg, 68%). 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.58 (ddd, J = 7.4, 1.4, 0.7 Hz, 2H), 
7.44 – 7.36 (m, 3H), 7.35 – 7.28 (m, 6H), 7.25 – 7.21 (m, 2H), 7.09 (d, J = 7.3 Hz, 1H), 6.55 (s, 
1H), 5.16 (s, 2H), 5.09 (s, 2H), 4.97 (s, 2H), 4.62 (s, 2H), 1.33 (s, 12H). 13C NMR (151 MHz, 
CDCl3) δ 168.7, 166.0, 158.7, 137.4, 137.1, 137.0, 136.9, 136.7, 128.9 (2C), 128.9, 128.6 (2C), 
128.3, 127.9, 127.9, 127.7, 127.3 (2C), 127.1 (2C), 123.4, 122.8, 120.5, 98.8, 83.8, 75.4, 70.9, 
70.6, 53.8, 52.4, 25.3 (2C), 25.2 (2C). HRMS (ESI) [M+H]+ for C35H37BNO5 562.2765, found 
562.2778. 
 
(5-(2-Chlorobenzyl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (12). A microwave vial 
was charged with 2a (100 mg, 0.18 mmol, 1 equiv.), 2-chlorobenzyl bromide (0.02 mL, 0.18 mmol, 
1.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (5 mg, 0.004 mmol, 0.025 equiv.). The 
tube was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and 
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purged with nitrogen (3 times), before the addition of tetrahydrofuran (2 mL) and 2M potassium 
carbonate (0.3 mL, 0.5 mmol, 3 equiv.) by syringe. The resulting mixture was heated at 95 °C for 
18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent 
was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) 
to give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.7 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the 
desired product 12 as white amorphous solid (23 mg, 34 %). 1H NMR (400 MHz, CDCl3) δ 11.75 
(s, 1H), 7.47 – 7.42 (m, 1H), 7.30 (m, 4H), 7.26 – 7.20 (m, 4H), 7.20 (d, J = 0.8 Hz, 1H), 6.44 (s, 
1H), 5.03 – 4.83 (m, 4H), 4.07 (s, 2H). 13C NMR (151 MHz, CDCl3) δ 162.0, 159.4, 157.9, 138.2, 
131.6, 131.1, 130.9, 130.6, 129.9, 128.6, 128.4, 127.5, 124.6, 123.8, 116.7, 109.8, 104.2, 103.7, 
90.7, 50.3 (2C), 33.1. HRMS (ESI) [M+H]+ for C22H19ClNO3 380.1053, found 380.1046. 
 
(5-(4-Chlorobenzyl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (13). A microwave vial 
was charged with 2a (100 mg, 0.18 mmol, 1 equiv.), 4-chlorobenzyl bromide (34 mg, 0.18 mmol, 
1.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (5 mg, 0.004 mmol, 0.025 equiv.). The 
tube was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and 
purged with nitrogen (3 times), before the addition of tetrahydrofuran (2 mL) and 2M potassium 
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carbonate (0.3 mL, 0.5 mmol, 3 equiv.) by syringe. The resulting mixture was heated at 95 °C for 
18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent 
was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) 
to give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.3 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the 
desired product 13 as white amorphous solid (18 mg, 26 %). 1H NMR (400 MHz, CDCl3) δ 7.26 
(s, 4H), 7.25 – 7.10 (m, 5H), 6.36 (s, 1H), 4.89 (s, 4H), 3.91 (s, 2H). 13C NMR (126 MHz, CDCl3) 
δ 170.6, 161.6, 158.0, 139.1 (2C), 132.2, 130.6 (2C), 130.5 (2C), 128.8 (2C), 127.9 (2C), 122.6 
(2C), 118.0, 109.3, 103.9, 50.3, 50.1, 34.6. HRMS (ESI) [M+H]+ for C22H19ClNO3 380.1053, 
found 380.1071. 
 
(2,4-Dihydroxy-5-(4-methylbenzyl)phenyl)(isoindolin-2-yl)methanone (14). A microwave vial 
was charged with 2a (100 mg, 0.18 mmol, 1 equiv.), 4-methylbenzyl bromide (48 mg, 0.18 mmol, 
1.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (5 mg, 0.004 mmol, 0.025 equiv.). The 
tube was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and 
purged with nitrogen (3 times), before the addition of tetrahydrofuran (2 mL) and 2M potassium 
carbonate (0.3 mL, 0.5 mmol, 3 equiv.) by syringe. The resulting mixture was heated at 95 °C for 
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18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent 
was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) 
to give the corresponding 5-substituted product, which was used further as obtained, and taken in 
dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.3 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the 
desired product 14 as white amorphous solid (18 mg, 26 %). 1H NMR (400 MHz, CDCl3) δ 11.68 
(s, 1H), 7.30 (m, 3H), 7.25 (m, 2H), 7.19 – 7.12 (m, 4H), 6.43 (s, 1H), 4.93 (s, 4H), 3.93 (s, 2H), 
2.35 (s, 3H). HRMS (ESI) [M+Na]+ for C23H21NO3Na 382.1419, found 382.1423. 
 
(5-(4-Fluorobenzyl)-2,4-dihydroxyphenyl)(isoindolin-2-yl)methanone (15). A microwave vial 
was charged with 2a (100 mg, 0.18 mmol, 1 equiv.), 4-methylbenzyl bromide (48 mg, 0.18 mmol, 
1.0 equiv.), and tetrakis(triphenylphosphine)palladium(0) (5 mg, 0.004 mmol, 0.025 equiv.). The 
tube was sealed with a cap lined with a disposable Teflon septum. The tube was evacuated and 
purged with nitrogen (3 times), before the addition of tetrahydrofuran (2 mL) and 2M potassium 
carbonate (0.3 mL, 0.5 mmol, 3 equiv.) by syringe. The resulting mixture was heated at 95 °C for 
18 h, cooled to rt, and filtered through a small pad of celite (elution with ethyl acetate). Solvent 
was removed and the residue purified by flash chromatography (SiO2, 1:3 ethyl acetate/hexanes) 
to give the corresponding 5-substituted product, which was used further as obtained, and taken in 
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dichloromethane (2 mL), cooled to 0 °C before the addition of 1 M solution of boron tribromide 
(0.3 mL). The resulting mixture was stirred for 6 h, quenched with water (5 mL) and extracted 
with dichloromethane (2 × 10 mL). The combined organic layers were washed with saturated 
sodium chloride solution (15 mL), dried over anhydrous sodium sulfate, filtered, and concentrated.  
The residue purified with flash chromatography (SiO2, 1:2 ethyl acetate/hexanes) to give the 
desired product 15 as white amorphous solid (18 mg, 26 %). 1H NMR (400 MHz, CDCl3) δ 11.70 
(s, 1H), 7.31 (m, 3H), 7.25 – 7.18 (m, 4H), 7.08 – 7.00 (m, 2H), 6.42 (s, 1H), 4.94 (s, 4H), 3.94 (s, 
2H). 19F NMR (376 MHz, CDCl3) δ – 117.4 (s, 1F). 
13C NMR (126 MHz, CDCl3) δ 170.7, 161.7, 
157.6, 130.6 (2C), 130.5, 130.2, 130.2, 128.4, 128.0, 124.0 (d, J = 87.1 Hz), 118.1, 115.7 (2C), 
115.5 (2C), 109.6, 104.1, 103.6, 53.6, 50.1, 34.5. HRMS (ESI) [M+H]+ for C22H19FNO3 364.1349, 
found 364.1366. 
Biological Protocols 
Fluorescence Polarization. The assay was performed in 96-well black, flat-bottom plates with 
a final volume of 100 µL. 25 µL of assay buffer (20 mM HEPES, pH 7.3, 50 mM KCl, 5 mM 
MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% NP-40) were added, followed 
by 25 µL of assay buffer containing 6 nM FITC-GDA (fluorescent tracer, stock in DMSO, diluted 
in assay buffer) and 50 µL of assay buffer containing 10 nM of either Grp94 (Enzo) or Hsp90α 
(Dickey Lab) were added to each well. For each plate, wells containing buffer only (background), 
tracer in buffer only (low polarization control) and protein, tracer, and 1% DMSO (final 
concentration, high polarization control) were included. Compounds were then added with a final 
concentration of DMSO = 1%. Plates were incubated at 4 ˚C with rocking for 24 h. Polarization 
values (in mP units) were measured at 37 ˚C with an excitation filter at 485 nm and an emission 
filter at 528 nm. Polarization values were correlated to % tracer bound and compound 
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concentrations. The concentration at which the tracer was 50% displaced by compound of 
interested were calculated and reported as apparent Kd’s. 
Cell Culture and Western blot. RPMI8226 cells (ATCC) were grown in a water jacketed 
incubator at 37 ˚C with 5% CO2 in RPMI1640 media supplemented with 10% FBS (Corning) and 
1% penicillin/streptomycin (Gibco). For anti-proliferation, cells were seeded in 96-well plates at 
2000 cell/well and 0.1 mL/well. Then placed in the incubator for 24 h. Compounds or vehicle were 
administered in DMSO (0.5% DMSO final concentration). After 72 h, the % viable cells were 
determined using the MTS/PMS cell proliferation kit (Promega) per the manufacturer’s 
instructions. Cells treated with vehicle were normalized to 100% viable and values adjusted 
accordingly. GI50 values were calculated via GraphPad Prism and reported as the average of >2 
independent experiments ± SEM. For western blot analysis, RPMI8226 cells were seeded at 
100,000 cells/mL in 10 cm dishes and placed back in the incubator for 24 h. Compounds or vehicle 
were dosed (0.1% DMSO final concentration) and incubated together for 24 h. Cells were 
harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease 
inhibitors (Roche) according the manufacturer’s instructions. Cell lysates were obtained by 
centrifugation at 15,000 rpm for 10 min at 4 ˚C. Protein concentrations were determined using the 
Pierce BCA assay kit following the manufacturer’s instructions. Equal amounts of protein were 
separated via gel electrophoresis under reducing conditions (10% acrylamide gels) then transferred 
to PVDF membranes (Invitrogen) and immunoblotted with the corresponding primary antibodies 
for 4h at room temperature. Primary antibody sources: LRP6 (Cell Signaling Technology, 2560); 
Survivin (Santa Cruz Biotechnology, sc-10811), Akt (Santa Cruz Biotechnology, sc-8312), and 
Actin (Santa Cruz Biotechnology, sc-1616); Hsp70 (Enzo Life Sciences, ADI-SPA-811). 
Membranes were then incubated with the correct HRP-labeled secondary antibody for 2h at room 
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temperature (anti-Rabbit, Cell Signaling Technology, 7074). Membranes were then developed 
with a chemiluminescent substrate (Clarity, Bio-Rad), and visualized using autoradiography film 
(MidSci). 
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5. The Development of TRAP1-selective Inhibitors 
Introduction 
The 90 kDa heat shock protein (Hsp90) family is comprised of four different isoforms: Hsp90α 
and Hsp90β reside in the cytosol, Grp94 is localized to the endoplasmic reticulum (ER), and 
TRAP1 is found in the mitochondria. Together, these proteins act as molecular chaperones that are 
responsible for the maturation of over 300 Hsp90-dependent (client) proteins through its protein 
folding machinery.1-3 Hsp90 client proteins are associated with all ten hallmarks of cancer, 
including important anticancer targets such as Her2, Raf, and BCR-Abl.4-5 Small molecule 
inhibition of Hsp90 results in disruption of the Hsp90 chaperone cycle and degradation of client 
proteins via the ubiquitin-proteasome pathway. Therefore, Hsp90 inhibition provides a 
multifaceted attack against cancer with a single agent through simultaneous disruption of multiple 
oncogenic signaling nodes.6-7  
Seventeen small molecule inhibitors of Hsp90 have entered into clinical trials, all of which 
exhibit pan-Hsp90 inhibitory activity.8 Unfortunately, these inhibitors have demonstrated 
toxicities, including ocular, gastrointestinal, and cardiotoxicity, which have dampened enthusiasm 
for Hsp90 as a therapeutic target.9-10 Recently, several studies have sought to elucidate the roles 
played by individual Hsp90 isoforms through the identification of client proteins that are 
dependent upon specific isoforms.11-12 The hERG channel was shown to be solely dependent upon 
the Hsp90α isoform, suggesting that inhibition of this isoform could be a contributing factor to the 
cardiotoxicity observed in the clinic.13 Additionally, Grp94-dependent client proteins have been 
identified, as well as disease states that rely upon this isoform, including glaucoma, metastasis, 
and multiple myeloma.14-18 These data suggest that identification of the roles played by individual 
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Hsp90 isoforms could prove useful for the therapeutic treatment of different disease states. 
However, the pursuit of these inhibitors is hindered by the high sequence identity present in the 
N-terminal ATP-binding site among all four Hsp90 isoforms. Grp94 is the most unique of the four 
isoforms, and Hsp90α and Hsp90β are most similar. The sequence similarity of TRAP1 resides 
between Grp94 and the cytosolic isoforms, and differs from Hsp90β by only four residues within 
its N-terminal ATP-binding site.19  
TRAP1 is predominantly localized to the mitochondria within cells and serves a cytoprotective 
role within this organelle.20 TRAP1 is highly expressed in cancerous cells, but is expressed at basal 
levels in normal cells.21 Genetic knockdown of TRAP1 activated apoptosis that culminates in the 
release of apoptogenic proteins into the cytosol, which initiates the caspase cascade and cell death. 
Further investigations into the role played by TRAP1 in mitochondrial apoptosis revealed that 
TRAP1 antagonizes the functions of cyclophilin D (CypD), which maintains mitochondrial 
integrity. CypD is a component of the mitochondrial membrane transition pore (MTP).22 When 
formed, the MTP results in mitochondrial membrane depolarization, which leads to activation of 
mitochondrial apoptosis. Formation of the MTP releases calcium ions from the mitochondria 
which, in turn, triggers the release of calcium from the ER and activation of the unfolded protein 
response (UPR) in the ER.23 The UPR results in activation of the pro-apoptotic transcription factor, 
C/EBP homologous protein (CHOP), which then activates apoptosis.24-27 Therefore, selective 
TRAP1 inhibition can induce apoptosis through activation of the pro-apoptotic protein CHOP, and 
consequently, provide a viable therapeutic opportunity for the treatment of cancer.  
Identification of TRAP1-selective Inhibitors 
Due to the limited number of solved TRAP1 co-crystal structures, the development of TRAP1-
selective inhibitors has been hindered. Prior co-crystal structures have been solved with purine-
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based inhibitors (non-hydrolysable ATP mimics or purine-based inhibitors), and as such, the 
development of resorcinol-based TRAP1-selective inhibitors has been underexplored. 
Nonetheless, these structures have provided some insight into mechanisms by which TRAP1 
selectivity can be achieved.  
The first co-crystal structure of TRAP1 solved with a non-hydrolysable ATP mimic, confirmed 
high identity within the N-terminal nucleotide binding pocket compared to the cytosolic Hsp90 
isoforms (Figure 5.1a).28 In fact, TRAP1 and Hsp90β differ by only four residues within their 
ATP-binding sites. More recently, a purine-based pan-Hsp90 inhibitor, PU-H71, was co-
crystallized with TRAP1 and revealed differences between TRAP1 and the other Hsp90 isoforms 
that could potentially be utilized to gain TRAP1 selectivity (Figure 5.1b).29  
 
Figure 5.1. TRAP1 co-crystal structures reveal differences that can be exploited for TRAP1 selectivity. (a) Non-
hydrolysable ATP mimic co-crystallized with TRAP1 (PDBID: 4IPE) demonstrating ordered lid (oval) and 
Asn171. (b) PU-H71 bound to TRAP1 (PDBID: 4Z1F) highlighting disordered lid (oval) and Asn171. (c) PU-
H71 bound to Hsp90α (PDBID: 2FWZ) highlighting Leu107 in place of Asn171 present in TRAP1. 
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Similar to the cytosolic Hsp90 isoforms, TRAP1 possesses a lid that closes over the N-terminal 
nucleotide pocket upon ATP binding.20 The most notable difference between these two TRAP1 
co-crystal structures is the lid. When co-crystallized with ATP, the lid was ordered (Figure 5.1a); 
however, when co-crystallized with PU-H71, the lid was disordered (Figure 5.1b). Interestingly, 
mechanistic studies into the TRAP1 ATPase cycle revealed the lid-closed conformation binds ATP 
with ~10-fold higher affinity as compared to the cytosolic Hsp90 isoforms in similar lid-closed 
conformations.30 Therefore, stabilization of the lid via a small molecule can take advantage of this 
higher affinity conformation. The only residue that differs between TRAP1 and the cytosolic 
Hsp90 isoforms that appears to be useful for the development of TRAP1-selective inhibitors is 
Asn171, which is located just before the TRAP1 lid, whereas the cytosolic isoforms and Grp94 
possess a Leu residue at this position (Figure 5.1c). Therefore, stabilization of the lid via 
interactions with Asn171 could produce TRAP1 selectivity. 
Due to a lack of structural information regarding the binding modes of resorcinol-based Hsp90 
inhibitors in the TRAP1 ATP-binding site, a small library (~170) of resorcinol-based Hsp90 
inhibitors was screened in a fluorescence polarization assay. Hits identified from this screen 
revealed structural characteristics associated with TRAP1 affinity. As highlighted in Figure 5.2, 
 




inhibitors derived from the isoindoline-containing scaffold exhibited the highest affinity for 
TRAP1. Furthermore, large substitutions at the 5-position increased TRAP1 affinity, as compared 
to small alkyl substitutions. The pan-Hsp90 inhibitor 1 was chosen as a lead compound for 
conversion into a TRAP1-selective inhibitor due to its high affinity for TRAP1 (apparent Kd = 
0.42 µM). 
In order to convert compound 1 into a TRAP1-selective inhibitor, modifications were sought 
based upon structural information from the other three Hsp90 isoforms. A key interaction between 
all known Hsp90 inhibitory scaffolds and the N-terminal ATP-binding pocket that is responsible 
for significant affinity is the interaction between the pharmacophore (colored moieties, Figure 
5.3a) and a conserved Asp residue at the base of the binding pocket.31-32 In fact, Hsp90 function 
in cells can be abolished with a single mutation of Asp to Asn.33 Therefore, development of a 
 
Figure 5.3. Hsp90 inhibitory scaffold interact with a conserved Asp residue in order to gain affinity. (a) 
Representative structures from 3 Hsp90 inhibitor scaffolds. Pharmacophores that interact with Asp residue are 
colored. (b-d) Interactions between pharmacophores and Asp93 of Hsp90α for the three scaffolds. (PDBIDs: 
1YET, 2FWZ, and 2XAB). 
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TRAP1-selective inhibitor must maintain this interaction for high affinity; however, since this 
interaction is conserved among all four Hsp90 isoforms, other subtle differences must be utilized 
to diminish binding to other isoforms.  
Similar to Hsp90β and Grp94, TRAP1 possesses an Ala residue (Ala120 for TRAP1) at the 
base of the ATP-binding pocket (Figure 5.4a); whereas Hsp90α possesses a Ser residue at this 
position (Figure 5.4b). Therefore, in order to reduce affinity for Hsp90α, compounds 2 and 3 
(Figure 5.4c) were proposed to eliminate interactions with the Ser residue in Hsp90α. Compounds 
 
Figure 5.4. Design of TRAP1-selective inhibitors. (a) Hsp90β, Grp94, and TRAP1 possess an Ala residue near 
the resorcinol binding region. (b) Hsp90α is the only isoform to possess a Ser residue at this position. (c) 
Compounds 2 and 3 were proposed to reduce affinity for Hsp90α. 
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2 and 3 were synthesized from commercially available benzoic acids (Scheme 5.1). EDCI-
mediated amide bond coupling between isoindoline and 2a or 3a, followed by methoxymethyl 
(MOM) ether protection of the phenol, provided intermediates 2b and 3b, respectively. The 
Scheme 5.1. Synthesis of 2 and 3 
 
Conditions: (a) isoindoline hydrochloride, EDCI, HOBT, Hunig’s base, DCM; (b) MOMCl, Hunig’s base, DCM; 
(c) indole, CuI, (+)-trans-1,2-diaminocyclohexane; K3PO4, Toluene; (d) p-TsOH, MeOH 


















Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
1 
 
0.42 ± 0.1 0.2 ± 0.05 0.47±0.02 0.32±0.02 2a n/a 2b 
2 
 
2.5 ± 0.05 >100 >100 >100 >40 >40 >40 
3 
 
>100 >100 n.d. n.d. n/a n/a n./a 
Apparent Kd values are the average of two independent experiments ± SEM. n.d. = not determined. n/a = non-
selective. a selective for Hsp90α. b selective for Grp94. 
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resulting aryl bromides were subjected to a copper-catalyzed cross coupling reaction with indole, 
followed by removal of the MOM protecting group to provide phenols 2 and 3.  
Evaluation of these analogues in a fluorescence polarization assay against TRAP1 revealed that 
2 exhibited TRAP1 affinity (apparent Kd = 2.5 µM, Table 5.1), whereas 3 did not. These data 
suggest that the 4-phenol provides affinity through an interaction with Asp158 within the TRAP1 
binding site.  
Evaluation of 2, via fluorescence polarization, against the other three Hsp90 isoforms revealed 
that this compound exhibits minimal affinity at 100 µM. Due to the importance of the 4-phenol’s 
interaction with the conserved Asp residue, the isoindoline amide is proposed to occupy the 
opposite side of the binding site as compared to previously reported co-crystal structures with this 
scaffold (described in Chapter 4). This orientation projects the amide carbonyl into close proximity 
with Asn171 to form a hydrogen bond, further increasing TRAP1 affinity. Similar to Grp94, 
TRAP1 possesses a 2 amino acid insertion into its primary sequence (residues 191 and 192), which 
appears to produce a secondary binding pocket that accounts for the ability of TRAP1 to 
accommodate the isoindoline ring in this region (Figure 5.5).19 The residues that appear to 
comprise this pocket in TRAP1 are similar to the S2 sub-pocket of Grp94. However, their spatial 
arrangement likely differs from that of Grp94, due to the smaller insertion of amino acids (2 for 
TRAP1 vs. 5 for Grp94), which can lead to decreased affinity of 2 for Grp94. Since no amino acid 
insertions occur in Hsp90α and Hsp90β, this region cannot accommodate such molecules and 
reduced affinity for these isoforms. 
206 
 
Evidence to support the existence of this pocket in TRAP1 is based on the purine-based Grp94-
selective inhibitors that utilize the S2 sub-pocket (e.g. PU-H54, Chapter 4). Some of these 
inhibitors exhibit low micromolar affinity for TRAP1, suggesting the presence of this pocket, but 
differs slightly from the S2 sub-pocket in Grp94 since these compounds exhibit Grp94 
selectivity.34-35 In addition, Asn171 of TRAP1 is replaced by Leu in the 3 other Hsp90 isoforms, 
and therefore, orientation of the amide carbonyl toward this region is likely detrimental (Figure 
5.5). 
Further evidence to support this proposed binding mode was pursued through modification of 
the isoindoline ring. In previous studies, modifications of this region improved or maintained 
 
Figure 5.5. Proposed binding mode of 2 in TRAP1 and Grp94. TRAP1 residues are listed in red and Grp94 
residues are listed in green. Black dotted lines are proposed hydrogen bonds. Red circle is a water molecule. 
Scheme 5.2. Synthesis of 4-8. 
Conditions: (a) MOMCl, Hunig’s base, DCM; (b) indole, CuI, (+)-trans-1,2-diaminocyclohexane; K3PO4, 
Tolueen; (c) LiOH, THF/Water/MeOH; (d) substituted isoindoline, EDCI, HOBT, Hunig’s base, DCM; (e) p-
TsOH, MeOH; (f) 3-dimethylamino-propyl chloride hydrochloride, K2CO3, nBu4N+I-, DMF 
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affinity for Hsp90, and consequently was used to modulate the pharmacokinetic properties of such 
inhibitors since these modifications project toward the solvent exposed region of the binding 
pocket.36 However, due to the proposed binding mode of 2, which projects the isoindoline ring 
into a hydrophobic pocket, these substitutions likely reduce TRAP1 affinity and support an 
alternative binding mode for this scaffold with TRAP1. Compounds 4-8 were designed for such 
investigation, and their preparation is outlined in Scheme 5.2. Commercially available methyl ester 
2c was converted to the MOM ether and then subjected to a copper-catalyzed cross coupling 
reaction with indole to provide 2d. Saponification of the methyl ester provided the corresponding 
benzoic acid, 2e, which was subjected to an EDCI-mediated amide bond coupling with 
isoindolines 4a-7a, followed by acidic deprotection of the MOM ether to provide phenols 4-8. 
Prior to cleavage of the MOM ether, 7 was reacted with 3-dimethylamino-propyl chloride 
hydrochloride in the presence of potassium carbonate and tetrabutylammonium iodide to provide 
8 after removal of the MOM protecting group. Evaluation of these analogues via fluorescence 
polarization revealed that substitutions at the 5”-position significantly reduced affinity for TRAP1 
Table 5.2. Evaluation of 4-8 via fluorescence polarization. 
 
Entry R Apparent Kd TRAP1 (µM) 
4 -F >100 
5 -Cl >100 
6 -OMe >100 
7 -OH >100 
8 -O(CH2)3NMe2 >100 
Apparent Kd values are the average of two independent experiments. 
208 
 
(TRAP1 apparent Kd >100 µM) compared to 2, further supporting the proposed binding mode of 
this scaffold projecting the isoindoline ring into a hydrophobic pocket (Table 5.2).  
Due to the loss in affinity upon modification of the isoindoline ring, structure-activity 
relationship studies were performed on the indole ring to further understand the requirements for 
TRAP1 affinity and selectivity. Synthesis of these analogues was performed in a manner similar 
to the synthesis of 2 (Scheme 5.1). The analogues were then evaluated for their affinity and 
selectivity against TRAP1, Hsp90α, and Grp94. Hsp90β was excluded due to its high identity with 
Hsp90α (>95%). Compounds that exhibited TRAP1 affinity and selectivity over Hsp90α and 
Grp94 were then evaluated against Hsp90β to confirm selectivity. 
As observed in Table 5.3, modifications to the 2’- and 3’-positions (9-11) resulted in a 
significant loss of affinity for TRAP1. Based on the proposed binding mode, this region of the 
binding pocket appears to be sterically restricted by Gly160, Ile161, and Gly162, and 
modifications at these positions produce detrimental steric interactions that reduce TRAP1 affinity 
(Figure 5.6). Modification of the 4’-, 5’-, 6’-, and 7’-positions were subsequently pursued as these 
positions appeared less sterically encumbered and potentially more amenable to substitution. Upon 
their synthesis, compounds 12-34 were evaluated via fluorescence polarization for TRAP1 affinity 
and selectivity. Many of these inhibitors exhibited good affinity and selectivity for TRAP1 (Table 






















Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
2 n/a 2.5 ± 0.05 >100 >100 >100 >40 >40 >40 
9 
 
78 ± 7 >100 >100 >100 n/a n/a n/a 
10 
 
>100 >100 n.d. >100 n/a n/a n/a 
Table 5.3. Evaluation of 9-34 via fluorescence polarization. 
 
 
Figure 5.6. Proposed binding model of 2 in the TRAP1 binding site. Modifications to the 2’- and 3’-positions 
produce steric interactions with Gly160, Ile161, and Gly162 (yellow lines). Black dotted lines represent proposed 
hydrogen bond interactions. Red circles are water molecules. 
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Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
11 
 
13.2 ± 1.3 >100 n.d. >100 >8 n/a >8 
12 
 
2.9 ± 0.7 >100 n.d. 22.3 ± 1.1 >34 n/a 7 
13 
 
4.56 ± 0.2 >100 >100 >100 >22 >22 >22 
14 
 
>50 >100 n.d. >100 n/a n/a n/a 
15 
 
>50 >100 n.d. >100 n/a n/a n/a 
16 
 
1.41 ± 0.2 >100 >100 >100 >71 >71 >71 
17 
 
2.46 ± 0.8 >100 >100 >100 >40 >40 >40 
18 
 
2.66 ± 0.4 >100 >100 >100 >38 >38 >38 
19 
 
>50 >100 n.d. >100 n/a n/a n/a 
20 
 
1.9 ± 0.3 31.3 ± 4.8 n.d. 5.9 ± 0.8 17 n.d. 3 
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Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
21 
 
>50 >100 n.d. >100 n/a n/a n/a 
22 
 
3.5 ± 0.8 >100 >100 >100 >29 >29 >29 
23 
 
21.6 ± 5.6 >100 n.d. n.d.  5 n.d. n.d. 
24 
 
6.0 ± 0.8 >100 >100 >100 >17 >17 >17 
25 
 
>50 >100 n.d. >100 n/a n/a n/a 
26 
 
2.4 ± 0.2 >100 n.d. 8.7 ± 0.6 >40 n.d. 4 
27 
 
>50 >100 n.d. >100 n/a n/a n/a 
28 
 
>50 >100 n.d. >100 n/a n/a n/a 
29 
 
>50 >100 n.d. >100 n/a n/a n/a 
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Apparent Kd values are the average of two independent experiments ± SEM. n.d. = not determined. n/a = not 
applicable; n.s. = non-selective. 
Evaluation of the analogues that contain modifications at the 4’-position (12-16) suggested that 
halogen or hydrogen bond donating groups were beneficial, but size-dependent, as the chloro (13) 
and phenol (16) exhibited good affinity and maintained selectivity for TRAP1, while the fluoro 
(14) and methoxy (15) did not. The phenol substituent produced a ~2-fold increase in TRAP1 
affinity and an apparent Kd of 1.41 µM along with >70-fold TRAP1 selectivity. Alternatively, 
favorable substitutions at the 5’-position appeared to result from small or hydrogen bond accepting 
groups, as the methyl ether (17) and fluoro (18) exhibited good affinities (TRAP1 apparent Kd’s = 
2.46 µM and 2.66 µM, respectively) and selectivities for TRAP1. Incorporation of the hydrogen 
bond donating phenol at the 5’-position (20) maintained TRAP1 affinity (TRAP1 apparent Kd = 
1.9 µM), but with a loss in selectivity versus Grp94 (~3-fold). A similar effect was observed with 
the 6’-phenol (26, apparent Kd = 2.4 µM, 4-fold selective over Grp94). This trend suggests that 

















Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
30 
 
>50 >100 n.d. >100 n/a n/a n/a 
31 
 
3.43 ± 0.2 2.86 ± 0.4 n.d. >100 n.s n.d >29 
32 
 
2.56 ± 0.1 5.48 ± 0.9 n.d. >100 2 n.d. >40 
33 
 
>50 >100 n.d. >100 n/a n/a n/a 
34 
 
>50 >100 n.d. >100 n/a n/a n/a 
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hydrogen bond donating groups at the 5’- and 6’-positions exhibit affinity for Grp94 likely through 
interactions with polar residues at the solvent exposed region of the binding pocket (e.g. Glu158, 
Figure 5.7).16 Other modifications to the 6’-position exhibited a similar trend as that observed for 
the 4’-position, wherein halogen or hydrogen bond donating abilities were important for affinity, 
as the 6’-chloro (24) substitution maintained TRAP1 affinity and selectivity. However, these 
interactions were also size dependent as suggested by the poor affinity manifested by the fluoro 
(30) substitution (apparent Kd >50 µM). Lastly, hydrogen bond accepting and donating groups (31 
and 32) at the 7’-position maintained affinity (TRAP1 apparent Kd’s 3.43 µM and 2.56 µM, 
respectively), but this was accompanied by a complete loss of selectivity, as increased affinity for 
Hsp90α was observed. 
 
Figure 5.7. Proposed interactions between the 5’- and 6’-positions of 2 and the polar residues of Grp94. Residues 
are numbered according to their respective isoforms (Red = TRAP1, Green = Grp94). Black dotted lines are prosed 
hydrogen bonds present in TRAP1. Green dotted lines are proposed hydrogen bonds between substitutions at the 




While the structure-activity relationship studies performed on the indole ring provided insight 
into the binding requirements for TRAP1 selectivity and affinity, these studies did not provide 
inhibitors with significant affinity. Therefore, other modifications to this scaffold were pursued. 
Based on the structure-activity relationship trends of 2, the indole was proposed to occupy the 
same region of the binding pocket in which the isoindoline amide had previously been observed 
to bind.36 Previous studies determined that incorporation of the isoindoline ring produced 
significant affinity for the pan-Hsp90 inhibitor AT13387. Therefore, a bis-isoindoline inhibitor 
(36) was proposed as a mechanism to increase TRAP1 affinity.37 Synthesis of these analogues is 
outlined in Scheme 5.3. The unsubstituted bis-isoindoline (36) was synthesized from 4-
hydroxyisophthalic acid (35a) via EDCI-mediated amide coupling with isoindoline. Compounds 
37-39 which possess various substitutions about the isoindoline ring were synthesized from 2-
hydroxy-5-(methoxycarbonyl)benzoic acid (35b) and corresponding isoindolines, followed by 
saponification of the methyl ester and subsequent coupling with isoindoline to provide the desired 
analogues 36-39.  
Scheme 5.3. Synthesis of 36-39. 
 
Conditions: (a) isoindoline hydrochloride, EDCI, HOBT, Hunig’s base, DCM; (b) 4a, 6a, or 7a; EDCI, HOBT, 
Hunig’s base, DCM; (c) LiOH, THF/Water/MeOH 
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Upon their preparation, compounds 36-39 were evaluated for TRAP1 affinity and selectivity 
(Table 5.4). Gratifyingly, bis-isoindoline 36 exhibited increased TRAP1 affinity (apparent Kd 0.41 
µM) compared to 2. Compound 36 also exhibited >240-fold selectivity over the cytosolic Hsp90 
isoforms and ~140-fold selectivity versus Grp94. Incorporation of hydrogen or halogen bond 
donating groups (37 and 39) at the 5’-position improved affinity (TRAP1 apparent Kd’s 0.19 µM 
and 0.18 µM, respectively), whereas incorporation of the hydrogen bond accepting methyl ether 
(38) resulted in ~2-fold loss in TRAP1 affinity (apparent Kd 0.86 µM) compared to 36. 
Unfortunately, the increased affinity for TRAP1 exhibited by 37 and 39 was accompanied by a 
significant increase in affinity for Grp94 (Grp94 apparent Kd’s 13.8 µM and 7.3 µM, respectively) 
resulting in reduced TRAP1 selectivity. Similar to the trends observed for hydrogen bond donating 
groups with the indole-isoindoline scaffold (e.g. 20 and 26), such modifications resulted in 
decreased TRAP1 selectivity (Figure 5.7).   


















Fold TRAP1 Selective 
Hsp90α Hsp90β Grp94 
36 -H 0.41±0.03 >100 >100 56.5 ± 4.4 >244 >244 138 
37 -F 0.19±0.06 >100 >100 13.8 ± 1.2 >526 >526 73 
38 -OMe 0.86±0.05 >100 n.d. n.d. >116 n.d n.d. 
39 -OH 0.18±0.02 >100 >100 7.3 ± 0.2 >556 >556 41 
Apparent Kd values are the average of two independent experiments ± SEM. n.d. = not determined.  
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Biological Evaluation of TRAP1-selective Inhibitors 
Based on the cytoprotective role played by TRAP1 in cancer, compounds that exhibited TRAP1 
affinity and selectivity were evaluated for anti-proliferative activity against cancer cell lines. 
Prostate (PC3-MM2), colorectal (HCT116), and cervical (HeLa) cancer cell lines were chosen as 
they have been used to study the roles of TRAP1.38-40 As seen in Table 5.5, the indole-isoindoline 
inhibitor 2 exhibited modest GI50 values against these cell lines. Surprisingly, the bis-isoindoline 
inhibitors, 36 and 37, did not exhibit any anti-proliferative activity against these cell lines until 
high micromolar concentrations, which is likely a consequence of reduced cell permeability or low 
mitochondrial permeability. In contrast, the chloro-substituted indole inhibitor 24 exhibited 
improved GI50 values against these cell lines as compared to 2. Therefore, compound 24 was 
chosen for further investigation for the induction of apoptosis via TRAP1-selective inhibition. 










47.5 ± 3.9 30.7 ± 5.6 44.7 ± 4.7 
16 
 
42.2 ± 5.8 54.0 ± 2.4 52.7 ± 2.4 
18 
 












17.5 ± 2.9 12.2 ± 2.6 13.9 ± 1.8 
36 
 
>100 >100 >100 
37 
 
>100 61.4 ± 5.9 50.3 ± 4.7 
DN401 
 
4.4 ± 0.7 3.6 ± 0.4 3.0 ± 0.9 
GI50 values are the average of two independent experiments ± SEM.  
As seen in Figure 5.8, western blot analysis of HeLa cells treated with compound 24 and the 
previously reported TRAP1-selective inhibitor, DN401, exhibited induction of the pro-apoptotic 
protein CHOP, suggesting that these compounds induce apoptosis. Flow cytometry analysis of 
HeLa cells treated with 24 or DN401 supported that these compounds result cell death due to the 
increased intensity of fluorescence upon staining with propidium iodide.41 Release of DNA from 
the nucleus suggests that the induction of CHOP, via TRAP1 inhibition, results in activation of 
apoptosis. Furthermore, 24 did not induce the degradation of Akt, a client protein dependent upon 
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cytosolic Hsp90 isoforms, nor did it induce the HSR as monitored by Hsp70 levels. This pattern 
contrasts the effects of the natural product and pan-Hsp90 inhibitor GDA, which produced both 
the degradation of Akt, and induction of Hsp70. As observed previously, DN401 produced 
degradation of Akt, which suggests that in addition to inhibition of TRAP1, DN401 also inhibits 
the cytosolic Hsp90 isoforms.40 These data suggest that 24 exhibited TRAP1 selectivity in a 
cellular environment and activated apoptosis without the liabilities associated with pan-Hsp90 
inhibitors. 
Conclusions and Future Directions  
Identification of scaffolds that exhibit selective inhibition of individual Hsp90 isoforms 
represents a significant advancement in Hsp90 drug discovery. Through screening of a small 
library of Hsp90 inhibitors, 1 was identified to exhibit TRAP1 affinity. Subsequent investigation 
of the roles played by the phenols led to the discovery of 2, which exhibited a TRAP1 apparent Kd 
Figure 5.8. Compound 24 exhibited TRAP1-selective inhibition in cells. Left: Western blot analysis of HeLa 
cells treated with vehicle control (D, DMSO, 0.25% final concentration), a pan-Hsp90 inhibitor (G, geldanamycin, 
0.5 µM), 24 (L = ½ GI50, H = 5x GI50), or DN401 (8-fold TRAP1-selective inhibitor, 20 µM). Right: Flow 
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of 2.5 µM and was >40-fold selective for TRAP1 versus the other Hsp90 isoforms. Structure-
activity relationship studies on the indole region of 2 led to the identification of trends necessary 
for TRAP1 binding, but did not produce improved affinity. Alternatively, substitution of the indole 
moiety with an isoindoline amide (36) resulted in increased TRAP1 affinity (apparent Kd = 0.41 
µM) and selectivity (>138-fold). These inhibitors were then evaluated for anti-proliferative activity 
against cervical, colorectal, and prostate cancer cell lines. Unfortunately, 36 and similar inhibitors 
did not produce anti-proliferative effects until high micromolar concentrations. However, 
substituted indoles (e.g. 24) exhibited moderate anti-proliferative activities against these cancers. 
Further evaluation of 24, via western blot analysis, demonstrated induction of the pro-apoptotic 
protein CHOP without degradation of the cytosolic Hsp90-dependent client protein, Akt, nor 
induction of Hsp70. Treatment with 24 resulted in cell death as monitored by flow cytometry 
suggesting that this inhibitor exhibits apoptotic activity in cells, via TRAP1-selective inhibition, 
without the detriments exhibited by pan-Hsp90 inhibitors. These inhibitors provide novel small 
molecule tools for further study of the roles played by TRAP1 in cancer and other diseases. In 
addition, this scaffold provides excellent leads for the further development of TRAP1-selective 
inhibitors that could improve TRAP1 affinity and selectivity. Future studies aimed to improve the 
cellular activity of the bis-isoindoline scaffold (e.g. 36) would be beneficial as this scaffold 
exhibits excellent affinity via fluorescence polarization, but this activity did not translate into 
cellular studies. Additional structural information, via the solution co-crystal structures of 2 and/or 
36 in complex with TRAP1, would greatly assist the design of future TRAP1-selective inhibitors. 
These inhibitors will expedite the discovery and validation of TRAP1-dependent processes in 




Chemistry General. Chemistry General. 1H NMR were recorded at 400 (Bruker AVIIIHD 
400 MHz NMR with a broadband X-channel detect gradient probe) or 500 MHz (Avance AVIII 
500 MHz spectrometer with a dual carbon/proton cryoprobe) and 13C NMR were recorded at 125 
MHz (Bruker AVIII spectrometer equipped with a cryogenically cooled carbon observe probe); 
chemical shifts are reported in δ (ppm) relative to the internal standard (CDCl3, 7.26 ppm for 
1H 
and 77.2 for 13C). HRMS spectra were recorded with a LCT Premier with ESI ionization. All 
biologically tested compounds were determined to be >95% pure. TLC analysis was performed on 
glass backed silica gel plates and visualized by UV light. All solvents were reagent grade and used 
without further purification.  
Synthetic Procedures. 
 
(2,4-Dihydroxy-5-(1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (1). A dry 10-20 mL 
microwave vial was charged with (5-bromo-2,4-bis(methoxymethoxy)phenyl)(isoindolin-2-
yl)methanone (100 mg, 0.23 mmol, 1 equiv.), indole (42 mg, 0.36 mmol, 1.5 equiv.), CuI (5 mg, 
0.02 mmol, 0.1 equiv.), and K3PO4 (126 mg, 0.59 mmol, 2.5 equiv.). The vial was then evacuated 
and backfilled (3x) with argon followed by the addition of dry toluene (3 mL) and (±)-trans-1,2-
diaminocyclohexane (0.01 mL, 0.1 mmol, 0.4 equiv.). Argon was bubbled through the solvent for 
5 minutes and the vial was sealed and heated at 115˚C for 36 h. The reaction was cooled to rt and 
partitioned between EtOAc (10 mL) and water (10 mL). The aqueous layer extracted with EtOAc 
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(2 x 10 mL). The combined organic layers were dried over Na2SO4, concentrated, and the residue 
was passed through a plug of silica gel. The crude material was dissolved in MeOH (3 mL) and p-
toluylsulfonic acid was added. The reaction stirred at rt for 12 h and quenched with saturated 
NaHCO3. The aqueous layer was extracted with EtOAc (2 x 10 mL), dried, and concentrated. The 
residue was purified by flash chromatography (EtOAc/Hexanes, 1:1) to provide 1 as a yellow 
amorphous solid (57 mg, 65%). 1H NMR (400 MHz, CDCl3) δ 12.01 (s, 1H), 7.76 – 7.71 (m, 1H), 
7.62 (s, 1H), 7.33 – 7.26 (m, 4H), 7.26 – 7.24 (m, 1H), 7.24 – 7.21 (m, 2H), 7.21 – 7.18 (m, 1H), 
6.79 – 6.71 (m, 2H), 5.04 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 169.7, 161.6, 157.0, 137.2, 129.3, 
128.4, 128.2, 127.7, 122.4, 122.1 (2C), 120.8 (2C), 120.0 (2C), 117.8, 110.3, 108.8, 104.7, 102.7 
(2C), 77.1 (2C). HRMS (ESI) m/z [M]+ for C23H18N2O3 370.1317, found 370.1320. 
General Procedure for the synthesis of 2b and 3b.  
Hunig’s base (6 equiv.) was added to a stirred solution of 2a or 3a (1 equiv.), EDCI (3 equiv.), 
isoindoline hydrochloride (3 equiv.), and HOBT (3 equiv.) in DCM (0.1 M). The reaction was 
stirred for 12 h before the addition of 1 N HCl. The organic layer was separated and washed with 
saturated NaHCO3 and brine then dried over Na2SO4 and concentrated. The residue was used 
without further purification. The residue was dissolved in dry DCM (~0.1M) and cooled to 0˚C. 
Hunig’s base was added (3 equiv.) followed by chloromethyl methyl ether (2 equiv.). The reaction 
was allowed to warm to room temperature and stirred for 12 h. Water was added, the organic layer 
separated, and the aqueous layer was extracted with DCM (2 x) The organic layers were combined, 
dried (Na2SO4), and concentrated. The residue was purified via flash chromatography 




(3-Bromo-4-(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (2b), off white amorphous 
solid (4.8 g, 56%). 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 2.1 Hz, 1H), 7.51 (dd, J = 8.5, 2.1 
Hz, 1H), 7.36 – 7.26 (m, 3H), 7.21 (d, J = 8.5 Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 5.30 (s, 2H), 5.00 
(s, 2H), 4.82 (s, 2H), 3.54 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 168.6, 155.3, 136.5, 136.4, 
132.6, 131.4, 128.0, 127.8, 127.7, 123.1, 122.6, 115.5, 112.8, 95.1, 56.7, 55.2, 52.8. HRMS (ESI) 
m/z [M+Na]+ for C17H16BrNO3Na 384.0211, found 384.0255. 
 
(5-Bromo-2-(methoxymethoxy)phenyl)(isoindolin-2-yl)methanone (3b). white amorphous solid 
(372 mg, 45%) 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.43 (m, 2H), 7.38 – 7.26 (m, 3H), 7.18 – 
7.07 (m, 2H), 5.17 (s, 2H), 4.99 (s, 2H), 4.64 (s, 2H), 3.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
166.6, 152.3, 136.4, 136.3, 133.5, 130.6, 129.8, 128.0, 127.8, 123.3, 122.7, 117.4, 114.9, 95.3, 
56.6, 53.6, 52.2. HRMS (ESI) m/z [M]+ for C17H16BrNO3 361.0314, found 361.0314. 
General Procedure for the Synthesis of 2, 10, 13-22, 24-34. 
A dry 10-20 mL microwave vial was charged with 2b (100 mg, 0.28 mmol, 1 equiv.), the 
corresponding indole (1.5 equiv.), CuI (5 mg, 0.02 mmol, 0.1 equiv.), and potassium phosphate 
tribasic (147 mg, 0.69 mmol, 2.5 equiv.). The vial was then evacuated and backfilled (3x) with 
223 
 
argon followed by the addition of dry toluene (3 mL) and (±)-trans-1,2-diaminocyclohexane (0.01 
mL, 0.1 mmol, 0.4 equiv.). Argon was bubbled through the solvent for 5 minutes and the vial was 
sealed and heated to 115˚C for 36 h. The reaction was cooled to rt and partitioned between EtOAc 
(10 mL) and water (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined organic layers were dried over Na2SO4, concentrated and the residue was passed through 
a plug of silica gel. The crude material was dissolved in MeOH (3 mL) and p-toluylsulfonic acid 
(10 eq.) was added. The reaction was stirred at rt for 12 h and was quenched with saturated 
NaHCO3. The aqueous layer was extracted with EtOAc (2 x 10 mL), dried, and concentrated. The 
residue was purified by flash chromatography (EtOAc/Hexanes, 1:1) to provide 2, 10, 13-22, 24-
34. 
 
(4-Hydroxy-3-(1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (2). Off white amorphous 
solid (44 mg, 45%). 1H NMR (400 MHz, CDCl3) δ 7.67 – 7.63 (m, 1H), 7.57 – 7.51 (m, 2H), 7.32 
– 7.26 (m, 3H), 7.25 – 7.20 (m, 2H), 7.19 – 7.09 (m, 4H), 6.68 (dt, J = 3.2, 0.9 Hz, 1H), 4.96 (s, 
2H), 4.86 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.5, 154.0, 136.7, 136.4, 136.2, 128.9, 128.7, 
128.6, 128.6, 128.0, 127.7, 127.6, 126.0, 123.1, 122.7, 122.5, 121.2, 120.6, 117.3, 110.7, 103.9, 




(2-Hydroxy-5-(1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (3). A dry 10-20 mL 
microwave vial was charged with 3b (100 mg, 0.28 mmol, 1 equiv.), indole (1.5 equiv.), CuI (5 
mg, 0.02 mmol, 0.1 equiv.), and potassium phosphate tribasic (147 mg, 0.69 mmol, 2.5 equiv.). 
The vial was then evacuated and backfilled (3x) with argon followed by the addition of dry toluene 
(3 mL) and (±)-trans-1,2-diaminocyclohexane (0.01 mL, 0.1 mmol, 0.4 equiv.). Argon was 
bubbled through the solvent for 5 minutes and the vial was sealed and heated to 115˚C for 36 h. 
The reaction was cooled to rt and partitioned between EtOAc (10 mL) and water (10 mL). The 
aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layers were dried 
over Na2SO4, concentrated and the residue was passed through a plug of silica gel. The crude 
material was dissolved in MeOH (3 mL) and p-toluylsulfonic acid (10 equiv.) was added. The 
reaction stirred at rt for 12 h and was quenched with saturated NaHCO3. The aqueous layer was 
extracted with EtOAc (2 x 10 mL), dried, and concentrated. The residue was purified by flash 
chromatography (EtOAc/Hexanes, 1:1) to provide 3 as a white amorphous solid (32 mg, 33%) 1H 
NMR (400 MHz, CDCl3) δ 11.13 (s, 1H), 7.77 – 7.70 (m, 2H), 7.52 (dd, J = 8.7, 2.6 Hz, 1H), 7.46 
(dq, J = 8.2, 0.9 Hz, 1H), 7.36 – 7.27 (m, 5H), 7.25 – 7.16 (m, 3H), 6.71 (dd, J = 3.2, 0.9 Hz, 1H), 
5.11 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 170.1, 159.5, 130.5, 128.6, 128.4, 124.9, 124.7, 124.0, 
123.0, 122.9, 121.7, 120.9, 120.8, 119.7, 118.6, 117.7, 110.6, 110.4, 104.2, 103.7, 90.9, 55.2, 50.5. 




Methyl 3-(1H-indol-1-yl)-4-(methoxymethoxy)benzoate (2d). Chloromethyl methyl ether (1.9 
mL, 26 mmol, 3 equiv.) was added to a stirred solution of methyl 3-bromo-4-hydroxybenzoate 
(2g, 8.7 mmol, 1 equiv.) and Hunig’s base (6 mL, 34 mmol, 4 equiv.) in dry DCM (90 mL) at 0˚C. 
The reaction was stirred at rt for 12 h. Water (100 mL) was added, the organic layer separated, and 
the aqueous layer was extracted with DCM (2 x 50 mL). The organic layers were combined, dried 
(Na2SO4), concentrated, and used without further purification. The residue (2.3 g, 8.2 mmol, 1 
eq.), indole (1.4 g, 12.3 mmol, 1.5 equiv.), CuI (156 mg, 0.8 mmol, 0.1 equiv.), and K3PO4 (4.36 
g, 20.5 mmol, 2.5 equiv.) were added to a dry 120 mL sealed tube. The tube was evacuated and 
backfilled with argon (3 x) followed by the addition of dry toluene (80 mL) and (±)-trans-1,2-
diaminocyclohexane (0.4 mL, 3.2 mmol, 0.4 equiv.). Argon was bubbled through the solvent for 
5 minutes and the tube was sealed and heated at 115˚C for 36 h. The tube was cooled to rt and 
partitioned between EtOAc (100 mL) and water (100 mL). The aqueous layer was extracted with 
EtOAc (2 x 50 mL). The combined organic layers were dried (Na2SO4), concentrated, and purified 
via flash chromatography (EtOAc/Hexanes, 3:7) to provide 2d as a white amorphous solid (2.39 
g, 89% yield). 1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 1.4 Hz, 1H), 8.08 (dd, J = 8.7, 2.8 Hz, 
1H), 7.69 (dd, J = 6.5, 1.9 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.27 (d, J = 3.4 Hz, 1H), 7.24 – 7.12 
(m, 3H), 6.69 (d, J = 3.3 Hz, 1H), 5.15 (s, 2H), 3.91 (s, 3H), 3.36 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 166.1, 156.0, 136.8, 130.4, 129.8, 129.0, 128.8, 128.6, 124.2, 122.1, 120.9, 120.2, 115.5, 





3-(1H-Indol-1-yl)-4-(methoxymethoxy)benzoic acid (2e). LiOH (1.84 g, 77 mmol, 10 equiv.) 
was added to a stirred solution of 2d (2.39 g, 7.7 mmol, 1 equiv.) in a THF:MeOH:Water mixture 
(2:1:1, 0.1 M). The reaction was heated at 70˚ for 12 h. Upon cooling to rt, 3 N HCl was added 
dropwise until the pH was ~7 followed by the addition of EtOAc (50 mL). The aqueous layer was 
extracted with EtOAc (2 x 50 mL). The organic layers were combined, dried, and concentrated to 
provide 2e (2.12 g 93%). 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 2.1 Hz, 1H), 8.09 (dd, J = 8.7, 
2.2 Hz, 1H), 7.71 – 7.65 (m, 1H), 7.38 (d, J = 8.7 Hz, 1H), 7.27 (d, J = 1.2 Hz, 1H), 7.23 – 7.13 
(m, 3H), 6.68 (dd, J = 3.3, 0.8 Hz, 1H), 5.14 (s, 2H), 3.35 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
168.3, 156.3, 136.9, 130.9, 130.3, 129.1, 128.9, 128.6, 124.3, 122.2, 121.0, 120.2, 115.6, 110.8, 
103.2, 94.8, 56.7. HRMS (ESI) m/z [M+H]+ for C17H16NO4 298.1079, found 298.1071. 
General procedure for the synthesis of 4-7. 
Hunig’s base (6 equiv.) was added to a stirred solution of 2e (1 equiv.), EDCI (3 equiv.), HOBT 
(3 equiv.) and a substituted isoindoline (3 equiv.) in DCM (0.1 M) and stirred at rt for 12 h. 1 N 
HCl was added and the organic layer was separated and washed with saturated NaHCO3 and brine. 
The organic layer was dried (Na2SO4), concentrated, and used without further purification. The 
residue was dissolved in MeOH and p-toluylsulfonic acid was added. The reaction stirred for 12 h 
at rt. The reaction was quenched with saturated NaHCO3 and extracted with EtOAc (3 x 20 mL). 
The combined organic layers were dried (Na2SO4), concentrated, and purified by flash 




(5-Fluoroisoindolin-2-yl)(4-hydroxy-3-(1H-indol-1-yl)phenyl)methanone (4) white 
amorphorous solid (15 mg, 24%).  1H NMR (400 MHz, CDCl3) δ 7.68 (dt, J = 7.5, 1.3 Hz, 1H), 
7.57 (t, J = 2.8 Hz, 2H), 7.27 (d, J = 3.3 Hz, 1H), 7.23 – 7.19 (m, 2H), 7.18 – 7.11 (m, 2H), 7.10 – 
6.83 (m, 3H), 6.73 – 6.70 (m, 1H), 4.95 (d, J = 12.1 Hz, 2H), 4.84 (d, J = 9.8 Hz, 2H). 13C NMR 
(126 MHz, CDCl3) δ 169.7, 154.3, 136.7, 131.8, 131.6, 129.0, 128.7, 128.4, 128.4, 127.8, 127.5, 
126.2, 124.4, 124.3, 123.9, 123.8, 122.4, 121.1, 120.4, 117.3, 115.4, 115.2, 115.1, 114.9, 110.7, 
110.3, 110.1, 109.8, 109.6, 103.5, 55.2, 54.7, 52.8, 52.2. HRMS (ESI) m/z [M+H]+ for 
C23H18FN2O2 373.1352, found 373.1340. 
 
(5-Chloroisoindolin-2-yl)(4-hydroxy-3-(1H-indol-1-yl)phenyl)methanone (5), tan amorphous 
solid (28 mg, 43%). 1H NMR (400 MHz, CDCl3) δ 7.73 – 7.68 (m, 1H), 7.64 – 7.56 (m, 2H), 7.30 
(d, J = 16.6 Hz, 1H), 7.25 – 7.16 (m, 6H), 6.76 (dd, J = 3.2, 0.8 Hz, 1H), 4.97 (d, J = 7.0 Hz, 2H), 
4.84 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.4, 154.0, 138.2, 136.7, 134.8, 129.2, 128.8, 128.8, 
128.7, 128.4, 128.4, 128.1, 127.7, 124.3, 123.7, 123.4, 122.8, 121.3, 120.8, 117.4, 115.4, 110.6, 
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104.1, 54.9, 54.8, 52.6, 52.4. HRMS (ESI) m/z [M+Na]+ for C23H17ClN2O2Na 411.0876, found 
411.0887.  
 
(4-Hydroxy-3-(1H-indol-1-yl)phenyl)(5-methoxyisoindolin-2-yl)methanone (6), off white 
amorphous solid (18 mg, 28%). 1H NMR (400 MHz, CDCl3) δ 7.76 – 7.69 (m, 1H), 7.62 (dd, J = 
8.4, 2.1 Hz, 1H), 7.59 (d, J = 2.1 Hz, 1H), 7.25 – 7.17 (m, 6H), 6.90 – 6.80 (m, 2H), 6.76 (dd, J = 
3.2, 0.8 Hz, 1H), 5.63 (s, 1H), 4.95 (d, J = 14.4 Hz, 2H), 4.82 (d, J = 11.7 Hz, 2H), 3.80 (d, J = 
13.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 169.6, 159.9, 159.6, 154.1, 137.7, 137.6, 136.7, 
129.0, 128.7, 128.4, 128.3, 128.2, 128.1, 127.5, 126.2, 123.8, 123.3, 122.5, 121.1, 120.5, 117.3, 
114.3, 114.2, 110.7, 107.8, 107.7, 103.6, 55.6, 55.4, 54.8, 53.0, 52.3. HRMS (ESI) m/z [M+Na]+ 
for C24H20N2O3Na 407.1372, found 407.1386. 
 
(4-Hydroxy-3-(1H-indol-1-yl)phenyl)(5-hydroxyisoindolin-2-yl)methanone (7), tan amorphous 
solid (43 mg, 69%). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 11.4 Hz, 
2H), 7.27 (s, 1H), 7.25 – 6.93 (m, 5H), 6.77 – 6.58 (m, 3H), 4.87 (s, 2H), 4.76 (d, J = 6.7 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 169.5, 156.9, 154.0, 136.7, 128.9, 128.7, 128.6, 127.6, 123.8, 
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123.4, 122.7, 122.7, 121.2, 120.6, 117.3, 115.4, 115.3, 110.7, 109.6, 109.2, 103.8, 54.9, 52.9. 
HRMS (ESI) m/z [M+H]+ for C23H19N2O3 371.1396, found 371.1387. 
 
(5-(3-(Dimethylamino)propoxy)isoindolin-2-yl)(4-hydroxy-3-(1H-indol-1-
yl)phenyl)methanone (8). A 2-5 mL microwave vial was charged with (3-(1H-indol-1-yl)-4-
(methoxymethoxy)phenyl)(5-hydroxyisoindolin-2-yl)methanone (50 mg, 0.12 mmol, 1 equiv.), 3-
dimethylamino-1-propyl chloride hydrochloride (29 mg, 0.18 mmol, 1.5 equiv.), K2CO3 (50 mg, 
0.36 mmol, 3 equiv.), nBu4N
+I- (cat.), and dry DMF (2 mL). The vial was sealed and heated at 
90˚C for 36 h. The reaction was cooled to rt and 1 N HCl (5 mL) was added followed by EtOAc 
(10 mL). The organic layer was washed with water (5 x 20 mL), dried (Na2SO4), concentrated, 
and used without further purification. The residue was dissolved in MeOH and p-toluylsulfonic 
acid was added and stirred for 12 h at rt. The reaction was quenched with saturated NaHCO3 and 
extracted with EtOAc (3 x 10 mL). The combined organic layers were dried (Na2SO4) and 
concentrated. The residue was purified via flash chromatography (MeOH/10% ammoniated DCM, 
1:49) to provide 8 as a clear oil (15 mg, 20%). 1H NMR (400 MHz, CDCl3) δ 7.69 (dt, J = 7.2, 1.3 
Hz, 1H), 7.62 – 7.56 (m, 2H), 7.25 (s, 1H), 7.23 – 7.00 (m, 5H), 6.85 – 6.65 (m, 3H), 4.93 (d, J = 
10.0 Hz, 3H), 4.80 (d, J = 10.7 Hz, 2H), 3.96 (dt, J = 18.2, 6.3 Hz, 2H), 2.45 (q, J = 7.7 Hz, 2H), 
2.23 (d, J = 4.5 Hz, 6H), 1.93 (q, J = 7.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 169.4, 159.2, 
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154.0, 136.8, 129.4, 129.3, 129.0, 129.0, 128.6, 128.6, 127.8, 126.4, 124.1, 123.6, 123.2, 121.6, 
121.1, 117.6, 115.1, 110.9, 108.8, 108.6, 104.8, 75.1, 66.8, 56.6, 55.1, 53.3, 45.6, 30.1. HRMS 
(ESI) m/z [M+H]+ for C28H30N3O3 456.2287, found 456.2289. 
 
(4-Hydroxy-3-(indolin-1-yl)phenyl)(isoindolin-2-yl)methanone (9). A microwave vial was 
charged with 2b (27 mg, 0.07 mmol, 1 equiv.), indoline (0.01 mL, 0.07 mmol, 1 equiv.), SPhos (3 
mg, 0.007 mmol, 0.1 equiv.), Pd(OAc)2 (1 mg, 0.003 mmol, 0.05 equiv.), and sodium tert-butoxide 
(10 mg, 0.1 mmol, 1.4 equiv.). The tube was evacuated and backfilled with argon (3 x) followed 
by the addition of toluene (1 mL). The resulting mixture was heated at 115 °C for 16 h, cooled to 
rt, and diluted with water (5 mL) and EtOAc (5 mL). The aqueous layer was extracted with EtOAc 
(2 x 10 mL). The combined organic layers were dried (Na2SO4), concentrated, and used as 
obtained. The residue was dissolved in MeOH and p-toluylsulfonic acid (10 equiv.) was added. 
The reaction was stirred at rt for 12 h, quenched with saturated NaHCO3, and extracted with EtOAc 
(3 x 5 mL). The combined organic layers were dried (Na2SO4), concentrated, and purified by flash 
chromatograph (EtOAc/Hexanes, 1:1) to provide 9 as a light brown amorphous solid (13 mg, 
49%). 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 2.0 Hz, 1H), 7.47 (dd, J = 8.3, 2.1 Hz, 1H), 7.30 
(d, J = 6.2 Hz, 3H), 7.22 (d, J = 7.5 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.09 – 7.03 (m, 1H), 6.83 
(td, J = 7.4, 1.0 Hz, 1H), 6.48 (s, 1H), 6.35 (d, J = 7.8 Hz, 1H), 4.98 (s, 2H), 4.82 (s, 2H), 3.75 (t, 
J = 8.1 Hz, 2H), 3.18 (t, J = 8.1 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 168.9, 154.8, 136.3, 
130.7, 128.9, 128.4, 127.8, 127.5, 127.5, 127.0, 124.9, 124.3, 123.1, 121.4, 121.0, 120.3, 116.9, 
231 
 
115.0, 110.3, 109.8, 105.0, 55.9, 55.1, 29.7, 29.1. HRMS (ESI) m/z [M+H]+ for C23H21N2O2 
357.1603, found 357.1594. 
 
4-Hydroxy-3-(3-methyl-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (10), off white 
amorphous solid (63 mg, 62%). 1H NMR (400 MHz, CDCl3) δ 7.67 – 7.62 (m, 1H), 7.62 – 7.55 
(m, 2H), 7.34 – 7.26 (m, 3H), 7.22 (d, J = 2.0 Hz, 1H), 7.18 (ddt, J = 8.5, 7.1, 1.1 Hz, 4H), 7.02 
(q, J = 1.1 Hz, 1H), 5.00 (s, 2H), 4.87 (s, 2H), 2.39 (d, J = 1.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 169.4, 153.4, 136.9, 136.4, 136.3, 129.6, 129.1, 128.5, 128.0, 127.7, 127.4, 126.2, 126.0, 
123.1, 123.0, 122.6, 120.3, 119.5, 117.1, 114.1, 110.4, 55.3, 52.9, 9.8. HRMS (ESI) m/z [M+Na]+ 
for C24H20N2O2Na 391.1422, found 391.1440. 
General procedure for the synthesis of 11, 12, and 23. 
A dry 10-20 mL microwave vial was charged with 2b (100 mg, 0.28 mmol, 1 equiv.), indazole, 
4-azaindole, or 6-azaindole (1.5 equiv.), CuI (3 mg, 0.01 mmol, 0.05 equiv.), and K3PO4 (147 mg, 
0.69 mmol, 2.5 equiv.). The vial was then evacuated and backfilled (3x) with argon followed by 
the addition of dry toluene (3 mL) and (1R,2R)-N,N’-dimethyl-1,2-diaminocyclohexane (8 mg, 
0.05 mmol, 0.2 equiv.). Argon was bubbled through the solvent for 5 minutes and the vial was 
sealed and heated at 115˚C for 36 h. The reaction was cooled to rt and portioned between EtOAc 
(10 mL) and water (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL). The 
combined organic layers were dried over Na2SO4, concentrated and the residue was passed through 
a plug of silica gel. The crude material was dissolved in MeOH (3 mL), p-toluylsulfonic acid (10 
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equiv.) was added and stirred at rt for 12 h. The reaction was quenched with saturated NaHCO3 
and the aqueous layer was extracted with EtOAc (2 x 10 mL), dried, and concentrated. The residue 
was purified by flash chromatography (EtOAc/Hexanes, 1:1) to provide 11, 12, and 23. 
 
(4-Hydroxy-3-(1H-indazol-1-yl)phenyl)(isoindolin-2-yl)methanone (11) off white amorphous 
solid (23 mg, 23%). 1H NMR (400 MHz, CDCl3) δ 10.09 (s, 1H), 8.29 (d, J = 0.9 Hz, 1H), 8.00 
(d, J = 2.1 Hz, 1H), 7.92 (dq, J = 8.6, 0.9 Hz, 1H), 7.86 (dt, J = 8.2, 1.0 Hz, 1H), 7.57 – 7.47 (m, 
2H), 7.38 – 7.27 (m, 4H), 7.24 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 7.4 Hz, 1H), 5.06 (s, 2H), 4.92 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 169.7, 151.8, 139.2, 136.8, 136.7, 135.5, 129.0, 128.6, 128.3, 
128.0, 126.9, 126.4, 124.7, 123.3, 123.0, 122.8, 122.2, 120.9, 118.8, 111.6, 55.7, 53.2. HRMS 
(ESI) m/z [M+Na]+ for C22H17N3O2Na 378.1218, found 378.1222. 
 
(4-Hydroxy-3-(1H-pyrrolo[3,2-b]pyridin-1-yl)phenyl)(isoindolin-2-yl)methanone (12) brown 
amorphous solid (15 mg, 15%). 1H NMR (400 MHz, CDCl3) δ 8.19 (dd, J = 4.9, 1.3 Hz, 1H), 7.63 
– 7.52 (m, 1zH), 7.41 (d, J = 3.4 Hz, 1H), 7.34 – 7.28 (m, 2H), 7.28 – 7.25 (m, 2H), 7.18 (d, J = 
7.3 Hz, 1H), 7.05 (dd, J = 8.3, 4.8 Hz, 1H), 6.45 (dd, J = 3.4, 0.9 Hz, 1H), 5.01 (s, 2H), 4.90 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 169.3, 155.0, 145.6, 142.1, 136.1, 136.0, 132.7, 130.0, 128.6, 
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127.8, 127.7, 127.5, 127.3, 125.6, 122.8, 122.3, 119.2, 118.2, 116.8, 102.9, 55.1, 52.7. HRMS 
(ESI) m/z [M+H]+ for C22H18N3O2 356.1399, found 356.1392. 
 
(3-(4-Chloro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (13), tan 
amorphous solid (48 mg, 45%). 1H NMR (400 MHz, CDCl3) δ 7.60 – 7.53 (m, 2H), 7.34 (d, J = 
3.3 Hz, 1H), 7.31 (d, J = 6.9 Hz, 2H), 7.25 (d, J = 7.0 Hz, 1H), 7.20 – 7.08 (m, 5H), 6.79 (dd, J = 
3.3, 0.7 Hz, 1H), 4.99 (s, 2H), 4.88 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.5, 154.1, 137.5, 
136.3, 136.1, 129.6, 128.7, 128.0, 127.7, 127.5, 127.4, 126.3, 125.9, 123.0 (2C), 122.5, 120.2, 
117.3, 109.5 (2C), 102.0, 55.3, 52.9. HRMS (ESI) m/z [M+H]+ for C23H18ClN2O2 389.1059, found 
389.1039. 
 
(3-(4-Fluoro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (14), off white 
amorphous solid (23 mg, 22%). 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 1H), 7.52 (dd, 
J = 8.4, 2.1 Hz, 1H), 7.29 (d, J = 6.8 Hz, 2H), 7.24 (d, J = 3.5 Hz, 2H), 7.15 (d, J = 7.7 Hz, 1H), 
7.12 – 7.05 (m, 2H), 7.00 (d, J = 8.2 Hz, 1H), 6.85 – 6.77 (m, 1H), 6.75 (d, J = 3.2 Hz, 1H), 4.97 
(s, 2H), 4.85 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.5, 156.3 (d, J = 247.2 Hz), 154.1, 129.0, 
128.9, 128.5, 128.0, 127.9, 127.6, 127.3, 122.9, 122.8, 122.8, 122.4, 117.3, 115.3, 106.8, 106.8, 
234 
 
105.2, 105.0, 99.3, 55.2, 52.8. HRMS (ESI) m/z [M+H]+ for C23H18FN2O2 373.1352, found 
373.1355. 
 
(4-Hydroxy-3-(4-methoxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (15), brown 
amorphous solid (27 mg, 25%). 1H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 7.44 (d, J = 8.5 Hz, 
1H), 7.29 (d, J = 11.4 Hz, 2H), 7.19 – 7.09 (m, 4H), 6.84 (d, J = 8.4 Hz, 2H), 6.79 (d, J = 3.3 Hz, 
1H), 6.57 (d, J = 7.6 Hz, 1H), 4.97 (s, 2H), 4.83 (d, J = 23.9 Hz, 2H), 3.96 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 170.9, 158.7, 153.4, 138.1, 136.2, 136.0, 129.0, 128.5, 127.9, 127.9, 127.5, 127.4, 
123.4, 122.9, 122.4, 122.4, 117.3, 115.2, 104.0, 100.9, 100.4, 55.4, 55.2, 52.7. HRMS (ESI) m/z 
[M+Na]+ for C24H20N2O3Na 407.1372, found 407.1391. 
 
(4-Hydroxy-3-(4-hydroxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (16) tan 
amorphous solid (37 mg, 36%). 1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 8.4, 2.0 Hz, 1H), 7.60 
(d, J = 2.1 Hz, 1H), 7.53 – 7.50 (m, 2H), 7.34 – 7.28 (m, 2H), 7.24 – 7.15 (m, 3H), 7.10 (t, J = 8.0 
Hz, 1H), 6.88 (d, J = 8.6 Hz, 1H), 6.79 (d, J = 8.3 Hz, 1H), 6.61 (d, J = 7.6 Hz, 1H), 5.02 (s, 2H), 
4.86 (d, J = 28.6 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 171.5, 161.6, 157.3, 129.2, 128.9, 128.7, 
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128.6, 128.5, 127.5, 122.1, 121.2, 117.7, 115.2, 111.7, 111.7, 111.6, 105.8, 103.3, 102.1, 101.8, 
101.2, 55.2, 52.8. HRMS (ESI) m/z [M+H]+ for C23H19N2O2 371.1396, found 371.1405. 
 
(4-Hydroxy-3-(5-methoxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (17), white 
amorphous solid (42 mg, 40%). 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.49 (m, 2H), 7.32 – 7.26 
(m, 2H), 7.24 (t, J = 3.1 Hz, 2H), 7.17 – 7.08 (m, 4H), 6.87 – 6.81 (m, 1H), 6.60 (dd, J = 3.2, 0.8 
Hz, 1H), 4.96 (s, 2H), 4.85 (s, 2H), 3.83 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 169.5, 154.6, 
153.9, 136.2, 136.0, 131.9, 129.4, 129.1, 128.2, 128.2, 127.9, 127.6, 127.3, 126.2, 122.9, 122.4, 
117.2, 112.6, 111.5, 103.3, 102.7, 55.9, 55.2, 52.7. HRMS (ESI) m/z [M+H]+ for C24H21N2O3 
385.1552, found 385.1564. 
 
(3-(5-Fluoro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (18) off white 
amorphous solid (39 mg, 38%). 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 2.1 Hz, 1H), 7.50 (dd, 
J = 8.4, 2.2 Hz, 1H), 7.30 (d, J = 3.3 Hz, 1H), 7.28 (d, J = 2.0 Hz, 2H), 7.26 (s, 2H), 7.13 (dd, J = 
8.8, 4.1 Hz, 2H), 7.09 (d, J = 8.4 Hz, 1H), 6.89 (td, J = 9.1, 2.5 Hz, 1H), 6.60 (dd, J = 3.2, 0.8 Hz, 
1H), 4.95 (s, 2H), 4.85 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.7, 159.2, 157.4, 154.1, 136.2, 
136.0, 133.3, 130.6, 129.0, 128.9, 128.4, 128.1, 128.0, 127.7, 127.4, 126.1, 123.0, 122.5, 117.2, 
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111.6, 111.5, 110.8, 110.6, 105.9, 105.7, 103.3, 103.3, 55.3, 52.8. HRMS (ESI) m/z [M+Na]+ for 
C23H17FN2O2Na 395.1172, found 395.1174. 
 
(4-Hydroxy-3-(5-nitro-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (19), yellow 
amorphous solid (15 mg, 14%). 1H NMR (500 MHz, CDCl3) δ 8.64 (d, J = 2.2 Hz, 1H), 8.09 (dd, 
J = 9.1, 2.2 Hz, 1H), 7.74 – 7.63 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 3.3 Hz, 1H), 7.37 
– 7.27 (m, 3H), 7.24 (d, J = 9.1 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 3.4 Hz, 1H), 5.03 (s, 
2H), 4.90 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 168.5, 153.6, 139.6, 136.1, 132.2, 130.8, 128.8, 
128.0, 127.9, 127.8, 127.7, 127.5, 123.0, 122.4, 118.2, 117.8, 116.0, 110.8, 105.3, 55.1, 52.8. 
HRMS (ESI) m/z [M]+ for C23H17N3O4 399.1219, found 399.1215. 
 
(4-Hydroxy-3-(5-hydroxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (20), brown 
amorphous solid (32 mg, 31%). 1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1H), 7.44 (d, J = 8.5 Hz, 
2H), 7.30 (s, 2H), 7.22 (d, J = 3.2 Hz, 1H), 7.13 (d, J = 7.8 Hz, 1H), 7.06 (d, J = 8.3 Hz, 1H), 6.85 
(d, J = 8.5 Hz, 2H), 6.76 (dd, J = 8.7, 2.5 Hz, 1H), 6.54 (d, J = 3.2 Hz, 1H), 4.97 (s, 2H), 4.83 (d, 
J = 21.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 172.5, 162.1, 158.8, 148.3, 147.0, 144.8, 142.7, 
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136.5, 135.1, 133.5, 132.8, 132.7, 130.8, 129.0, 128.1, 127.3, 127.0, 115.2, 109.8, 105.5, 103.2, 
55.2, 53.4. HRMS (ESI) m/z [M+H]+ for C23H19N2O3 371.1396, found 371.1403. 
 
(3-(5-Chloro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (21) tan amorphous 
solid (29 mg, 27%). 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 2.1 Hz, 1H), 7.55 – 7.49 (m, 2H), 
7.44 – 7.40 (m, 1H), 7.29 (d, J = 3.2 Hz, 2H), 7.17 – 7.07 (m, 4H), 6.88 – 6.79 (m, 1H), 6.59 (d, J 
= 3.1 Hz, 1H), 4.96 (s, 2H), 4.85 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.6, 154.1, 136.1, 
135.1, 130.3, 129.6, 129.0, 128.3, 127.9, 127.9, 127.6, 127.3, 125.9, 122.9, 122.5, 122.4, 120.2, 
117.2, 115.2, 111.9, 102.9, 55.2, 52.7. HRMS (ESI) m/z [M+H]+ for C23H18ClN2O2 389.1057, 
found 389.1072. 
 
1-(2-Hydroxy-5-(isoindoline-2-carbonyl)phenyl)-1H-indole-5-carbonitrile (22), yellow 
amorphous solid (48 mg, 46%). 1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 1.7 Hz, 1H), 7.57 – 
7.50 (m, 2H), 7.43 – 7.35 (m, 2H), 7.33 – 7.21 (m, 5H), 7.18 – 7.07 (m, 2H), 6.72 (d, J = 2.9 Hz, 
1H), 4.96 (s, 2H), 4.85 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.2, 153.9, 138.1, 135.9, 135.8, 
131.2, 128.5, 128.2, 127.9, 127.8, 127.5, 127.2, 126.3, 125.2, 124.9, 122.8, 122.3, 120.5, 117.0, 
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111.7, 103.7, 102.9, 55.0, 52.6. HRMS (ESI) m/z [M+Na]+ for C24H17N3O2Na 402.1218, found 
402.1236. 
 
(4-Hydroxy-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)phenyl)(isoindolin-2-yl)methanone (23), tan 
amorphous solid (24 mg, 24%). 1H NMR (400 MHz, DMSO-d6) δ 10.72 (s, 1H), 8.54 (s, 1H), 8.18 
(d, J = 5.4 Hz, 1H), 7.74 (d, J = 3.2 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.65 (dd, J = 8.4, 2.2 Hz, 
1H), 7.62 (dd, J = 5.4, 1.1 Hz, 1H), 7.39 (d, J = 6.6 Hz, 1H), 7.28 (s, 3H), 7.19 (d, J = 8.4 Hz, 1H), 
6.72 (dd, J = 3.1, 0.8 Hz, 1H), 4.89 (d, J = 24.8 Hz, 4H). 13C NMR (126 MHz, DMSO-d6) δ 167.9, 
153.6, 138.5, 137.2, 136.0, 134.1, 133.4, 133.0, 132.8, 128.5, 127.8, 127.4, 127.3, 127.1, 124.8, 
122.8, 122.8, 116.6, 115.0, 101.8, 54.4, 52.2. HRMS (ESI) m/z [M+H]+ for C22H18N3O2 356.1399, 
found 356.1411. 
 
(3-(6-Chloro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (24), off white 
amorphous solid (45 mg, 42%). 1H NMR (400 MHz, CDCl3) δ 7.57 – 7.52 (m, 3H), 7.31 – 7.26 
(m, 3H), 7.24 (d, J = 1.9 Hz, 1H), 7.23 – 7.22 (m, 1H), 7.18 (d, J = 7.2 Hz, 1H), 7.13 – 7.06 (m, 
2H), 6.64 (dd, J = 3.3, 0.9 Hz, 1H), 4.97 (s, 2H), 4.89 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
169.5, 154.0, 137.1, 136.2, 136.0, 129.7, 128.6, 128.2, 128.0, 127.9, 127.6, 127.3, 127.1, 125.6, 
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122.9, 122.5, 121.8, 120.9, 117.2, 110.8, 103.4, 55.3, 52.8. HRMS (ESI) m/z [M+Na]+ for 
C23H17ClN2O2Na 411.0876, found 411.0875. 
 
1-(2-Hydroxy-5-(isoindoline-2-carbonyl)phenyl)-1H-indole-6-carbonitrile (25), off white 
amorphous solid (32 mg, 31%). 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.67 (m, 1H), 7.59 – 7.52 
(m, 3H), 7.47 (dd, J = 3.2, 1.2 Hz, 1H), 7.33 (dt, J = 8.2, 1.4 Hz, 1H), 7.29 (s, 1H), 7.22 (s, 0H), 
7.18 (d, J = 7.0 Hz, 1H), 7.12 – 7.08 (m, 1H), 6.76 – 6.69 (m, 1H), 4.97 (s, 2H), 4.88 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 169.4, 154.1, 135.9, 135.6, 132.7, 131.9, 129.0, 128.7, 127.9, 127.9, 
127.7, 127.3, 125.2, 122.8, 122.5, 121.7, 121.6, 120.7, 117.0, 116.1, 104.2, 103.8, 55.2, 52.8. 
HRMS (ESI) m/z [M+Na]+ for C24H17N3O2Na 380.1399, found 380.1382. 
 
(4-Hydroxy-3-(6-hydroxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (26), brown 
amorphous solid (25 mg, 24%). 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 2.1 Hz, 1H), 7.39 (d, J 
= 8.5 Hz, 1H), 7.33 (dd, J = 8.4, 2.1 Hz, 1H), 7.27 (s, 1H), 7.27 – 7.19 (m, 2H), 7.13 (d, J = 7.4 
Hz, 1H), 6.98 (d, J = 3.3 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 6.69 (dd, J = 8.5, 2.2 Hz, 1H), 6.52 (d, 
J = 3.2 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 4.91 (s, 2H), 4.76 (s, 2H). 13C NMR (126 MHz, CDCl3) 
δ 170.1, 153.7, 153.0, 137.3, 136.0, 135.7, 127.9, 127.9, 127.6, 127.6, 127.4, 127.0, 126.4, 122.9, 
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122.5 (2C), 121.6, 117.2, 110.9, 103.8, 96.4, 55.1, 52.8. HRMS (ESI) m/z [M+Na]+ for 
C23H18N2O3Na 393.1215, found 393.1225. 
 
(4-Hydroxy-3-(6-methoxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (27), off white 
amorphous solid (17 mg, 16%). 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 1.9 Hz, 1H), 7.52 (d, J 
= 8.6 Hz, 1H), 7.45 – 7.39 (m, 1H), 7.29 (d, J = 8.5 Hz, 2H), 7.25 – 7.21 (m, 1H), 7.14 (dt, J = 4.0, 
2.4 Hz, 2H), 6.82 (td, J = 8.8, 1.8 Hz, 2H), 6.68 (d, J = 2.2 Hz, 1H), 6.61 (dd, J = 3.2, 1.0 Hz, 1H), 
4.98 (s, 2H), 4.87 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.5, 156.8, 154.1, 137.4, 136.2, 136.0, 
129.0, 128.5, 127.9, 127.8, 127.4, 126.0, 122.9, 122.7, 122.4, 121.6, 117.3, 115.2, 110.4, 103.5, 
94.2, 55.7, 55.2, 52.8. HRMS (ESI) m/z [M+Na]+ for C24H20N2O3Na 407.1372, found 407.1383. 
 
(3-(6-(3-(Dimethylamino)propoxy)-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-
yl)methanone (28), brown oil (8 mg, 6%). 1H NMR (400 MHz, CDCl3) δ 7.69 – 7.62 (m, 2H), 7.53 
(d, J = 8.6 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.35 – 7.27 (m, 3H), 7.20 – 7.14 (m, 2H), 6.85 – 6.81 
(m, 1H), 6.74 (d, J = 2.2 Hz, 1H), 6.60 (dd, J = 3.3, 0.8 Hz, 1H), 5.03 (s, 2H), 4.90 (s, 3H), 3.98 (t, 
J = 6.4 Hz, 2H), 2.47 – 2.40 (m, 2H), 2.23 (s, 6H), 1.97 – 1.92 (m, 2H). 13C NMR (126 MHz, 
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CDCl3) δ 168.9, 156.0, 153.7, 137.6, 130.7, 128.0, 128.0, 127.9, 127.6, 127.3, 127.3, 123.0, 122.9, 
122.8, 122.4, 121.3, 116.5, 110.4, 103.0, 95.4, 95.0, 66.8, 56.5, 56.5, 45.6, 45.5, 29.7, 27.7. HRMS 
(ESI) m/z [M]+ for C28H29N3O3 455.2209, found 455.2193. 
 
(4-Hydroxy-3-(6-nitro-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (29), yellow 
amorphous solid (13 mg, 12%). 1H NMR (500 MHz, CDCl3) δ 8.24 (s, 1H), 8.04 (td, J = 8.7, 8.3, 
2.1 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 7.67 – 7.52 (m, 3H), 7.48 – 7.43 (m, 1H), 7.28 (d, J = 8.2 
Hz, 3H), 7.16 – 7.11 (m, 1H), 6.77 (d, J = 3.3 Hz, 1H), 4.99 (s, 2H), 4.97 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 169.3, 154.0, 143.4, 135.4, 134.8, 133.5, 131.3, 129.1, 127.7, 127.2, 125.1, 124.4, 
120.9, 119.8, 117.3, 115.6, 114.9, 114.6, 111.2, 110.9, 108.0, 103.8, 55.4, 52.8. HRMS (ESI) m/z 
[M+Na]+ for C23H17N3O4Na 422.1117, found 422.1115. 
 
(3-(6-Fluoro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (30), white 
amorphous solid (22 mg, 13%). 1H NMR (500 MHz, CDCl3) δ 7.57 – 7.51 (m, 3H), 7.28 (d, J = 
8.5 Hz, 2H), 7.25 (d, J = 3.4 Hz, 2H), 7.16 (d, J = 7.4 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 6.94 – 
6.86 (m, 2H), 6.64 (d, J = 3.3 Hz, 1H), 4.97 (s, 2H), 4.86 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 
169.5, 160.1 (d, J = 238.1 Hz), 154.0, 136.0, 129.3, 129.0, 128.4, 127.9, 127.6, 127.2, 125.9, 125.0, 
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123.0, 122.4, 121.6, 117.2, 115.2, 108.9, 103.3, 97.2, 55.2, 52.7. HRMS (ESI) m/z [M+Na]+ for 
C23H17FN2O2Na 395.1172, found 395.1186. 
 
(4-Hydroxy-3-(7-methoxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (31), white 
amorphous solid (40 mg, 38%). 1H NMR (400 MHz, CDCl3) δ 7.53 – 7.43 (m, 2H), 7.27 (s, 1H), 
7.23 (dd, J = 7.9, 0.8 Hz, 3H), 7.12 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 3.2 Hz, 1H), 7.05 – 6.99 (m, 
2H), 6.64 – 6.59 (m, 2H), 4.93 (s, 2H), 4.85 (s, 2H), 3.64 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
169.9, 154.5, 147.5, 136.4, 136.2, 131.1, 130.2, 128.5 (2C), 128.3, 127.9, 127.6, 127.2, 126.7, 
123.0, 122.4, 121.1, 116.3, 114.0, 104.0, 103.9, 55.7, 55.3, 52.8. HRMS (ESI) m/z [M+Na]+ for 
C24H20N2O3Na 407.1372, found 407.1382. 
 
(4-Hydroxy-3-(7-hydroxy-1H-indol-1-yl)phenyl)(isoindolin-2-yl)methanone (32), brown 
amorphous solid (19 mg, 19%). 1H NMR (500 MHz, CDCl3) δ 7.63 – 7.60 (m, 1H), 7.54 – 7.49 
(m, 2H), 7.36 – 7.28 (m, 3H), 7.20 – 7.14 (m, 2H), 7.09 (dd, J = 6.2, 3.3 Hz, 1H), 6.90 – 6.86 (m, 
2H), 6.66 (d, J = 7.3 Hz, 1H), 5.02 (s, 2H), 4.83 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 170.2, 
160.8, 157.2, 156.6, 145.1, 135.9, 135.4, 135.3, 132.0, 131.7, 129.2, 127.7, 126.8, 126.7, 120.5, 
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115.2, 109.3, 108.9, 106.5, 100.3, 100.2, 55.1, 52.6. HRMS (ESI) m/z [M+Na]+ for C23H18N2O3Na 
393.1215, found 393.1220. 
 
(3-(7-Chloro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (33), yellow 
amorphous solid (35 mg, 33%). 1H NMR (500 MHz, CDCl3) δ 7.60 – 7.55 (m, 1H), 7.44 (d, J = 
8.4 Hz, 2H), 7.35 – 7.27 (m, 3H), 7.21 – 7.12 (m, 2H), 7.12 – 7.04 (m, 2H), 6.84 (d, J = 8.4 Hz, 
2H), 5.01 (s, 2H), 4.85 (d, J = 21.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 171.1, 158.7, 136.4, 
136.1, 131.3, 129.4, 129.0 (2C), 128.9, 127.8, 127.6, 127.5, 127.2, 124.0, 122.9, 122.4, 121.3, 
120.0, 116.4, 115.5 (2C), 104.4, 55.3, 52.8. HRMS (ESI) m/z [M+Na]+ for C23H17ClN2O2Na 
411.0876, found 411.0878. 
 
(3-(7-Fluoro-1H-indol-1-yl)-4-hydroxyphenyl)(isoindolin-2-yl)methanone (34), brown 
amorphous solid (32 mg, 31%). 1H NMR (500 MHz, CDCl3) δ 7.54 (q, J = 2.0 Hz, 1H), 7.53 – 
7.46 (m, 1H), 7.39 (dd, J = 7.9, 3.3 Hz, 1H), 7.29 – 7.23 (m, 3H), 7.20 – 7.13 (m, 2H), 7.07 – 6.96 
(m, 2H), 6.88 – 6.79 (m, 1H), 6.66 (d, J = 3.0 Hz, 1H), 4.95 (s, 2H), 4.86 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 169.8, 154.4, 150.0 (d, J = 246.1), 136.3, 136.0, 130.7, 128.4, 127.8, 127.6, 127.6, 
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127.5, 127.3, 122.9, 122.4, 120.4, 120.4, 116.8, 116.7, 116.5, 108.0, 107.9, 103.8, 55.1, 52.7. 
HRMS (ESI) m/z [M+Na]+ for C23H17FN2O2Na 395.1172, found 395.1179. 
 
(4-Hydroxy-1,3-phenylene)bis(isoindolin-2-ylmethanone) (36). Hunig’s base (1.2 mL, 6.6 
mmol, 12 equiv.) was added to a stirred solution of 4-hydroxyisophthalic acid (100 mg, 0.55 mmol, 
1 equiv.), EDCI (632 mg, 3.3 mmol, 6 equiv.), HOBT (445 mg, 3.3 mmol, 6 equiv.) and isoindoline 
hydrochloride (513 mg, 3.3 mmol, 6 equiv.) in DCM (0.05 M) and stirred at rt for 12 h. 1 N HCl 
was added and the organic layer was separated and washed with saturated NaHCO3 and brine. The 
organic layer was dried (Na2SO4), concentrated, and purified by flash chromatography 
(EtOAc/Hexanes, 1:1) to provide 36 as a tan amorphous solid (48 mg, 23%). 1H NMR (400 MHz, 
CDCl3) δ 7.99 (d, J = 2.1 Hz, 1H), 7.67 (dd, J = 8.6, 2.1 Hz, 1H), 7.40 – 7.27 (m, 7H), 7.20 (d, J 
= 7.5 Hz, 1H), 7.09 (d, J = 8.6 Hz, 1H), 5.13 (s, 4H), 5.05 (s, 2H), 4.88 (s, 2H). 13C NMR (126 
MHz, CDCl3) δ 169.8, 169.3, 161.8, 136.3, 136.1, 131.7 (2C), 128.0 (2C), 127.8 (2C), 127.5, 
126.4, 122.8, 122.5 (2C), 122.4, 117.7 (2C), 116.7, 55.1 (2C), 52.7 (2C). HRMS (ESI) m/z 
[M+Na]+ for C24H20N2O3 407.1372, found 407.1358. 
General procedure for the synthesis of 37a-39a. 
Hunig’s base (6 equiv.) was added to a stirred solution of 2-hydroxy-5-
(methoxycarbonyl)benzoic acid (1 equiv.), EDCI (3 equiv.), HOBT (3 equiv.) and a substituted 
isoindoline (3 equiv.) in DCM (0.1 M) and stirred at rt for 12 h. 1 N HCl was added and the organic 
layer was separated and washed with saturated NaHCO3 and brine. The organic layer was dried 
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(Na2SO4), concentrated, and purified by flash chromatography (EtOAc/Hexanes, 1:1) to provide 
37a-39a. 
 
Methyl 3-(5-fluoroisoindoline-2-carbonyl)-4-hydroxybenzoate (37a) white amorphous solid 
(17 mg, 35%). 1H NMR (400 MHz, CDCl3) δ 11.76 (s, 1H), 8.41 (d, J = 2.1 Hz, 1H), 8.06 (dd, J 
= 8.7, 2.1 Hz, 1H), 7.26 (s, 1H), 7.09 – 6.99 (m, 3H), 5.12 (s, 4H), 3.93 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 169.8, 166.4, 164.6, 146.8, 144.9, 143.9, 134.5 (2C), 130.4, 120.3, 118.2 (2C), 
101.0, 92.9, 53.4, 52.2 (2C). HRMS (ESI) m/z [M+H]+ for C17H15FNO4 316.0985, found 316.0977. 
 
Methyl 4-hydroxy-3-(5-methoxyisoindoline-2-carbonyl)benzoate (38a), white amorphous solid 
(23 mg, 46%). 1H NMR (400 MHz, CDCl3) δ 11.89 (s, 1H), 8.43 (d, J = 2.1 Hz, 1H), 8.06 (dd, J 
= 8.7, 2.0 Hz, 1H), 7.22 (s, 1H), 7.05 (d, J = 8.7 Hz, 1H), 6.87 (d, J = 8.4 Hz, 2H), 5.09 (s, 4H), 
3.93 (s, 3H), 3.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.7, 169.7, 166.4, 164.6, 145.9, 135.6, 
134.4, 131.6, 130.5, 121.9, 120.2, 118.2, 112.5, 100.0, 67.4, 64.2, 55.5, 52.2. HRMS (ESI) m/z 




Methyl 4-hydroxy-3-(5-hydroxyisoindoline-2-carbonyl)benzoate (39a), off white amorphous 
solid (19 mg, 40%). 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 8.7, 2.1 
Hz, 1H), 7.24 (s, 1H), 6.99 (d, J = 8.6 Hz, 1H), 6.71 (d, J = 30.1 Hz, 2H), 4.96 (s, 4H), 3.88 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 172.3, 172.1, 165.3, 155.2, 134.0, 130.3, 127.3, 125.0, 122.9, 
119.6, 117.7, 114.3, 110.7, 108.6, 100.0, 56.2, 53.7, 52.1. HRMS (ESI) m/z [M+H]+ for C17H16NO5 
314.1028, found 314.1040. 
General procedure for the synthesis of 37-39. 
LiOH (10 eq.) was added to a stirred solution of 37a-39a (1 equiv.) in a THF:MeOH:Water 
mixture (2:1:1, 0.1 M). The reaction was heated to 70˚C for 12 h then cooled to rt. 3 N HCl was 
added dropwise until the pH was ~7 followed by the addition of EtOAc. The organic layer was 
separated and the aqueous layer was extracted with EtOAc. The organic layers were combined, 
dried, and concentrated and used as obtained. The residue was dissolved in DCM to which 
isoindoline (3 equiv.), EDCI (3 equiv.), HOBT (3 equiv.), and Hunig’s base (6 equiv.) were added. 
The reaction stirred at rt for 12 h. 1 N HCl was added and the organic layer was separated and 
washed with saturated NaHCO3 and brine. The organic layer was dried (Na2SO4), concentrated, 




(5-Fluoroisoindolin-2-yl)(2-hydroxy-5-(isoindoline-2-carbonyl)phenyl)methanone (37), white 
amorphous solid (15 mg, 70%). 1H NMR (400 MHz, CDCl3) δ 11.36 (s, 1H), 7.97 (d, J = 2.1 Hz, 
1H), 7.72 – 7.63 (m, 1H), 7.42 – 7.27 (m, 4H), 7.24 – 7.18 (m, 1H), 7.09 (d, J = 8.6 Hz, 1H), 7.01 
(d, J = 8.6 Hz, 2H), 5.08 (d, J = 21.1 Hz, 6H), 4.88 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 169.9, 
169.3, 161.9, 136.3, 136.2, 131.9 (2C), 131.8, 128.2, 128.1 (2C), 128.0, 127.9, 127.6, 127.6, 126.5, 
123.0, 122.5, 117.8, 117.8 (2C), 116.7, 55.2, 52.8. HRMS (ESI) m/z [M+Na]+ for C24H19FN2O3Na 
425.1277, found 425.1273. 
 
(4-Hydroxy-3-(5-methoxyisoindoline-2-carbonyl)phenyl)(isoindolin-2-yl)methanone (38) tan 
amorphous solid (12 mg, 41%). 1H NMR (400 MHz, CDCl3) δ 11.48 (s, 1H), 7.98 (d, J = 2.1 Hz, 
1H), 7.66 (dd, J = 8.5, 2.1 Hz, 1H), 7.39 – 7.27 (m, 3H), 7.20 (d, J = 7.3 Hz, 2H), 7.08 (d, J = 8.5 
Hz, 1H), 6.89 – 6.73 (m, 2H), 5.05 (s, 6H), 4.87 (s, 2H), 3.81 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 170.2, 169.8, 162.3, 136.8, 136.6, 132.2, 128.6, 128.3, 128.0, 126.8, 123.8, 123.4, 122.9, 118.2, 
117.2, 114.9, 107.9, 55.9, 55.6, 53.2. HRMS (ESI) m/z [M+Na]+ for C25H22N2O4Na 437.1477, 




(4-Hydroxy-3-(5-hydroxyisoindoline-2-carbonyl)phenyl)(isoindolin-2-yl)methanone (39) tan 
amorphous solid (19 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 2.1 Hz, 1H), 7.65 (d, J 
= 2.1 Hz, 1H), 7.39 – 7.28 (m, 5H), 7.20 (d, J = 7.4 Hz, 1H), 7.09 (s, 1H), 6.82 (s, 1H), 5.07 (s, 
2H), 4.91 (d, J = 11.0 Hz, 4H), 4.81 (d, J = 6.6 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 169.8, 
169.8, 169.5, 169.4, 161.9, 131.5, 128.5, 128.0, 127.9, 127.7, 127.6, 123.1, 123.0, 122.6, 122.5, 
117.7, 55.3, 53.4, 53.0, 52.1. HRMS (ESI) m/z [M]+ for C24H21N2O4 387.1471, found 387.1476. 
Fluorescence polarization. The assay was performed in 96-well black, flat-bottom plates with 
a final volume of 100 μL. 25 μL of assay buffer (20 mM HEPES, pH 7.3, 50 mM KCl, 5 mM 
MgCl2, 20 mM Na2MoO4, 2 mM DTT, 0.1 mg/mL BGG, and 0.01% NP-40) were added, 
followed by 25 μL of assay buffer containing 6 nM FITC-GDA (fluorescent tracer, stock in 
DMSO, diluted in assay buffer) and 50 μL of assay buffer containing 10 nM of either Grp94, 
Hsp90β, or Hsp90α or 20 nM TRAP1 were added to each well. For each plate, wells containing 
buffer only (background), tracer in buffer only (low polarization control) and protein, tracer, and 
1% DMSO (final concentration, high polarization control) were included. Compounds were then 
added with a final concentration of DMSO = 1%. Plates were incubated at 4 ˚C with rocking for 
24 h. Polarization values (in mP units) were measured at 37 ˚C with an excitation filter at 485 nm 
and an emission filter at 528 nm. Polarization values were correlated to % tracer bound and 
compound concentrations. The concentration at which the tracer was 50% displaced by compound 
of interested were calculated and reported as apparent Kd’s. 
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Cell Culture. PC3-MM2, HeLa, and HCT116 (ATCC) were grown in a water jacketed 
incubator at 37˚C with 5% CO2 in DMEM (PC3-MM2), EMEM (HeLa), or McCoy’s (HCT116) 
media supplemented with 10% FBS and 1% penicillin/streptomycin.  
Anti-proliferation. Cells were counted via Trypan blue exclusion and seeded in 96-well plates 
at 2000 cells/0.1 mL/well then returned to the incubator for 24 h. Compounds in DMSO (1% final 
concentration) or vehicle were administered and the plates were returned to the incubator for 72 h. 
The % viable cells was determined using the MTS/PMS cell proliferation kit (Promega) per the 
manufacturer’s instructions. Cells treated with vehicle were normalized to 100% viable and 
compound treated cells were adjusted accordingly. GI50 values were calculated via GraphPad 
Prism and reported as the average of 2 independent experiements. 
Western Blot Analysis. HeLa were counted as described above and seeded at 100,000 cells/mL 
in 10 cm dishes. The dishes were returned to the incubator for 24 h at which point compounds or 
vehicle were added (0.25% DMSO final concentration) and incubated together for 24 h. Cells were 
harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease 
inhibitors (Roche) according to the manufacturer’s instructions. Cell lysates were obtained by 
centrifugation at 14,000 rpm for 10 min. Protein concentrations were determined using the Pierce 
BCA assay kit with serum albumin as the standard and following the manufacturer’s instructions. 
Equal amounts of protein were separated via SDS-PAGE under reducing conditions then 
transferred to PVDF membranes and immunoblotted with the corresponding primary antibodies 
for CHOP (Cell Signaling), Akt (Santa Cruz Biotechnology), Hsp70 (Enzo Life Sciences), and 
Actin (Santa Cruz Biotechnology). Membranes were then incubated with the correct HRP-
conjugated secondary antibody (Rabbit for Akt and Hsp70; Mouse for CHOP and Actin), 
developed with a chemiluminescent substrate (Bio-Rad), and visualized. 
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Flow Cytometry. HeLa cells were counted and seeded at 100,000 cells/mL in a 24 well plate 
and returned to the incubator for 24 h. Compounds or DMSO were then administered (0.25% 
DMSO final concentration) and returned to the incubator for 12 h. The cells were then washed 
with PBS, trypsinized, and diluted with media (2 x volume of trypsin). Propidium iodide (5 mM 
stock in DMSO) was added to each sample for a final concentration of 5 µM. Samples were 
incubated for 10 min at rt with rocking before analysis. 60 µL of each sample were analyzed via 
an Accuri C6 flow cytometer. 
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